<SEC-DOCUMENT>0001683168-25-006352.txt : 20250820
<SEC-HEADER>0001683168-25-006352.hdr.sgml : 20250820
<ACCEPTANCE-DATETIME>20250820171631
ACCESSION NUMBER:		0001683168-25-006352
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20250820
DATE AS OF CHANGE:		20250820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289745
		FILM NUMBER:		251237733

	BUSINESS ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		619-941-0360

	MAIL ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>aethlon_s1.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:AEMD="http://aethlonmedical.com/20250820">
<head>
     <title>AETHLON MEDICAL, INC. S-1</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_AEMD_aethlonmedical.com_20250820 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20250820_20250820 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0000882291 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000004" name="dei:EntityCentralIndexKey">0000882291</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aemd-20250820.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-20</xbrli:startDate>
        <xbrli:endDate>2025-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><a href="#s1_001"><span style="font-size: 7pt">Table of Contents</span></a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange Commission
on August 20, 2025</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><b>Registration Statement No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20250820__20250820_zJZMkVAJ25D7"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000009" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>REGISTRATION STATEMENT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>Under</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>THE SECURITIES ACT OF 1933</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_908_edei--EntityRegistrantName_c20250820__20250820_z6PDYGM0wh88"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000010" name="dei:EntityRegistrantName">AETHLON MEDICAL,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20250820__20250820_z7HhB9etmnd"><ix:nonNumeric contextRef="AsOf2025-08-20" format="ixt-sec:stateprovnameen" id="Fact000011" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3826</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20250820__20250820_z7pH8qxfoLb5"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000012" name="dei:EntityTaxIdentificationNumber">13-3632859</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of<br/>
incorporation or organization)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Primary Standard Industrial<br/>
Classification Code Number)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer<br/>
Identification Number)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20250820__20250820_zFFdkWNAxeL7"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000013" name="dei:EntityAddressAddressLine1">11555 Sorrento Valley Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250820__20250820_zqE3BQWYwke5"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000014" name="dei:EntityAddressAddressLine2">Suite 203</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20250820__20250820_zDDcddFlleD3"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000015" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20250820__20250820_ztXaBuTBmYi2"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000016" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20250820__20250820_zUnBfjkJhjp2"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000017" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_903_edei--CityAreaCode_c20250820__20250820_z7UnWqtRoHci"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000018" name="dei:CityAreaCode">(619)</ix:nonNumeric></span> <span id="xdx_904_edei--LocalPhoneNumber_c20250820__20250820_zGDXKEB8sgq4"><ix:nonNumeric contextRef="AsOf2025-08-20" id="Fact000019" name="dei:LocalPhoneNumber">941-0360</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Address, including zip code, and telephone number,
including area code, of registrant&#8217;s principal executive offices)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>James B. Frakes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Chief Executive Officer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aethlon Medical, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>11555 Sorrento Valley Road, Suite 203</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>San Diego, CA 92121</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(619) 941-0360</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>Copies to:</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><i>&#160;</i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dennis Doucette, Esq.<br/>
Procopio Cory Hargreaves &amp; Savitch, LLP<br/>
12544 High Bluff Drive<br/>
Suite 400<br/>
San Diego, CA 92130<br/>
Tel: (858) 720 6303</b></span></td>
    <td style="vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: top; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M. Ali Panjwani <br/>
Pryor Cashman LLP<br/>
7 Times Square <br/>
New York, NY 10036-6569 <br/>
Telephone: (212) 326-0846 <br/>
Fax: (212) 326-0806</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Approximate date of commencement of proposed sale
to public:</b>&#160;As soon as practicable after this Registration Statement is declared effective.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#160;&#160;&#160;&#160;&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment filed pursuant
to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.&#160;&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering.&#160;&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the
definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&#160;<b>&#9744;</b></span></td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&#160;<b>&#9744;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityFilerCategory_c20250820__20250820_ziVlGk325X2k"><ix:nonNumeric contextRef="AsOf2025-08-20" format="ixt-sec:entityfilercategoryen" id="Fact000020" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span>&#160;&#9746;</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&#160;<span id="xdx_900_edei--EntitySmallBusiness_c20250820__20250820_z0LGnzVL3Tl2"><ix:nonNumeric contextRef="AsOf2025-08-20" format="ixt:booleantrue" id="Fact000021" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&#160;<b><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250820__20250820_zDDkaFYmlcw8"><ix:nonNumeric contextRef="AsOf2025-08-20" format="ixt:booleanfalse" id="Fact000022" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;&#160;<b>&#9744;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><b>The registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further
amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a)
of the Securities Act or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section&#160;8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><b>The information contained in this preliminary
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an
offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><b>SUBJECT TO COMPLETION, DATED AUGUST 20, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">PRELIMINARY PROSPECTUS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="aethlonlogo.jpg" alt="" style="height: 73px; width: 225px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to [___] Shares of Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Pre-Funded Warrants to Purchase up to [___] Shares
of Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants to Purchase up to [___] Shares of Common
Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Placement Agent Warrants to Purchase up to [__]
shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares of Common Stock Issuable upon the Exercise
of the Warrants, Pre-Funded Warrants and Placement Agent Warrants. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>1,550,000 Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Issuable upon Exercise of Outstanding Warrants Offered
by Selling Stockholders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are offering in a best-efforts
offering up to [__] shares of common stock, par value $0.0001 per share (&#8220;common stock&#8221;), and accompanying warrants to purchase
up to [__] shares of our common stock at a combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share of common stock and accompanying warrant (the &#8220;Company Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are also offering to those
purchasers, if any, whose purchase of our common stock in this Company Offering would otherwise result in such purchaser, together with
its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following
the consummation of this Company Offering, the opportunity, in lieu of purchasing common stock, to purchase pre-funded warrants to purchase
shares of our common stock, or pre-funded warrants. Each pre-funded warrant will be exercisable for one share of our common stock (subject
to adjustment as provided for therein) at any time at the option of the holder until such pre-funded warrant is exercised in full, provided
that the holder will be prohibited from exercising pre-funded warrants for shares of our common stock if, as a result of such exercise,
the holder, together with its affiliates and certain related parties, would own more than 4.99% of the total number of shares of our common
stock then issued and outstanding. However, any holder may increase such percentage to any other percentage not in excess of 9.99%, provided
that any increase in such percentage shall not be effective until 61 days after notice to us. The purchase price of each pre-funded warrant
will equal the price per share at which shares of our common stock and accompanying warrants to purchase common stock are being sold to
the public in this Company Offering, minus $0.001, and the exercise price of each pre-funded warrant will equal $0.001 per share of common
stock. For each pre-funded warrant purchased in this Company Offering in lieu of common stock, we will reduce the number of shares of
common stock we are offering by one. Pursuant to this prospectus, we are also offering the shares of common stock issuable upon the exercise
of the warrants, pre-funded warrants and placement agent warrants offered hereby.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each share of our common stock,
or pre-funded warrant in lieu thereof, is being sold together with a warrant to purchase one share of our common stock. Each warrant will
have an exercise price per of $ per share (representing 100% of the combined public offering price per share of common stock (or pre-funded
warrant) and accompanying warrant in this offering), will be immediately exercisable and will expire on the fifth anniversary of the original
issuance date. The shares of our common stock and warrants are immediately separable and will be issued separately, but will be purchased
together in this Company Offering. The pre-funded warrants and warrants are not listed on any trading market and we do not intend to apply
for listing of these pre-funded warrants and warrants. Without an active market, the liquidity of these warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Company Offering will
terminate on within one year of the effective date, unless we decide to terminate (which we may do at any time in our discretion) prior
to that date. We will have one closing for all the securities purchased in this Company Offering by us. The combined public offering price
per share (or pre-funded warrant) and warrant will be fixed for the duration of this Company Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have engaged Maxim Group LLC,
or the placement agent, to act as our exclusive placement agent in connection with the securities offered by the Company in the Company
Offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered in the Company
Offering in this prospectus. Other than the placement agent warrants issued as compensation, the placement agent is not purchasing or
selling any of the securities we are offering, and the placement agent is not required to arrange the purchase or sale of any specific
number of securities or dollar amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, this prospectus also
relates to the resale from time to time, by the selling securityholders (the &#8220;Inducement Offering&#8221;) identified in this prospectus
under the caption &#8220;<a href="#s1_008">Selling Securityholders</a>&#8221; of up to 1,550,000 shares of our common stock which are issuable
upon the exercise of outstanding inducement warrants (the &#8220;Inducement Warrants&#8221;). We previously issued Inducement Warrants
to the Selling Securityholder in a private placement, pursuant to a Warrant Inducement Agreement dated March 16, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Securityholder may,
from time to time, sell, transfer or otherwise dispose of any or all of their common stock or interests in their common stock on any stock
exchange, market or trading facility on which the common stock is traded or in private transactions. These dispositions may be at fixed
prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined
at the time of sale, or at negotiated prices. See &#8220;<a href="#s1_013">Plan of Distribution</a>&#8221; in this prospectus for more
information. We will not receive any proceeds from the resale or other disposition of the common stock by the Selling Securityholder.
However, we will receive the proceeds of any cash exercise of the Inducement Warrants. See &#8220;<a href="#s1_007">Use of Proceeds</a>&#8221;
beginning on page 27 and &#8220;<a href="#s1_013">Plan of Distribution</a>&#8221; beginning on page 41 of this prospectus for more information.
The offering will settle delivery versus payment (&#8220;DVP&#8221;)/receipt versus payment (&#8220;RVP&#8221;). Accordingly, we and the
placement agent have not made any arrangements to place investor funds in an escrow account or trust account since the placement agent
will not receive investor funds in connection with the sale of the securities offered hereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is traded on
the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;AEMD.&#8221; On August 18, 2025, the last reported sale price
of our common stock as reported on Nasdaq was $1.17 per share. We are a &#8220;smaller reporting company&#8221; as defined under the federal
securities laws and, under applicable Securities and Exchange Commission rules, we have elected to comply with certain reduced public
company reporting and disclosure requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should read this prospectus,
together with additional information described under the headings &#8220;<a href="#s1_017">Where You Can Find More Information</a>,&#8221;
carefully before you invest in any of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to pay the placement
agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. See &#8220;<a href="#s1_013">Plan of Distribution</a>&#8221; section of this prospectus for more information regarding these arrangements. There is no minimum number of
shares of common stock or pre-funded warrants or minimum aggregate amount of proceeds that is a condition for this offering to close.
We may sell fewer than all of the shares of common stock and pre-funded warrants offered hereby, which may significantly reduce the amount
of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby.
In addition, because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be in a position
where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended uses of the
proceeds as described in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Pre-Funded Warrant</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees<sup>(1)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses to us<sup>(2)</sup></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to (i) pay the placement agent a cash fee equal to 6.5% of the aggregate gross proceeds raised at the closing of this offering and (ii) issue warrants to the placement agent exercisable for a number of shares of common stock equal to 4.0% of the total number of shares of common stock issued in this offering. We have also agreed to reimburse the placement agent for certain expenses and closing costs. See &#8220;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_013">Plan of Distribution</a></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8221; for additional information and a description of the compensation payable to the placement agent.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. For more information, see &#8220;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_013">Plan of Distribution</a></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>An investment in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties
described in the section captioned &#8220;Risk Factors&#8221; contained herein and in our Annual Report on Form 10-K
for the fiscal year ended March 31, 2025 filed with the Securities and Exchange Commission (the SEC) on June 26, 2025, and other filings
we make with the SEC from time to time, which are incorporated by reference herein in their entirety, together with other information
in this prospectus and the information incorporated by reference herein.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Neither the SEC nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation
to the contrary is a criminal offense.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Delivery of the common stock,
pre-funded warrants and accompanying warrants offered in the Company Offering is expected to be made on or about [__] subject to satisfaction
of certain customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Maxim Group LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The date of this Prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_001"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">About this Prospectus</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 93%"><a href="#s1_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="text-align: right">2<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s1_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Note Regarding Forward-Looking Statements</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s1_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Securityholders</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_009">Dilution</a></span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s1_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_012">Certain Material U.S. Federal Tax Consequences</a></span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s1_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>9</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_015">Experts</a></span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>9</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s1_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market and Industry Data</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>9</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#s1_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find More Information</span></a></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>9</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><a href="#s1_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Information by Reference</span></a></td>
    <td style="text-align: right">50</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 24.75pt"><b><span id="s1_002"></span>ABOUT THIS PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.75pt">You should read this prospectus, including the information
incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt">Neither we, the Selling Securityholders
nor the placement agent have authorized anyone to provide you with information that is different from that contained in this prospectus
or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may give you. Neither the delivery of this prospectus nor the
sale of our securities means that the information contained in this prospectus or any free writing prospectus is correct after the date
of this prospectus or such free writing prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our
securities in any circumstances under which the offer or solicitation is unlawful. The information contained in this prospectus is current
only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock or warrants.
Our business, financial condition, results of operations and prospects may have changed since that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt">For investors outside the United
States: We have not, and the placement agent has not, taken any action that would permit this offering or possession or distribution of
this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering
of the securities covered hereby and the distribution of this prospectus outside the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt; background-color: white">Unless
otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our
general expectations and market position, and market opportunity, is based on information from our own management estimates and research,
as well as from industry and general publications and research, surveys and studies conducted by third parties. Management estimates are
derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which
we believe to be reasonable. Our management estimates have not been verified by any independent source, and we have not independently
verified any third-party information. In addition, assumptions and estimates of our and our industry&#8217;s future performance are necessarily
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;<a href="#s1_005">Risk Factors</a>&#8221; These and other factors could cause our future performance to differ materially from our assumptions and estimates.
See &#8220;<a href="#s1_006">Special Note Regarding Forward-Looking Statements</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt; background-color: white">We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to the registration
statement of which this prospectus is a part were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or
covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt; background-color: white">This
prospectus contains references to our trademarks, including&#160;<span style="background-color: white">Aethlon Medical, Inc.</span> and
Hemopurifier, and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus,
including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to
indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable
licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks
to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_003"></span>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights information
contained in other parts of this prospectus. Because it is only a summary, it does not contain all the information you should consider
before investing in shares of our common stock and it is qualified in its entirety by, and should be read in conjunction with, the more
detailed information appearing elsewhere in this prospectus. You should read all such documents carefully, especially the risk factors
included herein and incorporated by reference herein and our audited consolidated financial statements and the related notes incorporated
by reference herein, before deciding to buy shares of our common stock. Unless the context requires otherwise, references in this prospectus
to &#8220;Aethlon,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Aethlon Medical, Inc.
and our subsidiaries following the closing of the Merger (as defined below) on the closing date.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Overview and Corporate History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a medical therapeutic company
focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral
infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized
and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential
to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action
has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening
infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a &#8220;Breakthrough Device&#8221;
for two independent indications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Oncology</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe that the Hemopurifier
may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove
harmful remove harmful extracellular vesicles particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned
subsidiary in Australia to initially conduct oncology-related clinical research, then seek regulatory approval and commercialize our Hemopurifier
in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We completed an&#160;<i>in vitro</i>&#160;binding
study of extracellular vesicles from cancer patient samples, to provide pre-clinical evidence to support our trial design and translational
endpoints. Our study indicated positive results from this study, providing evidence that our Hemopurifier removes extracellular vesicles,
or EVs, from plasma. This translational study provides pre-clinical evidence to support our phase 1 safety, feasibility and dose-finding
clinical trials of our Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy
treatment, such as Keytruda&#174; or Opdivo&#174;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have launched in an Australia
safety, feasibility and dose-finding clinical trials of the Hemopurifier in cancer patients with solid tumors who have stable or progressive
disease during anti-PD-1 monotherapy treatment, such as Keytruda&#174; (pembrolizumab) or Opdivo&#174; (nivolumab). The primary endpoint
of the approximately nine to 18-patients, is safety. Exploratory analyses will be conducted to explore the number of HP treatments required
to produce sustained reductions of EVs as well as improve anti-tumor T cell activity. We plan to open a similarly designed trial in India.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following three hospitals
in Australia have received ethics committee approval, have gone through training on our device and are open for patient enrollment: Royal
Adelaide Hospital in Adelaide, Australia and Pindara Private Hospital in the Gold Coast section of Australia and GenesisCare North Shore
Hospital in Sydney, Australia. As of June 26, 2025, we have treated three participants in the first of the three treatment cohorts. Once
these patients have completed the pre-specified 7-day safety follow-up period, the data will be presented to an independent Data Safety
Monitoring Board (DSMB). The DSMB will provide a recommendation to Aethlon senior leadership on advancing to the next cohort where participants
will receive 2 HP treatments during the one week treatment period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 15, 2025, DSMB, overseeing
its ongoing clinical trial AEMD-2022-06, completed its scheduled safety review and recommended advancing to the next patient cohort without
modification. The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors
Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab", is being conducted to assess
the Hemopurifier's safety, feasibility, and optimal dosing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company continues to pursue
approval of a similar clinical trial in India. HREC approval has previously been obtained at Medanta Medicity Hospital. Following this
a meeting with Subject Expert Committee (SEC) of the India Regulatory Agency CDSCO was held June 5, 2025. Subsequently, ee received the
formal approval letter of the CDSCO. The clinical trial at Medanta can commence following a Site Initiation Visit (SIV) by the company&#8217;s
India CRO, Qualtran.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Life-Threatening Viral Infections</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also believe that the Hemopurifier
can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed
with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat
individuals infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, in vitro, the Hemopurifier
has been demonstrated to capture Ebola, Marburg virus, Zika, Lassa, MERS-CoV, Cytomegalovirus, Epstein-Barr, Herpes simplex, Chikungunya,
Dengue, West Nile, H1N1 swine flu, H5N1 bird flu, and the reconstructed 1918 Spanish flu virus. In several cases, these studies were conducted
in collaboration with leading government or non-government research institutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Hemopurifier has previously
been studied under FDA and international regulatory frameworks for the treatment of severe SARS-CoV-2 infection. While we terminated our
U.S. and India-based COVID-19 studies due to low ICU patient volume and shifting priorities, these programs demonstrated real-world use
of the Hemopurifier in critically ill patients. We maintain an open IDE for viral indications to preserve optionality for future outbreaks
or emergent pathogens.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have sufficient inventory of
Hemopurifiers to support our ongoing oncology trial in Australia as well as any near-term expansion of that study or potential trial activity
in India. While we have received FDA approval to begin manufacturing at our San Diego facility under our IDE supplement, we are still
awaiting FDA approval of a separate supplement to qualify an additional supplier of a key Hemopurifier component. We continue to work
with the FDA on this process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Pre-Clinical Exploration of Additional Clinical Uses for the Hemopurifier</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Aethlon R&amp;D laboratory
continues to explore potential new indications for the Hemopurifier. We have published in the peer-reviewed journal&#160;<i>Transplant
Immunology</i>&#160;the ability of the device to remove extracellular vesicles and their microRNA cargo from acellular perfusates of discarded
kidneys that had undergone normothermic machine perfusion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 12, 2025, the results of
our pre-clinical ex vivo study entitled &#8220;Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device
containing a Galanthus nivalis agglutinin (GNA) affinity resin&#8221; were published in the pre-print vehicle bioRxiv. This manuscript
has been submitted to a peer-reviewed publication for review.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Platelet-derived extracellular
vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The
cargo contained within these EVs have been noted to take part in damage to blood vessels, activation of immune cells and spread of tumor
cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases including cancer, lupus, systemic sclerosis, multiple sclerosis,
Alzheimer&#8217;s disease, sepsis, acute and Long COVID.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We hypothesized that the Aethlon
Hemopurifier which contains a propriety GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred
milliliters on donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The
study results showed a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment. The results of this
study support the current Australian Clinical Trial in Oncology as well as open the investigation of the Hemopurifier in many indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Extracellular vesicles have been
implicated in the pathogenesis of Long COVID. As we had previously demonstrated removal of extracellular vesicles by the Hemopurifier
in a patient with severe acute COVID-19 infection, we hypothesized that patients with Long COVID would have extracellular vesicles with
the mannose sugar on their surface that would bind to the affinity resin in our device. We partnered with investigators at the Univ of
California San Francisco Medical Center Long COVID clinic to obtain samples from participants with Long COVID as well as controls that
had had COVID -10 infection but had recovered. The data to be presented will review the binding of larger and smaller extracellular vesicles
to the GNA lectin and the lectin affinity resin, respectively. We believe the data from this pre-clinical study calls for additional study
of the Hemopurifier and look forward to receiving feedback from the Long COVID scientific community at the Keystone Symposium.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Successful outcomes of human trials
will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some
of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment
technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the foregoing,
we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts
in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors
on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy,
we are unable to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures
and the ongoing military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical
research will depend on future developments, as well as the economic impact on national and international markets that are highly uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 10, 1999, Aethlon, Inc.,
a California corporation, Hemex, Inc., a Delaware corporation and the accounting predecessor to Aethlon, Inc., and Bishop Equities, Inc.,
a publicly traded Nevada corporation, completed an Agreement and Plan of Reorganization structured to result in Bishop Equities, Inc.&#8217;s
acquisition of all of the outstanding common stock of Aethlon, Inc. and Hemex, Inc. Under the plan&#8217;s terms, Bishop Equities, Inc.
issued shares of its common stock to the stockholders of Aethlon, Inc. and Hemex, Inc. such that Bishop Equities, Inc. then owned 100%
of each company. Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon Medical, Inc. Our executive offices are
located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address
is www.aethlonmedical.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated
into, this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The Mechanism of Action (MOA) of the Hemopurifier</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Hemopurifier is a lectin-affinity
plasmapheresis extracorporeal device designed for the removal of harmful extracellular vesicles and life-threatening enveloped viruses
from the plasma component of the bloodstream. In the United States, the Hemopurifier is classified as a combination product whose regulatory
jurisdiction is the Center for Devices and Radiological Health, or CDRH, the branch of FDA responsible for the premarket approval of all
medical devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In our current applications, our
Hemopurifier can be used with approved dialysis machines serving as a blood pump. It could also potentially be developed as part of a
proprietary closed system with its own pump and tubing set, negating the requirement for dialysis infrastructure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>The Hemopurifier - Clinical Experience</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Hepatitis C and HIV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial clinical development
of the Hemopurifier focused on the viral infections Hepatitis C and HIV. Clinical trials conducted in India and a safety trial demonstrated
the removal of both viruses from the bloodstream with a benign safety profile. Prior to FDA approval of the IDE feasibility study, we
conducted investigational HCV treatment studies at the Apollo Hospital, Fortis Hospital, and the Medanta Medicity Institute in India.
In the Medanta Medicity Institute study, 12 HCV-infected individuals were enrolled to receive three six-hour Hemopurifier treatments during
the first three days of a 48-week peginterferon+ribavirin treatment regimen. The study was conducted under the leadership of Dr. Vijay
Kher. Dr. Kher&#8217;s staff reported that Hemopurifier therapy was well tolerated and without device-related adverse events in the 12
patients treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Of these 12 patients, ten completed
the Hemopurifier-peginterferon+ribavirin treatment protocol, including eight genotype-1 patients and two genotype-3 patients. Eight of
the ten patients achieved a sustained virologic response, which is the clinical definition of treatment cure and is defined as undetectable
HCV in the blood 24 weeks after the completion of the 48-week peginterferon+ribavirin drug regimen. Both genotype-3 patients achieved
a sustained virologic response, while six of the eight genotype-1 patients achieved a sustained virologic response, which defines a cure
of the infection. Our IDE safety study in end stage renal disease patients on dialysis who were infected with HCV was conducted at DaVita
MedCenter Dialysis in Houston, Texas. We reported that there were no device-related adverse events in enrolled subjects who met the study
inclusion-exclusion criteria. We also reported that an average capture of 154 million copies of HCV (in International Units, I.U.) within
the Hemopurifier during four-hour treatments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The initial clinical development
of the Hemopurifier was focused on the viral infections Hepatitis C and HIV. Clinical trials conducted in India and a safety trial demonstrated
the removal of both viruses from the bloodstream with a benign safety profile. Prior to FDA approval of the IDE feasibility study, we
conducted investigational HCV treatment studies at the Apollo Hospital, Fortis Hospital, and the Medanta Medicity Institute in India.
In the Medanta Medicity Institute study, 12 HCV-infected individuals were enrolled to receive three six-hour Hemopurifier treatments during
the first three days of a 48-week peginterferon+ribavirin treatment regimen. The study was conducted under the leadership of Dr. Vijay
Kher. Dr. Kher&#8217;s staff reported that Hemopurifier therapy was well tolerated and without device-related adverse events in the 12
treated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Of these 12 patients, ten completed
the Hemopurifier-peginterferon+ribavirin treatment protocol, including eight genotype-1 patients and two genotype-3 patients. Eight of
the ten patients achieved a sustained virologic response, which is the clinical definition of treatment cure and is defined as undetectable
HCV in the blood 24 weeks after the completion of the 48-week peginterferon+ribavirin drug regimen. Both genotype-3 patients achieved
a sustained virologic response, while six of the eight genotype-1 patients achieved a sustained virologic response, which defines a cure
of the infection. Our IDE safety study in end stage renal disease patients on dialysis who were infected with HCV was conducted at DaVita
MedCenter Dialysis in Houston, Texas. We reported that there were no device-related adverse events in enrolled subjects who met the study
inclusion-exclusion criteria. We also reported that an average capture of 154 million copies of HCV (in International Units, I.U.) within
the Hemopurifier during four-hour treatments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to treating Ebola
and HCV-infected individuals, we also conducted a single proof-of-principle treatment study at the Sigma New Life Hospital in an AIDS
patient who was not being administered HIV antiviral drugs. In the study, viral load was reduced by 93% as the result of 12 Hemopurifier
treatments (each four hours in duration) that were administered over the course of one month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">With the advent of highly effective
anti-retroviral drugs for HIV (HAART), and curative direct acting antivirals (DACs) for Hepatitis C, clinical development for these indications
was abandoned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Ebola Virus-Single Patient Emergency Use</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Emergency use conditions
a single patient with Ebola infection with multiple organ dysfunction was treated with the Hemopurifier at Frankfurt University Hospital
in Germany. The patient tolerated a single 6.5-hour Hemopurifier treatment. Prior to treatment, the Ebola viral load was measured at 400,000
copies/ml. The post-treatment viral load was 1,000 copies/ml. Calculations by the treating physician indicated that 242 million copies
of Ebola virus were captured within the Hemopurifier during treatment. The patient made a full recovery. Based on this experience, the
Company filed an Expanded Access protocol with the FDA to treat Ebola virus infected patients in up to ten centers in the United States
and a corresponding protocol was approved by HealthCanada. These protocols remain open, allowing Hemopurifier treatment to be offered
to patients presenting for care in both countries. In 2018, the FDA designated the Hemopurifier as a Breakthrough Device &#8220;&#8230;
for the treatment of life-threatening viruses that are not addressed with approved therapies.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Severe Acute SARS-CoV-2/COVID-19</b>&#160;<b>Infection&#160;</b>&#8211;
Emergency Use and Clinical Trials</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SARS-COV-2, the causative agent
of COVID-19 is a member of the coronavirus family, which includes the original SARS virus, SARS-CoV, and the MERS virus. SARS-CoV-2, found
to contain mannose on the envelope surface. This suggests that the Hemopurifier could potentially clear it from biological fluids, including
blood.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under Single Patient Emergency
Use regulations, we have treated two patients with COVID-19 with the Hemopurifier. We published a manuscript reviewing case studies covering
those two Single Patient Emergency Use treatments entitled &#8220;Removal of COVID-19 Spike Protein, Whole Virus, Exosomes and Exosomal
microRNAs by the Hemopurifier&#174; Lectin-Affinity Cartridge in Critically Ill Patients with COVID-19 Infection&#8221; in the peer-reviewed
journal Frontiers in Medicine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The manuscript described the use
of the Hemopurifier for a total of nine sessions in two critically ill COVID-19 patients. The first case study demonstrated the improvement
in the patient who was a SARS-COV-2 positive COVID-19 present at entry to the hospital, with associated coagulopathy, or CAC, lung injury,
inflammation, and tissue injury despite the absence of demonstrable COVID-19 viremia at the start of treatment at Day 22.This patient
received eight Hemopurifier treatments without complications and eventually was weaned from a ventilator and was discharged from the hospital.
Plasma samples from this patient revealed a decrease in extracellular vesicle counts over the course of the eight treatments and decreases
in exosomal microRNAs associated with the development of coagulopathy and acute lung injury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The second patient case study
demonstrated in vivo removal of SARS-CoV-2 virus from the blood stream of an infected patient. This patient completed a six-hour Hemopurifier
treatment without complications and subsequently was placed on continuous renal replacement therapy, or CRRT. The patient ultimately expired
three hours after being placed on CRRT because of the advanced stage of the patient&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 17, 2020, the FDA approved
a supplement to our open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19
in a New Feasibility Study.&#160;<span style="background-color: white">That study was designed to enroll up to 40 subjects at up to 20
centers in the United States. Subjects had to have an established laboratory diagnosis of COVID-19, be admitted to an ICU, and have acute
lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study, in addition to safety, include
reduction in circulating virus, as well as clinical outcomes (NCT # 04595903). In June 2022, the Company completed the treatment protocol
for its first patient in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">In
June 2022, the Company completed the treatment protocol of the only participant enrolled in the study. study. The patient received one
HP treatment daily for 4 days. This patient died following cardiac arrest (not related to the HP treatment) as a consequence of severe
COVID-19 pneumonia. Blood samples taken from the patient did not reveal any evidence of viremia. Plasma sent for cytokine analysis revealed
a</span>&#160;numeric decrease in the levels of IP-10, MCP-1, and IL-10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A similarly designed trial was
also conducted in India. One patient was enrolled on February 16, 2022, at Medanta Medicity Hospital, Gurugram, Haryana 12200, India.
The patient tolerated one HP treatment daily for three days. On 19 February 2022, in the first 15 min during the 3rd treatment, one nonserious
Grade 2 AE was reported (hemolysis and leaking of the filter). The filter was replaced, and therapy resumed without sequalae. On Day #4
the patient suffered asystole and died due to clinical deterioration unrelated to the device. During the first Hemopurifier treatment
(T1) there was a gradual decrease in viral load from the baseline at 4923 copies/mL decreasing steadily to 1307 copies/mL over five hours,
indicating a 73% reduction from baseline. At the beginning of the second Hemopurifier treatment (T2), the viral load was 850 copies/mL,
dropped below the lower limit of quantification within an hour, and remained undetectable, suggesting rapid clearance. The viral load
before the third treatment (T3) was below the quantification limit but unexpectedly rose at 3 hours (636 copies/mL), peaking at 4 hours
(1583 copies/mL), and slightly decreasing at 5 hours (1104 copies/mL). This irregular pattern suggests possible delayed RNA release, sample
variability, or another biological factor affecting detection. The cumulative data shows a reduced SARs-CoV-2 viral load during the first
two Hemopurifier treatments but not during the third treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to lack of eligible patients
in the ICU the clinical trial was closed as of November 22, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Oncology- U.S. Clinical Trial in Head and Neck
Cancer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A single center clinical trial
entitled &#8220;Depleting Exosomes to Improve Response to Immune Therapy in Head and Neck Squamous Cell Cancer: An Early Feasibility Phase
I Clinical Trial&#8221; was conducted under a US IDE at the University of Pittsburgh. This was a single arm Phase 1 clinical trial designed
to evaluate the safety and efficacy of the Hemopurifier plus pembrolizumab for the treatment of patients with recurrent or metastatic
head and neck squamous cell cancer. All patients were treated with pembrolizumab every 21 days as standard of care. The patients were
to receive a 4-hour Hemopurifier treatment before Pembrolizumab infusions 2 occasions 21 days apart. A total of 2 patients were enrolled
in the study with the first occurring on Dec 14, 2020. The first patients received 2 HP treatments, and the second patient received one
HP treatment. The second treatment in the second patient was terminated due to operator error. Eighteen no serious adverse events occurred
in the two patients with none thought related to the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The only exploratory efficacy
laboratory analysis that was performed in this study was a determination of the total nanoparticle concentrations in the 1st patient prior
to and for 14 days after the second HP treatment. Total nanoparticle concentrations decreased following each Hemopurifier treatment. Following
Hemopurifier treatment, the total nanoparticle concentrations rose by about Day 7 but did not reach the baseline levels. Exosomes levels
are a component of the total nanoparticle concentration but exosome levels over time were not specifically determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Research and Development Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A substantial portion of our operating
budget is used for research and development activities. The cost of research and development, all of which has been charged to operations,
amounted to approximately $2,212,000 and $2,520,000 in the fiscal years ended March 31, 2025 and 2024, respectively. For the three-month
periods ended June 30, 2025 and 2024, research as development expenses were $524,368 and $414,658, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June 25, 2025, the Company received notice&#160;</span>from Nasdaq stating the Company has regained compliance with Listing Rule 5550(a)(2),
and that the matter is now closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Reverse
Split &#8211; Following the approval of a reverse stock split at a Special Meeting of Stockholders on May 13, 2025, our Board of Directors
approved a 1-for-8 reverse stock split of our outstanding shares of Common Stock, effective as of the close of business on June 6, 2025
with an effective trading date of June 9, 2025. Accordingly, each eight shares of outstanding common stock held by stockholders were combined
into one share of common stock. Our authorized common stock remained at 60,000,000 shares following the stock split. We issued an additional
77 shares as a result of rounding up fractional shares related to the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
June 2, 2025</span>&#160;a second patient was treated with the Hemopurifier at GenesisCare North Shore Hospital in Sydney, Australia.
The patient was treated with the Aethlon Hemopurifier for 4 hours in a single day and tolerated the procedure without complications. The
patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently own or have license
rights to a number of U.S. and foreign patents and patent applications and endeavor to continually improve our intellectual property position.
We consider the protection of our technology, whether owned or licensed, to the exclusion of use by others, to be vital to our business.
While we intend to focus primarily on patented or patentable technology, we also rely on trade secrets, unpatented property, know-how,
regulatory exclusivity, patent extensions and continuing technological innovation to develop our competitive position. We also own certain
trademarks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success depends in large part
on our ability to protect our proprietary technology, including the Hemopurifier product platform, and to operate without infringing the
proprietary rights of third parties. We rely on a combination of patent, trade secret, copyright and trademark laws, as well as confidentiality
agreements, licensing agreements and other agreements, to establish and protect our proprietary rights. Our success also depends, in part,
on our ability to avoid infringing patents issued to others. If we were judicially determined to be infringing on any third-party patent,
we could be required to pay damages, alter our products or processes, obtain licenses or cease sales of products or certain activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To protect our proprietary medical
technologies, including the Hemopurifier product platform and other scientific discoveries, we have a portfolio of over 32 issued patents
and pending applications worldwide. We currently have three issued U.S. patents and 14 issued patents in countries outside of the United
States. In addition, we have 15 patent applications pending worldwide related to our Hemopurifier product platform and other technologies.
We are seeking additional patents on our scientific discoveries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">It is possible that our pending
patent applications may not result in issued patents, that we will not develop additional proprietary products that are patentable, that
any patents issued to us may not provide us with competitive advantages or will be challenged by third parties and that the patents of
others may prevent the commercialization of products incorporating our technology. Furthermore, others may independently develop similar
products, duplicate our products or design around our patents. U.S. patent applications are not immediately made public, so it is possible
that a third party may obtain a patent on a technology we are actively using.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is a risk that any patent
applications that we file and any patents that we hold or later obtain could be challenged by third parties and declared invalid or unenforceable.
For many of our pending applications, patent interference proceedings may be instituted with the U.S. Patent and Trademark Office, or
the USPTO, when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity
of an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled
to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings,
and the USPTO&#8217;s decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent
applications, we may experience significant expenses and delays in obtaining a patent, and if the outcome of the proceeding is unfavorable
to us, the patent could be issued to a competitor rather than to us.&#160;Third parties can file post-grant proceedings in the USPTO,
seeking to have issued patent invalidated, within nine months of issuance. This means that patents undergoing post-grant proceedings may
be lost, or some or all claims may require amendment or cancellation, if the outcome of the proceedings is unfavorable to us. Post-grant
proceedings are complex and could result in a reduction or loss of patent rights. The institution of post-grant proceedings against our
patents could also result in significant expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patent law outside the United
States is uncertain and in many countries, is currently undergoing review and revisions. The laws of some countries may not protect our
proprietary rights to the same extent as the laws of the United States. Third parties may attempt to oppose the issuance of patents to
us in foreign countries by initiating opposition proceedings. Opposition proceedings against any of our patent filings in a foreign country
could have an adverse effect on our corresponding patents that are issued or pending in the United States. It may be necessary or useful
for us to participate in proceedings to determine the validity of our patents or our competitors&#8217; patents that have been issued
in countries other than the United States. This could result in substantial costs, divert our efforts and attention from other aspects
of our business, and could have a material adverse effect on our results of operations and financial condition. Outside of the United
States, we currently have pending patent applications or issued patents in Europe, India, Russia, Canada, Japan, Singapore and Hong Kong.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to patent protection,
we rely on unpatented trade secrets and proprietary technological expertise. It is possible that others could independently develop or
otherwise acquire substantially equivalent technology, somehow gain access to our trade secrets and proprietary technological expertise
or disclose such trade secrets, or that we may not successfully ultimately protect our rights to such unpatented trade secrets and proprietary
technological expertise. We rely, in part, on confidentiality agreements with our marketing partners, employees, advisors, vendors and
consultants to protect our trade secrets and proprietary technological expertise. We cannot assure you that these agreements will not
be breached, that we will have adequate remedies for any breach or that our unpatented trade secrets and proprietary technological expertise
will not otherwise become known or be independently discovered by competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Patents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table lists our
issued patents and patent applications, including their ownership status, including relevant patent term adjustments (PTA), which is a
process of extending the term of a U.S. patent:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Patents Issued in the United States</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PATENT #</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PATENT NAME</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 15%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>ISSUANCE</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>DATE</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 15%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>OWNED OR</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>LICENSED</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 30%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>EXPIRATION</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>DATE</b></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,707,333</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/18/17</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/6/29</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,364,601</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/14/16</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/30/29</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,288,172</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/16/12</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27<br/>
<br/>
05/30/29 (with 813 days Patent Term Adjustment (PTA))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Patent Applications Pending in the United States</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION #</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION NAME</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 12%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>FILING</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>DATE</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 13%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>OWNED OR</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>LICENSED</b></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17/918,085</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/10/22</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18/700571</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a viral infection and symptoms thereof</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/11/24</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Foreign Patents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PATENT #</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PATENT NAME</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 12%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>ISSUANCE</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>DATE</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>OWNED OR</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>LICENSED</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 12%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>EXPIRATION</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>DATE</b></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>60 2011 035 500.7</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for quantifying exosomes (Germany)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/01/17</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/07/31</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2591359</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for quantifying exosomes (France)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/01/17</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/07/31</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2591359</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for quantifying exosomes (Great Britain)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/01/17</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/07/31</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11804372</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Methods for quantifying exosomes (Spain)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/01/17</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/07/31</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2644855</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Canada)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/19/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>502019000055563</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Germany)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1993600</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Switzerland)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1993600</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Spain)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1993600</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (France)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1993600</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Great Britain)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>502019000055563</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Italy)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1993600</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Netherlands)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1993600</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Sweden)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/24/19</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1126138</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (Hong Kong)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/19/20</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/09/27</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Pending Foreign Patent Applications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION #</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION NAME</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FILING<br/>
DATE</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OWNED<br/>
OR<br/>
LICENSED</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8139/DELNP/2008</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal removal of microvesicular particles (exosomes) (India)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3/9/07</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021256402</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof (Australia)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10/16/22</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3178687</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof (Canada)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9/29/22</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21788894.0</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof (Europe)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10/26/22</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>62023077768.7</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof (Hong Kong)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>08/17/23</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>297109</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof (Israel)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10/6/22</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023-505809</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a coronavirus infection and symptoms thereof (Japan)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10/12/22</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022361924</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a viral infection and symptoms thereof (Australia)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>04/12/24</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024-522200</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a viral infection and symptoms thereof (Japan)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>04/12/24</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3235306</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a viral infection and symptoms thereof (Canada)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4/11/2024</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22881946.2</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a viral infection and symptoms thereof (Europe)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4/23/2024</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>62025103640</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices and methods for treating a viral infection and symptoms thereof (Hong Kong)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2/18/2025</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Pending International Patent Applications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION #</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION NAME</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 12%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FILING</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DATE</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OWNED OR</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LICENSED</b></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PCT/US2024/015614</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal of exosomes, ectosomes, mirnas, circulating nucleic acids, and viral particles with</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2/13/24</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Trademarks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPLICATION NAME</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Countries</b></span></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Priority Date</b></span></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OWNED OR LICENSED</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*SANSAGITTA</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Madrid, Australia, Canada, the EU, UK, and India</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/8/2021</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>*&#160;</b>The US Application for SANSAGITTA abandoned
on 12/2/24. It was used as the basis application for a Madrid registration, and the corresponding above-listed designated country registrations
can be converted to national applications to avoid abandonment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Trademarks</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the Tausome, Sansagitta
and Hemosagitta trademarks noted in the above table, we also have trademark registrations in the United States for Hemopurifier and Aethlon
Medical, Inc., and obtained a trademark registration in India for Hemopurifier. We also have common law trademark rights in Aethlon ADAPT&#8482;
and ELLSA&#8482;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Industry &amp; Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The industry for treating infectious
disease and cancer is extremely competitive, and companies developing new treatment procedures face significant capital and regulatory
challenges. As our Hemopurifier is a clinical-stage device, we have the additional challenge of establishing medical industry support,
which will be driven by treatment data resulting from human clinical studies. Should our device become market cleared by the FDA or the
regulatory body of another country, we may face significant competition from well-funded pharmaceutical organizations. Additionally, we
would likely need to establish large-scale production of our device in order to be competitive. Our competitors include blood filters
produced by ExThera Medical Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Hemopurifier is subject to
regulation by numerous regulatory bodies, primarily the FDA, and comparable international regulatory agencies. These agencies require
manufacturers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, labeling,
marketing, storage, distribution, advertising and promotion, and post-marketing surveillance reporting of medical devices. As the primary
mode of action of the Hemopurifier is attributable to the device component of this combination product, the CDRH has primary jurisdiction
over its premarket development, review and approval. Failure to comply with applicable requirements may subject a device and/or its manufacturer
to a variety of administrative sanctions, such as issuance of warning letters, import detentions, civil monetary penalties and/or judicial
sanctions, such as product seizures, injunctions and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>FDA&#8217;s Pre-market Clearance and Approval
Requirements &#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each medical device we seek to
commercially distribute in the United States will require either a prior 510(k) clearance, unless it is exempt, or a pre-market approval
from the FDA. Generally, if a new device has a predicate that is already on the market under a 510(k) clearance, the FDA will allow that
new device to be marketed under a 510(k) clearance; otherwise, a premarket approval, or PMA, is required. Medical devices are classified
into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III&#8212;depending on the degree of risk associated with each
medical device and the extent of control needed to provide reasonable assurance of safety and effectiveness. Class&#160;I devices are
deemed to be low risk and are subject to the general controls of the Federal Food, Drug and Cosmetic Act, such as provisions that relate
to: adulteration; misbranding; registration and listing; notification, including repair, replacement, or refund; records and reports;
and good manufacturing practices. Most Class&#160;I devices are classified as exempt from pre-market notification under section 510(k)
of the FD&amp;C Act, and therefore may be commercially distributed without obtaining 510(k) clearance from the FDA. Class&#160;II devices
are subject to both general controls and special controls to provide reasonable assurance of safety and effectiveness. Special controls
include performance standards, post market surveillance, patient registries and guidance documents. A manufacturer may be required to
submit to the FDA a pre-market notification requesting permission to commercially distribute some Class&#160;II devices. Devices deemed
by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially
equivalent to a previously cleared 510(k) device, are placed in Class&#160;III. A Class&#160;III device cannot be marketed in the United
States unless the FDA approves the device after submission of a PMA. However, there are some Class&#160;III devices for which FDA has
not yet called for a PMA. For these devices, the manufacturer must submit a pre-market notification and obtain 510(k) clearance in orders
to commercially distribute these devices. The FDA can also impose sales, marketing or other restrictions on devices in order to assure
that they are used in a safe and effective manner. We believe that the Hemopurifier will be classified as a Class III device and as such
will be subject to PMA submission and approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Pre-market Approval Pathway</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A pre-market approval application
must be submitted to the FDA for Class&#160;III devices for which the FDA has required a PMA. The pre-market approval application process
is much more demanding than the 510(k) pre-market notification process. A pre-market approval application must be supported by extensive
data, including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s
satisfaction reasonable evidence of safety and effectiveness of the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After a pre-market approval application
is submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive review and thus
whether the FDA will file the application for review. The FDA has 180 days to review a filed pre-market approval application, although
the review of an application generally occurs over a significantly longer period of time and can take up to several years. During this
review period, the FDA may request additional information or clarification of the information already provided. Also, an advisory panel
of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the
approvability of the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although the FDA is not bound
by the advisory panel decision, the panel&#8217;s recommendations are important to the FDA&#8217;s overall decision making process. In
addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System Regulation,
or QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA&#8217;s regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon completion of the PMA review,
the FDA may: (i)&#160;approve the PMA which authorizes commercial marketing with specific prescribing information for one or more indications,
which can be more limited than those originally sought; (ii)&#160;issue an approvable letter which indicates the FDA&#8217;s belief that
the PMA is approvable and states what additional information the FDA requires, or the post-approval commitments that must be agreed to
prior to approval; (iii)&#160;issue a not approvable letter which outlines steps required for approval, but which are typically more onerous
than those in an approvable letter, and may require additional clinical trials that are often expensive and time consuming and can delay
approval for months or even years; or (iv)&#160;deny the application. If the FDA issues an approvable or not approvable letter, the applicant
has 180 days to respond, after which the FDA&#8217;s review clock is reset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Emergency Use Authorizations,
or EUAs, are granted by FDA in public health emergencies but allow use of the authorized device only during the period of the respective
public health emergency, and do not change the requirement to ultimately seek PMA approval after the authorization period has ended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Clinical Trials</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Clinical trials are almost always
required to support pre-market approval and are sometimes required for 510(k) clearance. In the United States, for significant risk devices,
these trials require submission of an application for an IDE to the FDA. The IDE application must be supported by appropriate data, such
as animal and laboratory testing results, showing it is safe to test the device in humans and that the testing protocol is scientifically
sound. The IDE must be approved in advance by the FDA for a specific number of patients at specified study sites. During the trial, the
sponsor must comply with the FDA&#8217;s IDE requirements for investigator selection, trial monitoring, reporting and recordkeeping. The
investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition
of investigational devices and comply with all reporting and recordkeeping requirements. Clinical trials for significant risk devices
may not begin until the IDE application is approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinical
trial sites. An IRB is an appropriately constituted group that has been formally designated to review and monitor medical research involving
subjects and which has the authority to approve, require modifications in, or disapprove research to protect the rights, safety and welfare
of human research subjects. The FDA or the IRB at each site at which a clinical trial is being performed may withdraw approval of a clinical
trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits or a failure to comply
with FDA or IRB requirements. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and effectiveness
of the device, may be equivocal or may otherwise not be sufficient to obtain approval or clearance of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Ongoing Regulation by the FDA</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even after a device receives clearance
or approval and is placed on the market, numerous regulatory requirements apply. Even after a device receives clearance or approval and
is placed on the market, numerous regulatory requirements apply. These include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishment registration and device listing;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling regulations and the FDA prohibitions against the promotion of products for uncleared, unapproved or &#8220;off-label&#8221; uses and other requirements related to promotional activities;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">medical device reporting regulations, which require that manufactures report to the FDA if their device may have caused or contributed to a death or serious injury, or if their device malfunctioned and the device or a similar device marketed by the manufacturer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">corrections and removal reporting regulations, which require that manufactures report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the FDCA that may present a risk to health; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post market surveillance regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Some changes to an approved PMA
device, including changes in indications, labeling or manufacturing processes or facilities, require submission and FDA approval of a
new PMA or PMA supplement, as appropriate, before the change can be implemented. Supplements to a PMA often require the submission of
the same type of information required for an original PMA, except that the supplement is generally limited to that information needed
to support the proposed change from the device covered by the original PMA. The FDA uses the same procedures and actions in reviewing
PMA supplements as it does in reviewing original PMAs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Failure by us or by our suppliers
to comply with applicable regulatory requirements can result in enforcement action by the FDA or state authorities, which may include
any of the following sanctions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning or untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications, voluntary or mandatory recall or seizure of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions, partial suspension or total shutdown of production;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay in processing submissions or applications for new products or modifications to existing products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing approvals that have already been granted; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Medical Device Reporting laws
and regulations require us to provide information to the FDA when we receive or otherwise become aware of information that reasonably
suggests our device may have caused or contributed to a death or serious injury as well as a device malfunction that likely would cause
or contribute to death or serious injury if the malfunction were to recur. In addition, the FDA prohibits an approved device from being
marketed for off-label use. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label
uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial
monetary penalties and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Newly discovered or developed
safety or effectiveness data may require changes to a product&#8217;s labeling, including the addition of new warnings and contraindications,
and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting
from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory clearance or
approval of our products under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Healthcare Regulation</i>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to the FDA&#8217;s
restrictions on marketing of pharmaceutical products, the U.S. healthcare laws and regulations that may affect our ability to operate
include: the federal fraud and abuse laws, including the federal anti-kickback and false claims laws; federal data privacy and security
laws; and federal transparency laws related to payments and/or other transfers of value made to physicians (defined to include doctors,
dentists, optometrists, podiatrists and chiropractors) and other healthcare professionals (such as physicians assistants and nurse practitioners)
and teaching hospitals. Many states have similar laws and regulations that may differ from each other and federal law in significant ways,
thus complicating compliance efforts. For example, states have anti-kickback and false claims laws that may be broader in scope than analogous
federal laws and may apply regardless of payor. In addition, state data privacy laws that protect the security of health information may
differ from each other and may not be preempted by federal law. Moreover, several states have enacted legislation requiring pharmaceutical
manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public
disclosures on sales and marketing activities, report information related to drug pricing, require the registration of sales representatives,
and prohibit certain other sales and marketing practices. These laws may adversely affect our sales, marketing and other activities with
respect to any product candidate for which we receive approval to market in the United States by imposing administrative and compliance
burdens on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because of the breadth of these
laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities,
particularly any sales and marketing activities after a product candidate has been approved for marketing in the United States, could
be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal and state
laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative
penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs,
additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations
of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability
to operate our business and our results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture
and marketing of regulated products or the reimbursement thereof. For example, in the United States, the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, among other things, reduced and/or
limited Medicare reimbursement to certain providers and imposed an annual excise tax of 2.3% on any entity that manufactures or imports
medical devices offered for sale in the United States, with limited exceptions. However, the 2020 federal spending package permanently
eliminated, effective January 1, 2020, this ACA-mandated medical device tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge
on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed
by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other
things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The
IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary
maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or
congressional challenges in the future. It is unclear how such challenges and any additional healthcare reform measures will impact the
ACA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other legislative changes have
been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, as amended by subsequent legislation, further reduces
Medicare&#8217;s payments to providers by two percent through fiscal year 2032. These reductions may reduce providers&#8217; revenues
or profits, which could affect their ability to purchase new technologies. Furthermore, the healthcare industry in the United States has
experienced a trend toward cost containment as government and private insurers seek to control healthcare costs by imposing lower payment
rates and negotiating reduced contract rates with service providers. In July 2021, the Biden Administration released an executive order,
&#8220;Promoting Competition in the American Economy,&#8221; which contained provisions relating to prescription drugs. On September 9,
2021, in response to this executive order, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for
Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies
that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Further, the IRA, among
other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare
and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions
will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. HHS has and will continue
to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but is likely
to have a significant impact on the pharmaceutical industry. In addition, in response to the Biden administration&#8217;s October 2022
executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid
Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It
is unclear whether the models will be utilized in any health reform measures in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Legislation could be adopted in
the future that limits payments for our products from governmental payors. In addition, commercial payors such as insurance companies
could adopt similar policies that limit reimbursement for medical device manufacturers&#8217; products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Coverage and Reimbursement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In both the U.S. and international
markets, the use of medical devices is dependent in part on the availability of reimbursement from third-party payors, such as government
and private insurance plans. Healthcare providers that use medical devices generally rely on third-party payors to pay for all or part
of the costs and fees associated with the medical procedures being performed or to compensate them for their patient care services. Should
our Hemopurifier or any other products under development be approved for commercialization by the FDA, any such products may not be considered
cost-effective, reimbursement may not be available in the United States or other countries, if approved, and reimbursement may not be
sufficient to allow sales of our future products on a profitable basis. The coverage decisions of third-party payors will be significantly
influenced by the assessment of our future products by health technology assessment bodies. If approved for use in the United States,
we expect that any products that we develop, including the Hemopurifier, will be purchased primarily by medical institutions, which will
in turn bill various third-party payors for the health care services provided to patients at their facility. Payors may include the Centers
for Medicare &amp; Medicaid Services, or CMS, which administers the Medicare program and works in partnership with state governments to
administer Medicaid, other government programs and private insurance plans. The process involved in applying for coverage and reimbursement
from CMS is lengthy and expensive. Further, Medicare coverage is based on our ability to demonstrate that the treatment is &#8220;reasonable
and necessary&#8221; for Medicare beneficiaries. Even if products utilizing our Hemopurifier technology receive FDA and other regulatory
clearance or approval, they may not be granted coverage and reimbursement by any payor, including by CMS. Many private payors use coverage
decisions and payment amounts determined by CMS as guidelines in setting their coverage and reimbursement policies and amounts. However,
no uniform policy for coverage and reimbursement for medical devices exists among third-party payors in the United States. Therefore,
coverage and reimbursement can differ significantly from payor to payor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Manufacturing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Historically, manufacturing of
our Hemopurifier occurred in collaboration with a contract manufacturer based in California under current Good Manufacturing Practice,
or cGMP, regulations promulgated by the FDA.&#160;Our contract manufacturer is registered with the FDA. To date, our manufacture of the
Hemopurifier has been limited to quantities necessary to support our clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In May 2024, the FDA approved the use of our own manufacturing
facility to manufacture Hemopurifiers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our costs of compliance with federal, state and local
environmental laws have been immaterial to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Sources and Availability of Raw&#160;Materials&#160;and the Names of
Principal Suppliers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Aethlon personnel assemble the
various components of the Hemopurifier with materials from our various suppliers, which are purchased and released by Aethlon. Specifically,
the Hemopurifier contains three critical components with limited available suppliers. The GNA lectin is sourced from Vector Laboratories
Inc. and also is available from other suppliers. Our intended transition from Vector Laboratories to a new supplier for GNA is delayed
as we work with the FDA for approval of our supplement to our IDE, which is required to make this manufacturing change. The base cartridge
on which the Hemopurifier is constructed is sourced from Medica S.p.A and we are dependent on the continued availability of these cartridges.
Although there are other suppliers, the process of qualifying a new supplier takes time and regulatory approvals must be obtained. We
currently purchase the diatomaceous earth from Janus Scientific, Inc., as the distributor; however, the product is manufactured by Imerys
Minerals Ltd. There potentially are other suppliers of this product, but as with the cartridges, qualifying and obtaining required regulatory
approvals takes time and resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Sales and Marketing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not currently have any sales
and marketing capability. With respect to commercialization efforts in the future, we intend to build or contract for distribution, sales
and marketing capabilities for any product candidate that is approved. From time to time, we have had and are having strategic discussions
with potential collaboration partners for our product candidates, although no assurance can be given that we will be able to enter into
one or more collaboration agreements for our product candidates on acceptable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Product Liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The risk of product liability
claims, product recalls and associated adverse publicity is inherent in the testing, manufacturing, marketing and sale of medical products.
We have limited clinical trial liability insurance coverage. It is possible that future insurance coverage may not be adequate or available.
We may not be able to secure product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liability
for mandatory damages could exceed the amount of our coverage. A successful product liability claim against us could require us to pay
a substantial monetary award. Moreover, a product recall could generate substantial negative publicity about our products and business
and inhibit or prevent commercialization of other future product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of August 18, 2025, we had 9 full-time employees
and no part-time employees. All of our employees are located in the United States. We do intend to hire additional employees. We utilize,
whenever appropriate, consultants in order to conserve cash and resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We believe our employee relations
are good. None of our employees are represented by a labor union or are subject to collective-bargaining agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Summary Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 13.5pt; background-color: white"><i>Investing
in our securities involves a high degree of risk. You should consider carefully the risks described below, together with all of the other
information included or incorporated by reference in this prospectus, including the risks and uncertainties discussed under &#8220;Risk
Factors&#8221; in our Annual Report on Form 10-K for the year ended March&#160;31, 2025, which has been filed with the SEC and is incorporated
by reference in this prospectus, as well as any updates thereto contained in subsequent filings with the SEC or any free writing prospectus,
before deciding whether to purchase our securities in this offering. All of these risk factors are incorporated herein in their entirety.
The risks described below and incorporated by reference are material risks currently known, expected or reasonably foreseeable by us.
However, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently
deem immaterial may also affect our business, operating results, prospects or financial condition. If any of these risks actually materialize,
our business, prospects, financial condition, and results of operations could be seriously harmed. This could cause the trading price
of our common stock and the value of the warrants to decline, resulting in a loss of all or part of your investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Relating to Our Financial Position and Need
for Additional Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a history of significant operating losses and expect continued losses for the foreseeable future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have no revenue streams and may not obtain future government contracts or grants.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is substantial doubt about our ability to continue operations for 12 months following our most recent financial statements.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to raise capital via equity markets, but there is no assurance of success.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional financing is essential for operations, clinical trials, regulatory approvals, and product development.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity or convertible debt financing may significantly dilute existing stockholders and impact control.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External economic factors, including inflation and market volatility, may impair our ability to raise capital.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our status as a going concern is uncertain, which could harm our share price, credibility, and commercial relationships.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inability to continue as a going concern may lead to drastic cost-cutting or even ceasing operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee morale, key personnel retention, and vendor relationships may be adversely affected by going concern doubts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Securities and the Inducement
Offering and Company Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company Offering is on a best-efforts basis with no minimum; we may raise less capital than needed.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors may experience immediate and substantial dilution in the value of their shares upon purchase.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further dilution could occur from future option, warrant, or stock issuances.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have broad discretion in how we use offering proceeds, which may be used ineffectively.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future sales or the perception of sales of our common stock could depress our stock price.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant holders have no stockholder rights until exercise and may not realize value if our stock price stays low.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No public market exists for the offered warrants or pre-funded warrants, limiting their liquidity and value.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive meaningful funds upon the exercise of pre-funded warrants.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded warrants are subject to beneficial ownership limits, potentially preventing holders from exercising when it is financially advantageous.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
6, 2025, the Company completed a reverse split of its outstanding shares of common stock at a ratio of 1-for-8. In connection with the
reverse stock split, every 8 shares of the Company&#8217;s issued and outstanding common stock was automatically converted into one share
of the Company&#8217;s common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. All
common stock amounts and prices in this Offering Circular reflect the consummation of the reverse split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On March
10, 1999, Aethlon, Inc., a California corporation, Hemex, Inc., a Delaware corporation and the accounting predecessor to Aethlon, Inc.,
and Bishop Equities, Inc., a publicly traded Nevada corporation, completed an Agreement and Plan of Reorganization structured to result
in Bishop Equities, Inc.&#8217;s acquisition of all of the outstanding common stock of Aethlon, Inc. and Hemex, Inc. Under the plan&#8217;s
terms, Bishop Equities, Inc. issued shares of its common stock to the stockholders of Aethlon, Inc. and Hemex, Inc. such that Bishop Equities,
Inc. then owned 100% of each company. Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon Medical, Inc. Our
executive offices are located at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360.
Our website address is www.aethlonmedical.com. The information contained on, or that can be accessed through, our website is not part
of, and is not incorporated into, this prospectus, and you should not rely on any such information in making the decision of whether to
purchase our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Smaller Reporting Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We are
a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_004"></span>The Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock offered by the Selling Securityholders</span></td>
    <td style="vertical-align: bottom; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 1,550,000 shares of common stock issuable upon exercise of the Inducement Warrants.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock offered by us</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded warrants</span></td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We are also offering to those
    purchasers, if any, whose purchase of common stock in the Company Offering would otherwise result in such purchaser, together with its
    affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the
    consummation of this offering, the opportunity, in lieu of purchasing common stock, to purchase pre-funded warrants to purchase up to
    [__] shares of our common stock. For each pre-funded&#160;warrant we sell, the number of shares of common stock we are offering will be
    decreased on a&#160;one-for-one basis. The purchase price of each&#160;pre-funded&#160;warrant will equal the price per share at which
    the shares of common stock and accompanying warrants to purchase common stock are being sold to the public in the Company Offering, minus
    $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share of common stock.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each pre-funded warrant will be exercisable
    immediately upon issuance and will not expire. This prospectus also relates to the offering of the shares of common stock issuable
    upon exercise of such pre-funded warrants. See &#8220;<a href="#s1_022">Description of the Securities We are Offering
    &#8212; Pre-Funded Warrants</a>&#8221; for a discussion on the terms of the pre-funded warrants. Each pre-funded warrant is
    exercisable for one share of our common stock (subject to adjustment as provided therein) at any time at the option of the holder,
    provided that the holder will be prohibited from exercising its pre-funded warrant for shares of our common stock if, as a result of
    such exercise, the holder, together with its affiliates and certain related parties, would own more than 4.99% of the total number
    of shares of our common stock then issued and outstanding. However, any holder may increase such percentage to any other percentage
    not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to us.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</span></td>
    <td style="vertical-align: bottom; width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Warrants to purchase up to
    [__] shares of our common stock. Each share of our common stock, or pre-funded warrant in lieu thereof, is being sold together with a
    warrant to purchase one share of our common stock. Each warrant will have an initial exercise price of $ per share (representing 100%
    of the combined public offering price per share of common stock (or pre-funded warrant) in the Company Offering and accompanying warrant
    in this Company Offering), subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock
    combinations, reclassifications, reorganizations or similar events affecting our common stock. The warrants will be immediately exercisable
    and will expire on the fifth anniversary of the original issuance date. This prospectus also relates to the offering of the shares of
    common stock issuable upon exercise of such warrants.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To better understand the terms of the warrants, you
    should carefully read the &#8220;<a href="#s1_023">Description of Securities We are Offering &#8211; Warrants</a>&#8221;. You should also
    read the form of warrant, which is filed as an exhibit to the registration statement that includes this prospectus.</p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent warrants</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have agreed to issue to the placement agent warrants to purchase a number of shares of common stock equal to 4% of the total number of shares of common stock issued in this offering. The placement agent&#8217;s warrant will be&#160;non-exercisable for six (6) months after the date of the closing and will expire five years after the commencement of sales of the offering. The placement agent&#8217;s warrant will be exercisable for the purchase of shares of our common stock at a price per share equal to the combined purchase price per share of common stock (or pre-funded warrant) and accompanying warrant in this offering. We are also registering the shares of common stock issuable upon the exercise of the placement agent&#8217;s warrants.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock outstanding after the Company Offering and the Inducement Offering</span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[___] shares, assuming the exercise in full of the warrants in both the Company Offering and the Inducement Offering.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will not receive any proceeds from the sale of shares of common stock offered by the Selling Securityholders under this prospectus. However, Aethlon will receive the proceeds of any cash exercise of the Inducements Warrants which are currently worth less than what an investor would pay for the shares thus the Selling Securityholders are unlikely to exercise their Inducement Warrants. Cash proceeds associated with the exercise(s) of the warrants, if any, are dependent on the Company&#8217;s stock price at the time of exercise. However, if we receive proceeds, we currently intend to use the proceeds general corporate purposes which will include research and development expenses, clinical trial expenses, capital expenditures and working capital. We may also use a portion of the net proceeds from the Company Offering to in-license, acquire, or invest in complementary businesses, technologies, products or assets. P<span style="background-color: white">ending use of the net proceeds, we intend to invest the proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering Price</span></td>
    <td style="vertical-align: bottom; width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the Inducement Offering, the Selling Securityholders
    may sell all or a portion of their shares through public or private transactions at prevailing market prices or privately negotiated prices.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the Company Offering, [__] per share.</p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing Information</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;AEMD.&#8221;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An investment in our securities involves a high degree of risk. See the section entitled &#8220;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_005">Risk Factors</a></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8221; of this prospectus and the similarly titled sections in the documents incorporated by reference into this prospectus.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We along with and our officers, and directors have agreed with the placement agent, to not offer for sale, issue, sell, pledge or otherwise dispose of any common stock or securities convertible into common stock for a period of 60 days after the date of this prospectus.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The number of shares of our common
stock to be outstanding after this offering is based on [__] shares of common stock outstanding as of August [__], 2025 and excludes as
of such date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock issuable upon the exercise of outstanding stock options under our equity incentive plan at a weighted-average exercise price of $[__] per share;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock issuable pursuant to outstanding restricted stock units;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock reserved for future issuance under our equity incentive plan; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock reserved for issuance upon the exercise of outstanding warrants at a weighted-average exercise price of $[__] per share. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_005"></span>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white"><i>Investing
in our securities involves a high degree of risk. You should consider carefully the risks described below, together with all of the other
information included or incorporated by reference in this prospectus, including the risks and uncertainties discussed under &#8220;Risk
Factors&#8221; in our Annual Report on Form 10-K for the year ended March&#160;31, 2025, which has been filed with the SEC and is incorporated
by reference in this prospectus, as well as any updates thereto contained in subsequent filings with the SEC or any free writing prospectus,
before deciding whether to purchase our securities in this offering. All of these risk factors are incorporated herein in their entirety.
The risks described below and incorporated by reference are material risks currently known, expected or reasonably foreseeable by us.
However, the risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently
deem immaterial may also affect our business, operating results, prospects or financial condition. If any of these risks actually materialize,
our business, prospects, financial condition, and results of operations could be seriously harmed. This could cause the trading price
of our common stock and the value of the warrants to decline, resulting in a loss of all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Risks Relating to Our Financial Position and Need for Additional Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We have incurred significant losses and expect to continue to incur
losses for the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never been profitable.
We did not generate any revenue during the fiscal years ended March 31, 2025 and March 31, 2024. In prior fiscal years we did record revenue
from government contracts. We do not currently have any research grants or contracts. It is possible that we may not be able to enter
into future government contracts. Future profitability, if any, will require the successful commercialization of our Hemopurifier technology
or any other product that we develop or from additional government contract or grant income we may obtain. We may not be able to successfully
commercialize the Hemopurifier or any other products, and even if commercialization is successful, we may never be profitable. While we
currently have over $5.5 million in cash and cash equivalents and have been carrying out certain expense reductions since November 2023,
our planned additional expense reductions may not materialize and/or our patient recruitment may occur more rapidly than expected along
with the concomitant increases in expenses; therefore there is substantial doubt that our cash on hand will carry the company for 12 months
beyond the filing date of the financial statements included in the Annual Report for the period ended March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do plan to access the equity
markets for additional capital, however, there can be no assurance that we will be able to access such additional capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We will require additional financing to sustain
our operations, achieve our business objectives and satisfy our cash obligations, which may dilute the ownership of our existing stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will require significant additional
financing for our operations and for expected additional future clinical trials in the United States, India and Australia, regulatory
clearances, and continued research and development activities for the Hemopurifier and other future products. In addition, as we expand
our activities, our overhead costs to support personnel, laboratory materials and infrastructure will increase. We may also choose to
raise additional funds in debt or equity financings if they are available to us on reasonable terms to increase our working capital and
to strengthen our financial position. Any sale of additional equity or convertible debt securities could result in dilution of the equity
interests of our existing stockholders. Additionally, new investors may require that we and certain of our stockholders enter into voting
arrangements that give them additional voting control or representation on our Board of Directors. If required financing is unavailable
to us on reasonable terms, or at all, we may be unable to support our operations, including our research and development activities, which
would have a material adverse effect on our ability to commercialize our products or continue our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our ability to raise additional
funds may be adversely impacted by our ability to remain listed on Nasdaq, the potential worsening global economic conditions and disruptions
to and volatility in the credit and financial markets in the United States, including due to&#160;<span style="background-color: white">bank
failures, actual or perceived changes in interest rates and economic inflation</span>, and worldwide resulting from macroeconomic factors.
Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased
expenses and cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>We may not currently
or in the future be able to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The financial
statements in this Annual Report have been prepared on a going concern basis of accounting, which assumes that we will continue as a going
concern, and do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company&#8217;s
ability to continue as a going concern is dependent on our ability to generate revenues and raise capital. To date, we have not generated
sufficient revenues to provide cash flows that enable us to finance our operations internally. In connection with an evaluation conducted
by our management during the preparation of the financial statements included in this Annual Report, management concluded that there were
conditions and events which raised substantial doubt as to the Company&#8217;s ability to continue as a going concern within twelve months
after the date of the issuance of the financial statements included in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The uncertainty
regarding our ability to continue as a going concern could materially adversely affect our share price and our ability to service our
indebtedness, raise new capital or enter into commercial transactions. To address these matters, we may take actions that materially and
adversely affect our business, including significant reductions in research, development, administrative and commercial activities, reduction
of our employee base, and ultimately curtailing or ceasing operations, any of which could materially adversely affect our business, financial
condition, results of operations and share price. In addition, doubts about our ability to continue as a going concern could impact our
relationships with partners, vendors and other third parties and our ability to obtain, maintain or renew contracts with them, or negatively
impact our negotiating leverage with such parties, which could have a material adverse effect on our business, financial condition and
results of operations. Furthermore, any loss of key personnel, employee attrition or material erosion of employee morale arising out of
doubts about our ability to operate as a going concern could have a material adverse effect on our ability to effectively conduct our
business and could impair our ability to execute our strategy and implement our business objectives, thereby having a material adverse
effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Risks Related to Our Securities
and the Inducement Offering and Company Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Inducement Warrants being registered are
currently worth less than the exercise price, the Selling Securityholders are unlikely to exercise their Inducement Warrants and cash
proceeds from an exercise are dependent upon the Company&#8217;s stock price.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Inducement
Warrants being registered in the registration statement of which this prospectus forms a part of, have an exercise price of $2.99 per
share, while the closing price of the common stock was $1.17 per share on August 18, 2025. Since both the Inducement Warrants are currently
worth less than what an investor would pay per share, the Selling Securityholders are unlikely to exercise. Cash proceeds associated with
the exercise(s) of the Inducement Warrants, if any, are dependent on the Company&#8217;s stock price at the time of exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Company Offering is a best-efforts offering,
no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business
plans, including our near-term business plans.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The placement agent has agreed
to use its reasonable best efforts to solicit offers to purchase the securities in the Company Offering. The placement agent has no obligation
to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities.
There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no
minimum offering amount required as a condition to the closing of the Company Offering, the actual offering amount, placement agent fees
and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth herein. We may sell
fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in
this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations,
including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in
the short-term and may need to raise additional funds to complete such short-term operations. Such additional fundraises may not be available
or available on terms acceptable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>If you purchase our securities in either the Company Offering or
the Inducement Offering you may incur immediate and substantial dilution in the book value of your shares.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The combined public offering price
per share of our common stock and accompanying warrant may be substantially higher than the net tangible book value per share of our common
stock immediately prior to the offering. After giving effect to the assumed sale of shares of our common stock and accompanying warrants
in this Company Offering, at an assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share and accompanying warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on August &#160;&#160;&#160;&#160;,
2025), and after deducting the placement agent fees and estimated offering expenses payable by us and attributing no value to the warrants
sold in this offering, purchasers of our common stock in this offering will incur immediate dilution of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share in the net tangible book value of the common stock they acquire. In the event that you exercise your warrants, you may experience
additional dilution to the extent that the exercise price of the warrants is higher than the tangible book value per share of our common
stock. For a further description of the dilution that investors in this offering may experience, see &#8220;<a href="#s1_009">Dilution</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, to the extent that
outstanding stock options or warrants, including the Inducement Warrants have been or may be exercised, outstanding restricted stock units
have been or may be settled or other shares are issued, you may experience further dilution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>We have broad discretion in the use of the net proceeds we receive
from the Company Offering and may not use them effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management will have broad
discretion in the application of the net proceeds we receive in the Company Offering, including for any of the purposes described in the
section entitled &#8220;<a href="#s1_007">Use of Proceeds</a>,&#8221; and you will not have the opportunity as part of your investment
decision to assess whether our management is using the net proceeds appropriately. Because of the number and variability of factors that
will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business and cause the price of our common stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Future sales of substantial amounts of our common stock could adversely
affect the market price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. If additional capital is raised through the sale of equity or convertible debt securities, or perceptions that those sales could
occur, the issuance of these securities could result in further dilution to investors purchasing our common stock in this offering or
result in downward pressure on the price of our common stock, and our ability to raise capital in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Holders of our warrants and pre-funded warrants will have no rights
as a common stockholder until they acquire our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until you acquire shares of our
common stock upon exercise of your warrants or pre-funded warrants, you will have no rights with respect to shares of our common stock
issuable upon exercise of your warrants or pre-funded warrants. Upon exercise of your warrants or pre-funded warrants, you will be entitled
to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>The warrants may not have any value.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each warrant will have an exercise
price of not less than 100% of the last reported sale price of our common stock as of the close of the trading day immediately preceding
the pricing of this offering and will expire on the [_] anniversary of the date they first become exercisable. In the event our common
stock price does not exceed the exercise price of the warrants during the period when the warrants are exercisable, the warrants may not
have any value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>There is no public market for the warrants to purchase shares of
our common stock or pre-funded warrants being offered in this offering.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no established public
trading market for the warrants or pre-funded warrants being offered in this offering, and we do not expect a market to develop. In addition,
we do not intend to apply to list the warrants or pre-funded warrants on any national securities exchange or other nationally recognized
trading system, including The Nasdaq Capital Market. Without an active trading market, the liquidity of the warrants and pre-funded warrants
will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>We will not receive
any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Each
Pre-Funded Warrant will be exercisable until it is fully exercised and by means of payment of the nominal cash purchase price upon exercise.
Accordingly, we will not receive any meaningful additional funds upon the exercise of the Pre-Funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Significant holders
or beneficial holders of shares of our common stock may not be permitted to exercise the Pre-Funded Warrants that they hold.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">A holder
of the Pre-Funded Warrants will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise,
would cause: (i) the aggregate number of shares of our common stock beneficially owned by such holder (together with its affiliates) to
exceed 4.99% (or, upon election of holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect
to the exercise; or (ii) the combined voting power of our securities beneficially owned by such holder (together with its affiliates)
to exceed 4.99% (or, upon election of holder, 9.99%) of the combined voting power of all of our securities outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. As
a result, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock at a time when it would be financially
beneficial for you to do so. In such a circumstance, you could seek to sell your Pre-Funded Warrants to realize value, but you may be
unable to do so in the absence of an established trading market and due to applicable transfer restrictions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_006"></span>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus and the documents
incorporated herein by reference contain forward-looking statements. The forward-looking statements are contained principally in the sections
entitled &#8220;Summary,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations&#8221; and &#8220;Business&#8221; in this prospectus or the documents incorporated herein by reference. These statements
relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully commercialize our products and technology, including our Hemopurifier;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise additional capital to meet our working capital needs;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and results of future clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully complete our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to identify and work with large-scale contracts with medical device manufacturers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to manufacture the Hemopurifier;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of inflation, recent bank failures and military conflicts, as well as related political and economic responses on our business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract and retain executive management and directors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory landscape for our products, domestically and internationally and our ability to comply with changing government regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with the continued listing requirements of the Nasdaq Capital Market and maintain our listing on the Nasdaq Capital Market;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding growth potential for our business in the organ transplant setting;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to secure regulatory clearance or approval, domestically and internationally, for the clinical use of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any estimates regarding expenses, future revenue and capital requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect our proprietary technology through patent protection;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our product liability exposure;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to sustain and manage growth, including our ability to develop new products and enter new markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to achieve sufficient market acceptance of any of our products or product candidates; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expected net proceeds from this offering and the use of the net proceeds from this offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In some cases, you can identify
these statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;continue,&#8221; &#8220;seek,&#8221;
&#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions.
You should be aware that the occurrence of any of the events discussed under the heading &#8220;<a href="#s1_005">Risk Factors</a>&#8221;
in this prospectus and any documents incorporated by reference herein could substantially harm our business, operating results and financial
condition and that if any of these events occurs, it could adversely affect the value of an investment in our common stock. In addition,
statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all potentially available relevant information. In addition, even if our results of
operations, financial condition and cash flows and the development of the markets in which we operate, are consistent with the forward-looking
statements contained in this prospectus, those results or developments may not be indicative of results or developments in subsequent
periods. New factors emerge from time to time that may cause our business not to develop as we expect, and it is not possible for us to
predict all of them. Factors that could cause actual results and outcomes to differ from those reflected in forward-looking statements
include, among others, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates of our addressable market, market growth, future revenue, expenses, capital requirements and our needs for additional financing&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation of our business model and strategic plans for our products and technologies&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitive companies and technologies and our industry&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to develop and commercialize new products&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the performance of third party suppliers&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to hire and retain key personnel and to manage our future growth effectively&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain additional financing in future offerings&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the volatility of the trading price of our common stock&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding use of proceeds from this offering;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential effects of government regulation&#894;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of trade wars and global instability; and</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations about market trends.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We discuss many of these risks
in greater detail under the section titled &#8220;Risk Factors&#8221; in this prospectus and in our Annual Report on Form 10-K. Given
these uncertainties, you should not place undue reliance on these forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You should carefully read this
prospectus, the documents that we incorporate by reference into this prospectus and the documents we reference in this prospectus and
have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our
actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus
by these cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except as required by law, we
assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially
from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus also refers to
estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our
industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate
are necessarily subject to a high degree of uncertainty and risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_007"></span>USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inducement Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The Selling Securityholders will
be offering the shares of common stock underlying the Inducement Warrants being covered by this prospectus at prevailing market prices
or privately negotiated prices. We will not receive any proceeds from the sale of shares of common stock offered by the Selling Securityholder
under this prospectus. However, we will receive the proceeds of any cash exercise of the Inducement Warrants. If all of the Inducement
Warrants were exercised for cash, we would receive aggregate proceeds of approximately $4,634,500.Since the Inducement Warrants are currently
worth less than what an investor would pay per share, the Selling Securityholder is unlikely to exercise. Cash proceeds associated with
the exercise(s) of the Inducement Warrants, if any, are dependent on the Company&#8217;s stock price at the time of exercise. If we receive
proceeds, we currently intend to use the proceeds for general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Company Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We estimate that the net proceeds
of the Company Offering will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, based
on the assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and
accompanying warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on August&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025), after deducting the placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from
the exercise of the warrants. Each $0.10 increase (decrease) in the assumed combined public offering price of $&#160;&#160;&#160;&#160;per
share and accompanying warrant would increase (decrease) the net proceeds to us from this offering by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
million, assuming the number of shares and warrants offered by us, as set forth on the cover page of this prospectus, remains the same,
after deducting the placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of
shares of our common stock and warrants we are offering. Each 1.0&#160;million share increase (decrease) in the number of shares sold
in this offering would increase (decrease) the expected net proceeds of the offering to us by approximately $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
assuming that the assumed combined public offering price per share and accompanying warrant remains the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We currently intend to use the
net proceeds of the Company Offering for general corporate purposes, which will include research and development expenses, clinical trial
expenses, capital expenditures and working capital. We may also use a portion of the net proceeds from the Company Offering to in-license,
acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current plans, commitments or obligations
to do so. P<span style="background-color: white">ending use of the net proceeds, we intend to invest the proceeds in a variety of capital
preservation instruments, including short-term, investment-grade, interest-bearing instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot currently allocate specific
percentages of the net proceeds to us from the Company Offering that we may use for the purposes specified above and our management will
have broad discretion in the allocation of the net proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_008"></span>SELLING SECURITYHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus covers the resale
or other disposition by the Selling Securityholders identified in the table below of up to 1,550,000 shares of common stock issuable upon
the exercise Inducement Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are registering the shares
of common stock underlying the Inducement Warrants in order to permit the Selling Securityholders to offer the shares of common stock
for resale from time to time. The registration of such common stock does not necessarily mean, however, that any of the shares of common
stock will be offered or sold by the Selling Securityholders. We will not receive any proceeds from the sale of the common stock by the
Selling Securityholders, and we have borne and will continue to bear the costs relating to the registration of these shares of common
stock, other than commissions and discounts of agents or broker-dealers and transfer taxes, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Inducement Warrants held by
the Selling Securityholders contain limitations which prevent the holder from exercising those Inducement Warrants if such exercise or
conversion would cause the Selling Securityholders, together with certain related parties, to beneficially own a number of shares of common
stock which would exceed 4.99% of our then outstanding common stock following such exercise or conversion, excluding for purposes of such
determination, common stock issuable upon exercise of the Inducement Warrants which have not been exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The table below sets forth, as
of August [__], 2025, the following information regarding the Selling Securityholders:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name of the Selling Securityholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of common stock owned by the Selling Securityholders prior to this offering, without regard to any beneficial ownership limitations contained in the Inducement Warrants;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of common stock to be offered by the Selling Securityholders in this offering;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of common stock to be owned by the Selling Securityholders assuming the sale of all of the shares of common stock covered by this prospectus; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the percentage of our issued and outstanding shares of common stock to be owned by the Selling Securityholders assuming the sale of all of the common stock covered by this prospectus based on the number of shares of common stock issued and outstanding as of [__].</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except as described above, the
number of shares of common stock beneficially owned by the Selling Securityholders have been determined in accordance with Rule 13d-3
under the Exchange Act and includes, for such purpose, shares of common stock that the Selling Securityholders have the right to acquire
within 60 days after [__].</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Because the Selling Securityholders
identified in the table may sell some or all of the shares of common stock beneficially owned and covered by this prospectus, and because
there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares of common stock, no estimate
can be given as to the number of shares of common stock available for resale hereby that will be held by the Selling Securityholders upon
termination of this offering. In addition, the Selling Securityholders may have sold, transferred or otherwise disposed of, or may sell,
transfer or otherwise dispose of, at any time and from time to time, the shares of common stock they beneficially own in transactions
exempt from the registration requirements of the Securities Act after the date on which they provided the information set forth in the
table below. We have, therefore, assumed for the purposes of the following table, that the Selling Securityholders will sell all of the
shares of common stock owned beneficially that are covered by this prospectus, but will not sell any other shares of common stock that
they presently own. The Selling Securityholders have not held any position or office, or otherwise had a material relationship, with us
or any of our subsidiaries within the past three years other than as a result of the ownership of our common stock or other securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name of Selling Securityholder</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares of <br/> Common Stock<br/> Beneficially<br/> Owned prior <br/> to the Offering</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maximum Number of<br/> Shares of Common Stock<br/> to be Sold <br/> Pursuant to this<br/> Prospectus</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares of Common <br/> Stock Beneficially<br/> Owned after <br/> Offering</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage<br/> of Shares <br/> Beneficially <br/> Owned after <br/> Offering(2)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 32%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital, LLC<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">1,550,000</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1[____]%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital, LLC (&#8220;Armistice Capital&#8221;) is the investment manager of Armistice Capital Master Fund Ltd. (the &#8220;Master Fund&#8221;), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage is based on [__] shares of common stock outstanding as of August [__], 2025 assuming the resale of all of the shares of common stock covered by this prospectus and giving effect to the 4.99% beneficial ownership blockers in the Warrants.</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes the sale of 1,550,000 shares of common stock underlying the Inducement Warrants. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_009"></span>DILUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If you purchase our securities
in the Company Offering, you may experience dilution to the extent of the difference between the combined public offering price per share
and accompanying warrant in the Company Offering and our as adjusted net tangible book value per share immediately after the Company Offering,
assuming no value is attributed to the warrants, and such warrants are accounted for and classified as equity. Net tangible book value
per share is equal to the amount of our total tangible assets, less total liabilities, divided by the number of outstanding shares of
our common stock. As of June 30, 2025, our net tangible book value was approximately $[__], or approximately $[__] per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">After giving effect to the assumed
sale by us of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock
(assuming no pre-funded warrants in lieu of common stock are issued) and warrants to purchase up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
shares of our common stock in this offering at an assumed combined public offering price of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share and accompanying warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025), assuming no exercise of the warrants or the placement agent&#8217;s warrant and after deducting the placement agent fees and estimated
offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2025 would have been approximately $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
or approximately $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. This represents an immediate increase
in net tangible book value of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share to existing stockholders
and an immediate dilution of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share to new investors purchasing
shares of our common stock and accompanying warrants in this offering, attributing none of the assumed combined public offering price
to the warrants offered hereby. The following table illustrates this per share dilution:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom; width: 69%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed combined public offering price per share and accompanying warrant</span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 12%; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 12%; text-align: right">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per share as of June 30, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__]</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share after this offering</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value per share after this offering</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A $0.10 increase in the assumed
combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and accompanying
warrant (the last reported sale price of our common stock on The Nasdaq Capital Market on August&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025) would result in an increase in our as adjusted net tangible book value after this offering of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
or approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, and the dilution per share to investors
purchasing common stock and accompanying warrants in this offering would be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share, assuming that the number of shares of our common stock and accompanying warrants sold by us remains the same, after deducting the
placement agent fees and estimated offering expenses payable by us. Similarly, a decrease of $0.10 in the assumed combined public offering
price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and accompanying warrant would result in a decrease in our as adjusted net
tangible book value after this offering of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
or approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, and the dilution per share to investors
purchasing common stock and accompanying warrants in this offering would be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share, assuming that the number of shares of our common stock and accompanying warrants sold by us remains the same, after deducting the
placement agent fees and estimated offering expenses payable by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may also increase or decrease
the number of shares of common stock and accompanying warrants we are offering from the number of shares of common stock and accompanying
warrants set forth above. An increase of 1.0&#160;million in the assumed number of shares of common stock and accompanying warrants sold
by us in this offering would result in an increase in our as adjusted net tangible book value of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
million, or approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share, and the dilution per share
to investors purchasing common stock and accompanying warrants in this offering would be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
per share, assuming that the assumed combined public offering price per share of common stock and accompanying warrant remains the same,
after deducting the placement agent fees and estimated offering expenses payable by us. A decrease of 1.0&#160;million in the assumed
number of shares of common stock and accompanying warrants sold by us in this offering would result in a decrease in our as adjusted net
tangible book value after this offering of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; million,
or approximately per share, and the dilution per share to investors purchasing common stock and accompanying warrants in this offering
would be approximately $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, assuming that the assumed
combined public offering price per share of common stock and accompanying warrant remains the same, after deducting the placement agent
fees and estimated offering expenses payable by us. The information discussed above is illustrative only and will adjust based on the
actual public offering price, the actual number of shares of common stock and accompanying warrants sold in this offering and other terms
of this offering determined at pricing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The discussion and table above
assume&#160;(i) no exercise of the placement agent&#8217;s warrant or the warrants issued in this offering and (ii) no sale of pre-funded
warrants in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities could result in further dilution to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table and discussion above
are based on [__] shares of our common stock outstanding as of [__] and excludes as of such date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock issuable upon the exercise of outstanding stock options under our equity incentive plan at a weighted-average exercise price of $[__] per share;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock issuable pursuant to outstanding restricted stock units;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__] shares of common stock reserved for future issuance under our equity incentive plan; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[__]shares of common stock reserved for issuance upon the exercise of outstanding warrants at a weighted-average exercise price of $[__] per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_010"></span>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following description of our
capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based
upon, and is qualified in its entirety by reference to, our articles of incorporation, our bylaws and applicable provisions of Nevada
corporate law. You should read our articles of incorporation and bylaws, which have been publicly filed with the SEC, for the provisions
that are important to you.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Authorized Capital Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our authorized capital consists
of 60,000,000 shares of common stock, par value $0.001 per share. As of August [__], 2025, there were&#160;<span style="background-color: white">[__]</span>&#160;shares
of common stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The holders of our common stock
are entitled to one vote per share on all matters to be voted on by the stockholders. Holders of common stock are entitled to receive
ratably such dividends as may be declared by the Board of Directors out of funds legally available therefor. If we liquidate, dissolve
or wind up, holders of common stock are entitled to share ratably in all assets remaining after payment of all debts and other liabilities.
Holders of common stock have no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions applicable
to the common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that stockholders
representing a majority of the voting power of our capital stock, represented in person or by proxy (regardless of whether the proxy has
authority to vote on all matters), are necessary to constitute a quorum for the transaction of business at any meeting, but at any time
during which shares of our capital stock are listed for trading on Nasdaq, stockholders representing not less than 33 1/3% of the voting
power of our capital stock, represented in person or by proxy (regardless of whether the proxy has authority to vote on all matters),
are necessary to constitute a quorum for the transaction of business at any meeting of stockholders. Except as otherwise required or permitted
by Nevada law or our articles of incorporation or bylaws, action by the stockholders entitled to vote on a matter, other than the election
of directors, is approved by and is the act of the stockholders if the number of votes cast in favor of the action exceeds the number
of votes cast in opposition to the action. If a quorum is present, directors are elected by a plurality of the votes cast.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Anti-Takeover Effects of Certain Provisions of Nevada Law and Our Articles
of Incorporation and Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nevada&#8217;s &#8220;combinations
with interested stockholders&#8221; statutes, NRS 78.411 through 78.444, inclusive, prohibit specified types of business &#8220;combinations&#8221;
between certain Nevada corporations and any person deemed to be an &#8220;interested stockholder&#8221; for two years after such person
first becomes an &#8220;interested stockholder&#8221; unless the corporation&#8217;s board of directors approves the combination (or the
transaction by which such person becomes an &#8220;interested stockholder&#8221;) in advance, or unless the combination is approved by
the board of directors and sixty percent of the corporation&#8217;s voting power not beneficially owned by the interested stockholder,
its affiliates and associates. Further, in the absence of prior approval certain restrictions may apply even after such two year period.
However, these statutes do not apply to any combination of a corporation and an interested stockholder after the expiration of four years
after the person first became an interested stockholder. For purposes of these statutes, an &#8220;interested stockholder&#8221; is any
person who is (1) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares
of the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial
owner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. The definition
of the term &#8220;combination&#8221; is sufficiently broad to cover most significant transactions between a corporation and an &#8220;interested
stockholder.&#8221; These statutes generally apply to Nevada corporations with 200 or more stockholders of record. However, a Nevada corporation
may elect in its articles of incorporation not to be governed by these particular laws, but if such election is not made in the corporation&#8217;s
original articles of incorporation, the amendment (1) must be approved by the affirmative vote of the holders of stock representing a
majority of the outstanding voting power of the corporation not beneficially owned by interested stockholders or their affiliates and
associates, and (2) is not effective until 18 months after the vote approving the amendment and does not apply to any combination with
a person who first became an interested stockholder on or before the effective date of the amendment. We did not make such an election
in our original articles of incorporation and have not amended our articles of incorporation to so elect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nevada&#8217;s &#8220;acquisition
of controlling interest&#8221; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling
interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling
interest&#8221; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the
corporation elects to restore such voting rights. Our bylaws provide that these statutes do not apply to us or any acquisition of our
common stock. Absent such provision in our bylaws, these laws would apply to us as of a particular date if we were to have 200 or more
stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times during the 90 days immediately
preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless our articles of incorporation
or bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person
acquires a &#8220;controlling interest&#8221; whenever a person acquires shares of a subject corporation that, but for the application
of these provisions of the NRS, would enable that person to exercise (1) one fifth or more, but less than one third, (2) one third or
more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors.
Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within
the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control
shares&#8221; to which the voting restrictions described above apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NRS 78.139 also provides that
directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or
potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances,
contingencies or constituencies pursuant to NRS 78.138(4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, our authorized but
unissued shares of common stock are available for our Board of Directors to issue without stockholder approval. We may use these additional
shares for a variety of corporate purposes, including future public or private offerings to raise additional capital, corporate acquisitions
and employee benefit plans. The existence of our authorized but unissued shares of common stock could render more difficult or discourage
an attempt to obtain control of our company by means of a proxy contest, tender offer, merger or other transaction. Our authorized but
unissued shares may be used to delay, defer or prevent a tender offer or takeover attempt that a stockholder might consider in its best
interest, including those attempts that might result in a premium over the market price for the shares held by our stockholders. The Board
of Directors is also authorized to adopt, amend or repeal our Bylaws, which could delay, defer or prevent a change in control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Nasdaq Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on The Nasdaq Capital Market
under the symbol &#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Transfer Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar for our common stock
is Computershare Investor Services. The transfer agent&#8217;s address is P.O. Box 30170, College Station, TX 77842.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_011"></span>DESCRIPTION OF SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b>Company Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">We
are offering (i) up to [__] shares of our common stock or pre-funded warrants and (ii) warrants to purchase up to an aggregate of [__]
shares of our common stock. Each share of common stock or&#160;pre-funded&#160;warrant is being sold together with a warrant to purchase
one share of common stock. The shares of common stock or&#160;pre-funded&#160;warrants and accompanying warrants will be issued separately.
We are also registering the shares of common stock issuable from time to time upon exercise of the&#160;pre-funded&#160;warrants and warrants
offered hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The material terms and provisions
of our common stock and each other class of our securities which, if designated and issued, qualifies or limits our common stock are described
under the caption &#8220;<a href="#s1_010">Description of Capital Stock</a>&#8221; in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="s1_022"></span>Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The following
summary of certain terms and provisions of the pre-funded warrants that are being offered hereby is not complete and is subject to, and
qualified in its entirety by the provisions of, the pre-funded warrant. Prospective investors should carefully review the terms and provisions
of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The term
&#8220;pre-funded&#8221; refers to the fact that the purchase price of each pre-funded&#160;warrant, at closing, will equal the price
per share at which shares of our common stock and accompanying warrants to purchase common stock are being sold to the public in this
offering, minus $0.001, and the exercise price of each pre-funded warrant will equal $0.001 per share of common stock. The purpose of
the&#160;pre-funded&#160;warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99%
(or, upon election of the holder, 9.99%) of our outstanding common stock following the consummation of this offering the opportunity to
invest capital into us without triggering their ownership restrictions, by receiving&#160;pre-funded&#160;warrants in lieu of our common
stock to the extent it would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to purchase the shares underlying
the pre-funded warrants at such nominal price at a later date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Duration</i>.
The pre-funded&#160;warrants offered hereby will entitle the holders thereof to purchase shares of our common stock at a nominal exercise
price of $0.001 per share, commencing immediately on the date of issuance. The pre-funded warrants do not expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Exercise
Limitation.</i> A holder will not have the right to exercise any portion of the&#160;pre-funded warrant if the holder (together with its
affiliates and certain related parties) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number
of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the&#160;pre-funded&#160;warrants. However, any holder may increase or decrease such percentage, provided
that any increase will not be effective until the 61st day after notice of such election is provided to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Exercise
Price.</i>&#160;The&#160;pre-funded&#160;warrants will have an exercise price of $0.001 per share. The exercise price is subject to appropriate
adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events
affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Transferability.</i>&#160;Subject
to applicable laws, the pre-funded warrants may be offered for sale, sold, transferred or assigned without our consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Exchange
Listing.</i> There is no established trading market for the&#160;pre-funded warrants and we do not expect a market to develop. In addition,
we do not intend to apply for the listing of the pre-funded warrants on any national securities exchange or other trading market. Without
an active trading market, the liquidity of the&#160;pre-funded warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Fundamental
Transactions</i>.&#160;If a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and
may exercise every right and power that we may exercise and will assume all of our obligations under the&#160;pre-funded&#160;warrants
with the same effect as if such successor entity had been named in the pre-funded&#160;warrant itself. If holders of our common stock
are given a choice as to the securities, cash or property to be received in a fundamental transaction, then the holder shall be given
the same choice as to the consideration it receives upon any exercise of the pre-funded warrant following such fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Rights
as a Stockholder.</i> Except as otherwise provided in the pre-funded&#160;warrants or by virtue of such holder&#8217;s ownership of shares
of our common stock, the holder of a pre-funded warrant does not have the rights or privileges of a holder of our common stock, including
any voting rights, until the holder exercises the pre-funded warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="s1_023"></span>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following summary of certain
terms and provisions of the warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions
of the warrant, the form of which has been filed as an exhibit to the registration statement of which this prospectus is a part. Prospective
investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions
of the warrants.&#160;<span style="background-color: white">In addition, the terms of the warrant to be issued to the placement agent
will generally be the same as the warrants issued to investors in this offering, except that such warrant will not be exercisable for
six months following the&#160;</span>effective date of the registration statement of which this prospectus forms a part<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Form.</i>&#160;The warrants
will be issued as individual warrant agreements to the investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Exercisability.</i>&#160;The
warrants are exercisable at any time after their original issuance, expected to be March&#160;&#160;&#160;&#160;, 2024, and at any time
up to the date that is five years after their original issuance. The warrants will be exercisable, at the option of each holder, in whole
or in part by delivering to us a duly executed exercise notice&#160;<span style="background-color: white">and, at any time a registration
statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is effective and available
for the issuance of such shares, or an exemption from registration under the Securities Act is available for the issuance of such shares</span>,
by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise.&#160;<span style="background-color: white">If
a registration statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is not
effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, the</span>&#160;holder
may, in its sole discretion, elect to exercise the warrant through a cashless exercise, in which case the holder would receive upon such
exercise the net number of shares of common stock determined according to the formula set forth in the warrant. No fractional shares of
common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holder an amount
in cash equal to the fractional amount multiplied by the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Exercise Limitation.&#160;</i>A
holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates and certain related
parties) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common stock
outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of
the warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the
61st day after notice of such election is provided to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Exercise Price.</i>&#160;The
warrants will have an exercise price of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits,
stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including
cash, stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Transferability.</i>&#160;Subject
to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Exchange Listing.</i>&#160;There
is no established trading market for the warrants and we do not expect a market to develop. In addition, we do not intend to apply for
the listing of the warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity
of the warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Fundamental Transactions.</i>&#160;If
a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and
power that we may exercise and will assume all of our obligations under the warrants with the same effect as if such successor entity
had been named in the warrant itself. If holders of our common stock are given a choice as to the securities, cash or property to be received
in a fundamental transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of
the warrant following such fundamental transaction. In addition, in the event of a fundamental transaction which is within our control
and approved by our Board of Directors, the holders of warrants have the right to require us or a successor entity to redeem the warrant
for cash in the amount of the Black-Scholes value of the unexercised portion of the warrant on the date of the consummation of the fundamental
transaction. In the event of a fundamental transaction which is not within our control or approved by our Board of Directors, the holders
of the&#160;warrants shall only be entitled to receive from us or any successor entity, as of the date of consummation of such fundamental
transaction, the same type or form of consideration (and in the same proportion) as if the holder exercised the warrant upon such fundamental
transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Rights as a Stockholder.</i>&#160;Except
as otherwise provided in the warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a warrant
does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_012"></span>CERTAIN MATERIAL U.S. FEDERAL TAX CONSEQUENCES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a discussion
of certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of our shares of common stock.
This discussion applies only to shares of common stock that are held as capital assets for U.S. federal income tax purposes and is applicable
only to holders who are receiving our shares of common stock being offered in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This discussion is a summary only
and does not describe all of the tax consequences that may be relevant to you in light of your particular circumstances, including but
not limited to the alternative minimum tax, the Medicare tax on certain investment income and the different consequences (such as the
effects of Section 451 of the Code) that may apply if you are subject to special rules that apply to certain types of investors, including
but not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions or financial services entities;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies or instrumentalities thereof;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expatriates or former long-term residents of the U.S.;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or constructively own five percent or more of our voting shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dealers or traders subject to a mark-to-market method of accounting with respect to the common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding the common stock as part of a &#8220;straddle,&#8221; hedge, integrated transaction or similar transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. holders (as defined below) whose functional currency is not the U.S. dollar;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of such entities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This discussion is based on the
Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations as of the date hereof,
which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may
affect the tax consequences described herein. This discussion does not address any aspect of state, local or non-U.S. taxation, or any
U.S. federal taxes other than income taxes (such as gift and estate taxes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have not sought, and will not
seek, a ruling from the IRS as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein,
and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative
rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. You are urged to consult your
tax advisor with respect to the application of U.S. federal tax laws to your particular situation, as well as any tax consequences arising
under the laws of any state, local or foreign jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This discussion does not consider
the tax treatment of partnerships or other pass-through entities or persons who hold our common stock through such entities. If a partnership
(or other entity or arrangement classified as a partnership or other pass-through entity for United States federal income tax purposes)
is the beneficial owner of our common stock, the United States federal income tax treatment of a partner or member in the partnership
or other pass-through entity generally will depend on the status of the partner or member and the activities of the partnership or other
pass-through entity. If you are a partner or member of a partnership or other pass-through entity holding our common stock, we urge you
to consult your own tax advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS DISCUSSION IS ONLY A SUMMARY
OF CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK.
EACH PROSPECTIVE INVESTOR IN OUR COMMON STOCK IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES
TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK, INCLUDING THE APPLICABILITY AND EFFECT OF ANY UNITED
STATES FEDERAL NON-INCOME, STATE, LOCAL, AND NON-U.S. TAX LAWS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>U.S. holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This section applies to you if you are a &#8220;U.S.
holder.&#8221; A U.S. holder is a beneficial owner of our shares of common stock who or that is, for U.S. federal income tax purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust, if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under Treasury Regulations to be treated as a U.S. person.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Taxation of Distributions</i>.
If we pay distributions in cash or other property (other than certain distributions of our stock or rights to acquire our stock) to U.S.
holders of shares of our common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to
the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions
in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce
(but not below zero) the U.S. holder&#8217;s adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized
on the sale or other disposition of the common stock and will be treated as described under &#8220;<i><a href="#s1_024">U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of common stock</a></i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Dividends we pay to a U.S. holder
that is a taxable corporation generally will qualify for the dividends received deduction if the requisite holding period is satisfied.
With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction
limitations), and provided certain holding period requirements are met, dividends we pay to a non-corporate U.S. holder may constitute
&#8220;qualified dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the holding
period requirements are not satisfied, then a corporation may not be able to qualify for the dividends received deduction and would have
taxable income equal to the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at regular ordinary
income tax rates instead of the preferential rate that applies to qualified dividend income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span id="s1_024"></span>Gain or Loss on Sale, Taxable
Exchange or Other Taxable Disposition of common stock</i>. Upon a sale or other taxable disposition of our common stock, a U.S. holder
generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. holder&#8217;s
adjusted tax basis in the common stock. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder&#8217;s
holding period for the common stock so disposed of exceeds one year. If the holding period requirements are not satisfied, any gain on
a sale or taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at regular ordinary
income tax rates. Long-term capital gains recognized by non-corporate U.S. holders will be eligible to be taxed at reduced rates. The
deductibility of capital losses is subject to limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Generally, the amount of gain
or loss recognized by a U.S. holder is an amount equal to the difference between (i) the sum of the amount of cash and the fair market
value of any property received in such disposition and (ii) the U.S. holder&#8217;s adjusted tax basis in its common stock so disposed
of. A U.S. holder&#8217;s adjusted tax basis in its common stock generally will equal the U.S. holder&#8217;s acquisition cost for the
common stock or less, in the case of a share of common stock, any prior distributions treated as a return of capital. In the case of any
shares of common stock originally acquired as part of an investment unit, the acquisition cost for the share of common stock that were
part of such unit would equal an allocable portion of the acquisition cost of the unit based on the relative fair market values of the
components of the unit at the time of acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Information Reporting and Backup
Withholding</i>. In general, information reporting requirements may apply to dividends paid to a U.S. holder and to the proceeds of the
sale or other disposition of our shares of common stock, unless the U.S. holder is an exempt recipient. Backup withholding may apply to
such payments if the U.S. holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified
by the IRS that it is subject to backup withholding (and such notification has not been withdrawn).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any amounts withheld under the
backup withholding rules generally should be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability
provided the required information is timely furnished to the IRS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Non-U.S. holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This section applies to you if
you are a &#8220;Non-U.S. holder.&#8221; As used herein, the term &#8220;Non-U.S. holder&#8221; means a beneficial owner of our common
stock who or that is for U.S. federal income tax purposes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a non-resident alien individual (other than certain former citizens and residents of the U.S. subject to U.S. tax as expatriates);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a foreign corporation or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate or trust that is not a U.S. holder;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">but generally does not include
an individual who is present in the U.S. for 183 days or more in the taxable year of disposition. If you are such an individual, you should
consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition
of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Taxation of Distributions</i>.
In general, any distributions we make to a Non-U.S. holder of shares of our common stock, to the extent paid out of our current or accumulated
earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes
and, provided such dividends are not effectively connected with the Non-U.S. holder&#8217;s conduct of a trade or business within the
United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. holder
is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility
for such reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E). Any distribution not constituting a dividend will be treated first
as reducing (but not below zero) the Non-U.S. holder&#8217;s adjusted tax basis in its shares of our common stock and, to the extent such
distribution exceeds the Non-U.S. holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the common
stock, which will be treated as described under &#8220;<i><a href="#s1_025">Non-U.S. Holders&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of common stock</a></i>&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The withholding tax does not apply
to dividends paid to a Non-U.S. holder who provides a Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S.
holder&#8217;s conduct of a trade or business within the United States. Instead, the effectively connected dividends will be subject to
regular U.S. income tax as if the Non-U.S. holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise.
A Non-U.S. corporation receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax&#8221;
imposed at a rate of 30% (or a lower treaty rate).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span id="s1_025"></span>Gain on Sale, Taxable Exchange
or Other Taxable Disposition of common stock</i>. A Non-U.S. holder generally will not be subject to U.S. federal income or withholding
tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our common stock, unless:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively connected with the conduct of a trade or business by the Non-U.S. holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the Non-U.S. holder); or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are or have been a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. holder held our common stock, and, in the case where shares of our common stock are regularly traded on an established securities market, the Non-U.S. holder has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. holder&#8217;s holding period for the shares of our common stock. There can be no assurance that our common stock will be treated as regularly traded on an established securities market for this purpose.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless an applicable treaty provides
otherwise, gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates
as if the Non-U.S. holder were a U.S. resident. Any gains described in the first bullet point above of a Non-U.S. holder that is a foreign
corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower treaty rate).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the second bullet point above
applies to a Non-U.S. holder, gain recognized by such holder on the sale, exchange or other disposition of shares of our common stock
will be subject to tax at generally applicable U.S. federal income tax rates, and a buyer of such shares may be required to withhold U.S.
federal income tax at a rate of 15% of the amount realized upon the disposition. We expect not to be classified as a &#8220;U.S. real
property holding corporation&#8221; for U.S. federal income tax purposes. However, such determination is factual in nature and subject
to change and no assurance can be provided as to whether we will be a &#8220;U.S. real property holding corporation&#8221; for U.S. federal
income tax purposes in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Information Reporting and Backup
Withholding</i>. Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale
or other disposition of our shares of common stock. A Non-U.S. holder may have to comply with certification procedures to establish that
it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures
required to claim a reduced rate of withholding under a treaty will generally satisfy the certification requirements necessary to avoid
the backup withholding as well. The amount of any backup withholding from a payment to a Non-U.S. holder will be allowed as a credit against
such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information
is timely furnished to the IRS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>FATCA Withholding Taxes</i>.
Sections 1471 through 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred
as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) generally impose withholding at a rate of 30% in certain
circumstances on dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale
or other disposition of, securities (including shares of our common stock) which are held by or through certain foreign financial institutions
(including investment funds), unless any such institution (i) enters into, and complies with, an agreement with the IRS to report, on
an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S.
persons and by certain non-U.S. entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii)
if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information
to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the
United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which shares of our common
stock are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject
to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock held by an
investor that is a non-financial non-U.S. entity that does not qualify under certain exceptions will generally be subject to withholding
at a rate of 30%, unless such entity either (i) certifies to the applicable withholding agent that such entity does not have any &#8220;substantial
United States owners&#8221; or (ii) provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221;
which will in turn be provided to the U.S. Department of Treasury.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Under the applicable Treasury
Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends in respect of our common stock.
While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities
(including shares of our common stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely.
Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult
their tax advisors regarding the possible implications of FATCA on their investment in shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_013"></span>PLAN OF DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inducement Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Securityholder, which
as used herein, includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in
shares of common stock received after the date of this prospectus from the Selling Securityholders as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests
in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions.
These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market
price, at varying prices determined at the time of sale, or at negotiated prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders may
use any one or more of the following methods when disposing of shares or interests therein:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent, but may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers may agree with the Selling Securityholders to sell a specified number of such shares at a stipulated price per share;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such methods of sale; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders may,
from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by it and, if it defaults in
the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to
time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act amending the list of Selling Securityholders to include the pledgee, transferee or other successors in interest as Selling Securityholders
under this prospectus. The Selling Securityholders also may transfer the shares of common stock in other circumstances, in which case
the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the sale of
our common stock or interests therein, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The Selling
Securityholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan
or pledge the common stock to broker-dealers that in turn may sell these securities. The Selling Securityholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or
other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate proceeds to the
Selling Securityholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts
or commissions, if any. The Selling Securityholders reserve the right to accept and, together with their agents from time to time, to
reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the
proceeds from this Inducement Offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price
of the Inducement Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders also
may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that
it meets the criteria and conforms to the requirements of that rule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders and
any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221;
within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Any Selling Securityholder who is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To the extent required, the shares
of our common stock to be sold, the name of the Selling Securityholder, the respective purchase prices and public offering prices, the
names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set
forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes
this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order to comply with the securities
laws of certain states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers
or dealers. In addition, in some states, the common stock may not be sold unless (i) it has been registered or qualified for sale or (ii)
an exemption from registration or qualification requirements is available and is complied with.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have advised the Selling Securityholders
that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities
of the Selling Securityholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as
it may be supplemented or amended from time to time) available to the Selling Securityholders for the purpose of satisfying the prospectus
delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions
involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify the
Selling Securityholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the
registration of the shares offered by this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed with the Selling
Securityholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such
time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement
or (2) the date on which all of the shares may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 of the Securities
Act and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Company Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to an engagement
agreement, dated as of July 16, 2025, we have engaged Maxim Group LLC, or the placement agent, to act as our exclusive placement agent
to solicit offers to purchase the securities offered in the Company Offering pursuant to this prospectus on a reasonable best-efforts
basis. The engagement agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the
placement agent will have no authority to bind us by virtue of the engagement agreement. The placement agent is not purchasing or selling
any of the securities offered by us under this prospectus, nor is it required to arrange for the purchase or sale of any specific number
or dollar amount of securities. The placement agent does not guarantee that it will be able to raise new capital in any prospective offering.
This offering will terminate within one year of the effective date, unless we decide to terminate the offering (which we may do at any
time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public
offering price per share of common stock (or pre-funded warrant) and accompanying warrant, in the Company Offering, will be fixed for
the duration of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will enter into a securities
purchase agreement directly with certain institutional investors, at such investor&#8217;s option, which purchase our securities in this
offering. Investors that do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the
purchase of our securities in this offering. There is no minimum number of securities or amount of proceeds that is a condition to closing
of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Fees and Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows the
p<span style="background-color: white">er share and accompanying warrant and per&#160;pre-funded&#160;warrant and accompanying warrant</span>&#160;and
total placement agent fees we will pay in connection with the sale of the securities in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Share and<br/> Accompanying Warrant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Per Pre-Funded</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrant and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Accompanying Warrant</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt">Placement Agent Fees</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to pay the placement
agent a cash fee equal to 6.5% of the gross proceeds raised at the closing of this offering. We also agreed to issue warrants to the placement
agent for the purchase of a number of shares of common stock equal to 4% of the total number of shares of common stock issued in this
offering. In addition, we have agreed to reimburse the placement agent for its legal fees and expenses and other out-of-pocket expenses
in an amount up to $100,000. We estimate the total offering expenses of this offering that will be payable by us, excluding the placement
agent fees and expenses, will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Placement Agent Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition,
we have agreed to issue to the placement agent or its designees warrants to purchase up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
shares of common stock (which represents 4% of the aggregate number of shares of common stock issued in this offering) with an exercise
price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share (representing 100% of the combined public
offering price per share of common stock (or pre-funded warrant) and accompanying warrant in this offering). The placement agent warrants
will be non-exercisable for six (6) months after the date of the closing and will expire five years after the commencement of sales of
the offering. The form of the placement agent warrants has been included as an exhibit to this registration statement of which this prospectus
is a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Lock-up&#160;Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We and each of our officers and
directors have agreed with the placement agent to be subject to a&#160;lock-up&#160;period of 60 days following the date of closing of
the offering pursuant to this prospectus. This means that, during the applicable&#160;lock-up period, we and such persons may not offer
for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose
of, directly or indirectly, any of our shares of common stock or any securities convertible into, or exercisable or exchangeable for,
shares of common stock, subject to customary exceptions. The placement agent may waive the terms of these lock-up agreements in its sole
discretion and without notice. In addition, we have agreed to not issue any securities that are subject to a price reset based on the
trading prices of our common stock or upon a specified or contingent event in the future or enter into any agreement to issue securities
at a future determined price for a period of one year following the closing date of this offering. The placement agent may waive this
prohibition in its sole discretion and without notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Regulation M</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The placement agent may be deemed
to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act, and any commissions received by it and any profit
realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions
under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities Act
and the Securities Exchange Act of 1934, as amended, or the Exchange Act, including, without limitation, Rule 10b-5 and Regulation M under
the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the placement agent acting
as principal. Under these rules and regulations, the placement agent (i)&#160;may not engage in any stabilization activity in connection
with our securities and (ii)&#160;may not bid for or purchase any of our securities or attempt to induce any person to purchase any of
our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Indemnification</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify the
placement agent against certain liabilities, including certain liabilities arising under the Securities Act, or to contribute to payments
that the placement agent may be required to make for these liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Determination of Offering Price&#160;and&#160;Warrant Exercise Price</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The actual offering price of the
securities we are offering has been negotiated between us&#160;and the investors in the offering&#160;based on the trading of our shares
of common stock prior to the offering, among other things. Other factors considered in determining the public offering price of the securities
we are offering include our history and prospects, the stage of development of our business, our business plans for the future and the
extent to which they have been implemented, an assessment of our management, the general conditions of the securities markets at the time
of the offering and such other factors as were deemed relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Electronic Offer, Sale and Distribution of Securities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A prospectus in electronic format
may be made available on the websites maintained by the placement agent, if any, participating in this offering and the placement agent
may distribute prospectuses electronically. Other than the prospectus in electronic format, the information on these websites is not part
of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the
placement agent, and should not be relied upon by investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Other Relationships</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, the placement agent or its affiliates
have in the past or may in the future provide, various advisory, investment and commercial banking and other services to us in the ordinary
course of business, for which they have received and may continue to receive customary fees and commissions. However, except as disclosed
in this prospectus, we have no present arrangements with the placement agent for any further services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Listing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our shares of common stock are listed on The Nasdaq
Capital Market under the symbol &#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Offer Restrictions Outside the United States</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other
than in the United States, no action has been taken by us or the placement agents that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may
not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection
with the offer and sale of any such securities be distributed or published, in any jurisdiction, except under circumstances that will
result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes
are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>European Economic Area</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In relation to each member state
of the European Economic Area, no offer of securities which are the subject of the offering has been, or will be made to the public in
that Member State, other than under the following exemptions under the Prospectus Directive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">to fewer than 150 natural or legal persons
    (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the
    Representatives for any such offer; or</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances falling within Article&#160;3(2) of the Prospectus Directive,</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>provided</i>&#160;that no such offer of securities
referred to in (a)&#160;to (c)&#160;above shall result in a requirement for the Company or the placement agent to publish a prospectus
pursuant to Article&#160;3 of the Prospectus Directive, or supplement a prospectus pursuant to Article&#160;16 of the Prospectus Directive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Each person located in a Member
State to whom any offer of securities is made or who receives any communication in respect of an offer of securities, or who initially
acquires any shares of our securities will be deemed to have represented, warranted, acknowledged and agreed to and with the placement
agent and the Company that (1)&#160;it is a &#8220;qualified investor&#8221; within the meaning of the law in that Member State implementing
Article&#160;2(1)(e) of the Prospectus Directive; and (2)&#160;in the case of any shares of our securities acquired by it as a financial
intermediary as that term is used in Article&#160;3(2) of the Prospectus Directive, the securities acquired by it in the offer have not
been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than
qualified investors, as that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the placement
agent has been given to the offer or resale; or where our securities have been acquired by it on behalf of persons in any Member State
other than qualified investors, the offer of those securities to it is not treated under the Prospectus Directive as having been made
to such persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">The Company, the placement agent
and their respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus has been prepared
on the basis that any offer of our securities in any Member State will be made pursuant to an exemption under the Prospectus Directive
from the requirement to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an offer in that
Member State of our securities which are the subject of the offering contemplated in this prospectus may only do so in circumstances in
which no obligation arises for the Company or the placement agent to publish a prospectus pursuant to Article&#160;3 of the Prospectus
Directive in relation to such offer. Neither the Company nor the placement agent have authorized, nor do they authorize, the making of
any offer of securities in circumstances in which an obligation arises for the Company or the placement agent to publish a prospectus
for such an offer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the purposes of this provision,
the expression an &#8220;offer of our securities to the public&#8221; in relation to any of our securities in any Member State means the
communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as
to enable an investor to decide to purchase or subscribe for the securities, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State, the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC
(as amended) and includes any relevant implementing measure in each Member State. The above selling restriction is in addition to any
other selling restrictions set out below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in the United Kingdom</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, in the United Kingdom,
this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who
are &#8220;qualified investors&#8221;(as defined in the Prospectus Directive) (i)&#160;who have professional experience in matters relating
to investments falling within Article&#160;19 (5)&#160;of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the &#8220;Order&#8221;) and/or (ii)&#160;who are high net worth companies (or persons to whom it may otherwise be lawfully
communicated) falling within Article&#160;49(2)(a) to (d)&#160;of the Order (all such persons together being referred to as &#8220;relevant
persons&#8221;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the
United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with,
relevant persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Switzerland</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The securities may not be publicly
offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated
trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of
the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document
nor any other offering or marketing material relating to our securities or the offering may be publicly distributed or otherwise made
publicly available in Switzerland.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Neither this document nor any other
offering or marketing material relating to the offering, the Company or our securities have been or will be filed with or approved by
any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of our securities will not be supervised
by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of our securities has not been and will not be authorized
under the Swiss Federal Act on Collective Investment Schemes (&#8220;CISA&#8221;). The investor protection afforded to acquirers of interests
in collective investment schemes under the CISA does not extend to acquirers of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in the Dubai International Financial
Centre</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus relates to an Exempt
Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (&#8220;DFSA&#8221;). This prospectus
is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered
to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt
Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility
for the prospectus. The securities to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective
purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of
this prospectus you should consult an authorized financial advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Australia</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">No placement document, prospectus,
product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (&#8220;ASIC&#8221;),
in relation to the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus does not constitute a prospectus,
product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;) and does
not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the
Corporations Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any offer in Australia of our securities
may only be made to persons (the &#8220;Exempt Investors&#8221;) who are &#8220;sophisticated investors&#8221; (within the meaning of
section 708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations
Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the
securities without disclosure to investors under Chapter 6D of the Corporations Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The securities applied for by Exempt
Investors in Australia must not be offered for sale in Australia in the period of 12&#160;months after the date of allotment under the
offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant
to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies
with Chapter 6D of the Corporations Act. Any person acquiring our securities must observe such Australian on-sale restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus contains general
information only and does not take account of the investment objectives, financial situation or particular needs of any particular person.
It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to
consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek
expert advice on those matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Hong Kong</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The securities have not been offered
or sold and will not be offered or sold in Hong Kong, by means of&#160;any document, other than (a)&#160;to &#8220;professional investors&#8221;
as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&#160;in other
circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap.&#160;32)
of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document
relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of issue,
whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of
Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are
intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the Securities
and Futures Ordinance and any rules made under that Ordinance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Japan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The securities have not been and
will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and, accordingly, will
not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale,
directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial
guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of
this paragraph, &#8220;Japanese Person&#8221; shall mean any person resident in Japan, including any corporation or other entity organized
under the laws of Japan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Singapore</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus has not been registered
as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection
with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in
Singapore other than (i)&#160;to an institutional investor under Section&#160;274 of the Securities and Futures Act, Chapter 289 of Singapore
(the &#8220;SFA&#8221;), (ii)&#160;to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in
accordance with the conditions specified in Section&#160;275, of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with
the conditions of, any other applicable provision of the SFA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Where the securities are subscribed or purchased under
Section&#160;275 of the SFA by a relevant person which is:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section&#160;239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that trust has acquired the securities pursuant to an offer made under Section&#160;275 of the SFA except:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to an institutional investor or to a relevant person defined in Section&#160;275(2) of the SFA, or to any person arising from an offer referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where no consideration is or will be given for the transfer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the transfer is by operation of law;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as specified in Section&#160;276(7) of the SFA; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as specified in Regulation&#160;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&#160;2005 of Singapore.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Canada</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The securities may be sold only
to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106&#160;<i>Prospectus
Exemptions</i>&#160;or subsection&#160;73.3(1) of the&#160;<i>Securities Act</i>&#160;(Ontario), and are permitted clients, as defined
in National Instrument 31-103&#160;<i>Registration Requirements, Exemptions and Ongoing Registrant Obligations</i>. Any resale of&#160;the
securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable
securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Securities legislation in certain
provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment
thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the
time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or
consult with a legal advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to section 3A.3 (or, in
the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105&#160;<i>Underwriting
Conflicts</i>&#160;(<b>NI 33-105</b>), the placement agent is not required to comply with the disclosure requirements of NI 33-105 regarding
underwriter conflicts of interest in connection with this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Notice to Prospective Investors in Israel</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The securities offered by this
prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been
registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication
of a prospectus. The ISA has not issued permits, approvals or licenses in connection with this offering or publishing the prospectus;
nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality
of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus
is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_014"></span>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The validity of the securities
being offered by this prospectus supplement will be passed upon for us Procopio Cory Hargreaves &amp; Savitch, LLP, San Diego, California.
Carter Ledyard&#160;&amp; Milburn LLP, New York, New York, has acted as special New York counsel to the Company by providing an opinion
on the validity of the Common Stock Warrants and the Placement Agent Warrants offered by this prospectus. Certain legal matters in connection
with this offering will be passed upon for the placement agent by Pryor Cashman LLP, New York, New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_015"></span>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements
of Aethlon Medical, Inc. for the year ended March&#160;31, 2025 incorporated by reference in this Registration Statement and Prospectus
have been so incorporated by reference in reliance on the report, which includes an explanatory paragraph describing conditions that raise
substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial
statements, of Haskell &amp; White, LLP, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The consolidated financial statements
of Aethlon Medical, Inc. as of March 31, 2024 and for the year in the period ended March 31, 2024, incorporated by reference in this Registration
Statement and Prospectus, have been so incorporated by reference in reliance upon the report, which includes an explanatory paragraph
describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note
1 to the consolidated financial statements, of Baker Tilly US, LLP, independent registered public accountants, which upon the authority
of said firm as experts in accounting and auditing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_016"></span>MARKET AND INDUSTRY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated, information
contained in this prospectus concerning the medical device industry, including our market opportunity, is based on information from independent
industry analysts, third-party sources and management estimates. Management estimates are derived from publicly available information
released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions
made by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we
believe the market opportunity information included in this prospectus is generally reliable and is based on reasonable assumptions, such
data involves risks and uncertainties and are subject to change based on various factors, including those discussed under the heading
&#8220;<a href="#s1_005">Risk Factors</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_017"></span>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We have
filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities being offered by this
prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information
with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements
contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in
each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these
statements is qualified in all respects by this reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">You can
read our SEC filings, including the registration statement, over the Internet at the SEC&#8217;s website at www.sec.gov. You may also
request a copy of these filings, at no cost, by writing us at 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 or telephoning
us at (619) 941-0360.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We are
subject to the information and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and
other information with the SEC. These periodic reports, proxy statements and other information are available at the website of the SEC
referred to above. We maintain a website at www.aethlonmedical.com. You may access our annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of
the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed
with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference
in, and is not part of, this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 49; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_018"></span>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The SEC
allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of
this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the
date of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We incorporate
by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed
below (except in each case the information contained in such document to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;)
that we have filed with the SEC:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882291/000168316825004780/aethlon_i10k-033125.htm">Annual Report on Form 10-K</a></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the fiscal year ended March 31, 2025 filed with the SEC on June 26, 2025;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882291/000168316825006049/aethlon_i10q-063025.htm">Quarterly Report on Form 10-Q</a> for the quarter ended June 30, 2025, filed with the SEC on August 13, 2025;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our </span><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316825002685/aethlon_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">definitive proxy statement on Schedule 14A</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed with the SEC on April 18, 2025;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Reports on Form 8-K</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882291/000168316825003490/aemd_8k.htm">May 13, 2025</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882291/000168316825004248/aethlon_8k.htm">June 5, 2025</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882291/000168316825004784/aemd_8k.htm">June 27, 2025</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/882291/000168316825006042/aemd_8k.htm">August 13, 2025</a>; and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on </span><a href="http://www.sec.gov/Archives/edgar/data/882291/000101968715002644/aethlon_8a12b.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 8-A</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, filed with the SEC on July 8, 2015, including any amendment or reports filed for the purpose of updating such description. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition,
all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of
the offering (excluding any information furnished rather than filed) shall be deemed to be incorporated by reference into this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We will
provide to each person, including any beneficial owners, to whom a prospectus is delivered, a copy of any or all of the reports or documents
that have been incorporated by reference in the prospectus contained in the registration statement but not delivered with the prospectus.
We will provide these reports or documents upon written or oral request at no cost to the requester. You should direct any written requests
for documents to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Aethlon Medical, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">11555 Sorrento Valley Road,
Suite 203</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">San Diego, California 92121</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Telephone: (619) 941-0360</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">You also
may access these filings through the SEC website at www.sec.gov or on our website at www.aethlonmedical.com. Information contained on
or accessible through our website is not a part of this prospectus or the registration statement of which it forms a part, and the inclusion
of our website address in this prospectus is an inactive textual reference only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In accordance
with Rule 412 of the Securities Act, (i)&#160;any statement contained in a document incorporated by reference herein shall be deemed modified
or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to
be incorporated by reference herein modifies or supersedes such statement, and (ii)&#160;any statement contained in a document that is
deemed to be incorporated by reference herein after the date of this prospectus may modify or replace existing statements contained herein.
You should rely only on the information contained in, or incorporated by reference into, this prospectus, or in any free writing prospectus
filed by us with the SEC. We have not authorized anyone to provide you with different or additional information. We are not offering to
sell or soliciting any offer to buy any securities in any jurisdiction where the offer or sale is not permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="background-color: white"><b>Aethlon Medical,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Up to [___] Shares of Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Pre-Funded Warrants to Purchase up to [___] Shares
of Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Warrants to Purchase up to [___] Shares of Common
Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Placement Agent Warrants to Purchase up to [__]
shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares of Common Stock Issuable upon the Exercise
of the Warrants, Pre-Funded Warrants and Placement Agent Warrants. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>[____] Shares of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Issuable upon Exercise of Outstanding Warrants Offered
by Selling Stockholders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>, 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 13. Other Expenses of Issuance and Distribution</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the costs and expenses, payable by the Company in connection with the registration of the securities being registered. All amounts are
estimates except the SEC registration fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA filing fee</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing and engraving expenses</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer agent fees and expenses</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous fees and expenses</span></td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total expenses</span></td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[____]</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 14. Indemnification of Directors and Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We are
incorporated in Nevada. Section 78.7502(1) of the Nevada Revised Statutes, or NRS, provides that a corporation may indemnify, pursuant
to that statutory provision, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation)
by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation or other enterprise or as a manager of a limited liability
company, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by him or her in connection with such action, suit or proceeding if he is not liable pursuant to NRS 78.138 or if he acted in good faith
and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. NRS 78.138(7) provides that, subject to limited
statutory exceptions and unless the articles of incorporation or an amendment thereto (in each case filed on or after October 1, 2003)
provide for greater individual liability, a director or officer is not individually liable to the corporation or its stockholders or creditors
for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless the presumption established
by NRS 78.138(3) has been rebutted and it is proven that (i) his or her act or failure to act constituted a breach of his or her fiduciary
duties as a director or officer, and (ii) such breach involved intentional misconduct, fraud or a knowing violation of the law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">NRS 78.7502(2)
permits a corporation to indemnify, pursuant to that statutory provision, any person who was or is a party or is threatened to be made
a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor
by reason of the fact that such person acted in any of the capacities set forth above against expenses, including amounts paid in settlement
and attorneys&#8217; fees actually and reasonably incurred by him or her in connection with the defense or settlement of such action or
suit if he acted under similar standards, except that no indemnification pursuant to NRS 78.7502 may be made in respect of any claim,
issue or matter as to which such person shall have been adjudged by a court of competent jurisdiction, after any appeals taken therefrom,
to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in
which such action or suit was brought or other court of competent jurisdiction determines that, in view of all the circumstances of the
case, such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper. NRS 78.751(1) provides that
a corporation shall indemnify any person who is a director, officer, employee or agent of the corporation, against expenses actually and
reasonably incurred by the person in connection with defending an action (including, without limitation, attorney&#8217;s fees), to the
extent that the person is successful on the merits or otherwise in defense of any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative, including, without limitation, an action by or in the right of the corporation,
by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the
request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
enterprise or as a manager of a limited liability company, or any claim, issue or matter in such action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">NRS 78.751
provides that the indemnification pursuant to NRS 78.7502 shall not be deemed exclusive or exclude any other rights to which the indemnified
party may be entitled (except that indemnification may not be made to or on behalf of any director or officer finally adjudged by a court
of competent jurisdiction, after exhaustion of any appeals taken therefrom, to be liable for intentional misconduct, fraud or a knowing
violation of the law and such intentional misconduct, fraud or a knowing violation of the law was material to the cause of action) and
that the indemnification shall continue as to directors, officers, employees or agents who have ceased to hold such positions, and to
their heirs, executors and administrators. NRS 78.752 permits a corporation to purchase and maintain insurance on behalf of a director,
officer, employee or agent of the corporation against any liability asserted against him or her or incurred by him or her in any such
capacity or arising out of his or her status as such whether or not the corporation would have the power to indemnify him or her against
such liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Bylaws</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our bylaws
include express provisions providing for the indemnification of our directors and officers to the fullest extent permitted under the NRS,
and the mandatory payment by us of expenses incurred by such persons in defending a civil or criminal action, suit or proceeding in advance
of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer
to repay the amount if it is ultimately determined that such person is not entitled to be indemnified by us. Our bylaws also permit us
to purchase and maintain insurance or make other financial arrangements on behalf of any such person for certain liability and expenses,
whether or not we have the authority to indemnify such person against such liability and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Liability
Insurance</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We maintain
directors&#8217; and officers&#8217; liability insurance covering our directors and officers against expenses and liabilities arising
from certain actions to which they may become subject by reason of having served in such role, including insurance for claims against
these persons brought under securities laws. Such insurance is subject to the coverage amounts, exceptions, deductibles and other conditions
set forth in the policy as in effect at the time of a claim, if any. There is no assurance that we will maintain liability insurance for
our directors and officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 15. Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Within the past three years, the Registrant did not
sell any unregistered securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 16. Exhibits and Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i><span id="s1_019"></span>(a) Exhibits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following exhibits are
being filed with this Registration Statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>(b) Financial Statement
Schedules</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">No financial statement schedules
are provided because the information called for is not required or is shown either in the financial statements or the notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed Herewith</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822006480/aethlon_8k.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation, as amended</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 19, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819002910/aethlon_8k.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of the Company</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 12, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Certificate</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-201334</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2014</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0414.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-234712</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0415.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter Warrant</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-234712</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316820000188/aethlon_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 17, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316824003612/aethlon_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Class A Warrant to Purchase Common Stock, issued on May 17, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 17, 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed Herewith</b></span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316824003612/aethlon_ex0402.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Class B Warrant to Purchase Common Stock, issued on May 17, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 17, 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316824003612/aethlon_ex0403.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant to Purchase Common Stock, issued on May 17, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 17, 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316824003612/aethlon_ex0404.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant to Purchase Common Stock, issued on May 17, 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 17, 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316825004780/aethlon_ex0409.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Aethlon Medical, Inc.&#8217;s Securities</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-3787</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316825001631/aemd_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">orm of New Warrant to purchase Common Stock issued on March 17, 2025</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 17, 2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (current offering)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant (current offering)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">*</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agency Agreement (current offering)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Warrant (current offering)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Procopio, Cory, Hargreaves &amp; Savitch, LLP</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Carter Ledyard &amp; Milburn, LLP</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1++</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822001002/aethlon_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aethlon Medical, Inc. Amended and Restated Non-Employee Director Compensation Policy, as Modified on February 10, 2022</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 14, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2++</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1003.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, by and between Aethlon Medical, Inc. and James Frakes, dated December 12, 2018</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3++</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823009061/aethlon_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Executive Employment Agreement, effective as of November 7, 2023, by and between the Company and James B. Frakes</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 22, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4++</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1004.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement for Officers and Directors</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1005.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Option Grant Agreement for Officers and Directors</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2019</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed Herewith</b></span></td></tr>

<tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1006.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Directors</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2019</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1007.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Executives</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2019</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819003664/aethlon_ex-1027.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment Agreement, by and between Aethlon Medical, Inc. and London Health Sciences Center Research Inc., dated November 7, 2006</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 15, 2019</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>

<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316824006850/aethlon_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aethlon Medical, Inc. 2020 Equity Incentive Plan as amended,, Form of Restricted Stock Grant, Form of Option Grant and Agreement</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 2, 2024</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316820003665/aethlon_8k-ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between the Company and Dr. Fisher, dated October 30, 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 3, 2020</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823008454/aethlon_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation Agreement between the Company and Dr. Fisher, effective as of November 27, 2023</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 27, 2023</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1003.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease, by and between the Company and San Diego Inspire 1, LLC. and San Diego Inspire 2, LLC, effective December 7, 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 10, 2021</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1005.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement between the Company and Guy Cipriani, dated January 1, 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 10, 2021</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823009061/aethlon_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Executive Employment Agreement, effective as of November 7, 2023, by and between the Company and Guy F. Cipriani</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-3748<b>7</b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 22, 2023</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1006.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement between the Company and Steven P. LaRosa, MD, dated January 4, 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 10, 2021</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16++</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823000822/aethlon_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, by and between Aethlon Medical, Inc. and Lee D. Arnold, Ph.D., dated February 1, 2023</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 13, 2023</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821005369/aethlon_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease between Aethlon Medical, Inc. and San Diego Inspire 5, LLC, effective October 27, 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 9, 2021</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="9" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed Herewith</b></span></td></tr>

<tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822001925/aethlon_ex0101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Market Offering Agreement, dated March 24, 2022, by and between Aethlon Medical, Inc. and H.C. Wainwright &amp; Co., LLC</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 24, 2022</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19++</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823004487/aethlon_ex1018.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Executive Employment Agreement, by and between Aethlon Medical, Inc. and Lee D. Arnold, Ph.D., dated May 1, 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 28, 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316825001631/aemd_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement Letter dated March 17, 2025</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 17, 2025</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (current offering)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316825004780/aethlon_ex1901.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316825004780/aethlon_ex2101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="aethlon_ex2301.htm">Consent of Haskell &amp; White LLP, Independent Registered Public Accounting Firm</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td>&#160;</td>
    <td><a href="aethlon_ex2302.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Baker Tilly US, LLP, Independent Registered Public Accounting Firm</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Procopio Cory Hargreaves &amp; Savitch, LLP (included in Exhibit 5.1) </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Carter Ledyard &amp; Milburn LLP (included in Exhibit 5.2) </span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#s1_021">Power of Attorney</a></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(see signature page)</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316825004780/aethlon_ex9701.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive Compensation Recoupment Policy</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center">10-K</td>
    <td>&#160;</td>
    <td style="text-align: center">001-37487</td>
    <td>&#160;</td>
    <td style="text-align: center">97.1</td>
    <td>&#160;</td>
    <td style="text-align: center">June 26, 2025</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101 INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101 SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">I<span style="font-family: Times New Roman, Times, Serif">nline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="aethlon_ex107.htm">Filing Fee Table</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* to be filed by amendment</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">** furnished herewith</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Item 17. Undertakings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The undersigned
registrant hereby undertakes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in; background-color: white">(i)
To include any prospectus required by Section&#160;10(a)(3) of the Securities Act;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in; background-color: white">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in; background-color: white">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial&#160;<i>bona fide</i>&#160;offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">(4) That,
for the purpose of determining liability under the Securities Act to any purchaser: each prospectus filed pursuant to Rule 424(b) as part
of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="s1_020"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.75pt">Pursuant to the requirements of the Securities Act
of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized
in the city of San Diego, California, on this 20<sup>th</sup> day of August 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AETHLON MEDICAL, Inc.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="vertical-align: top; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James B. Frakes</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="border-top: black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James B. Frakes<br/>
Chief Executive Officer &amp; Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 24.75pt"><b><span id="s1_021"></span>POWER OF ATTORNEY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">KNOW ALL BY THESE PRESENTS, that each person whose
signature appears below hereby constitutes and appoints James B. Frakes, his or her true and lawful agent, proxy and attorney-in-fact,
with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities,
to (i)&#160;act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments)
to this registration statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant
to Rule 462(b) under the Securities Act, together with all schedules and exhibits thereto, (ii)&#160;act on, sign and file such certificates,
instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii)&#160;act on and file any
supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed
pursuant to Rule 462(b) under the Securities Act and (iv)&#160;take any and all actions which may be necessary or appropriate to be done,
as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such
agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Act,
this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.75pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ JAMES B. FRAKES</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">James B. Frakes</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt">Chief Accounting Officer
    and Director</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">August 20, 2025</td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ EDWARD G. BROENNIMAN</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Edward G. Broenniman</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
20, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ NICOLAS GIKAKIS</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nicolas Gikakis</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">August 20, 2025</td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/&#160;ANGELA ROSSETTI</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Angela Rossetti</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center">August 20, 2025</td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">/s/ CHETAN S. SHAH</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Chetan S. Shah, M.D.</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
20, 2025</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 61; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LNoNFN2bDhVxiowhvhYXpbg1I61zfpJ/abchhkBI7j25QozElja6RIbLKkshx6oulUPI8IaM5orekez2MfiZ4V1bx8q4fv2BCXkGPTMbh8rfe2ejLRYxyPkkXEyiKchZLCNYHkTQ6QmZmy7QOK1KUKaAE1PNGp3i9/AhVy0Zqt590hnZajIxhGM5yB+IZBjBkRr1In5YSNNEBKO+ArFletbetW4dmo6EdYmVj7MD/e/gC8XwSlI= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>aethlon_ex2301.htm
<DESCRIPTION>CONSENT OF HASKELL & WHITE LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
this Registration Statement on Form S-1 of Aethlon Medical, Inc. (the &ldquo;Company&rdquo;) of our report dated June 26, 2025, relating
to our audit of the Company&rsquo;s consolidated financial statements as of March 31, 2025, and for the year then ended, included in the
Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our report includes an explanatory paragraph expressing
substantial doubt regarding the Company&rsquo;s ability to continue as a going concern. Our report also relates to the adjustments described
in Note 4 to the consolidated financial statements that were applied retroactively to reflect the June 9, 2025 one-for-eight reverse stock
split, as well as the comparative disclosures for the adoption of new segment reporting requirements as described in Note 9 to the consolidated
financial statements as of and for the year ended March 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us under the
heading &ldquo;Experts&rdquo; in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in"><I>/s/ Haskell &amp; White
LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 227pt; text-align: justify; text-indent: 0.5in">HASKELL &amp;
WHITE LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Irvine, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">August 20, 2025</P>
<P STYLE="margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>aethlon_ex2302.htm
<DESCRIPTION>CONSENT OF BAKER TILLY US, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in Registration
Statement Form S-1 (File No.&nbsp;333-08257) of our report dated June 27, 2024, relating to the consolidated financial statements of
Aethlon Medical, Inc. as of and for the year ended March 31, 2024, which appears in the Form 10-K for the year ended March 31, 2025.
Our report contains an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as
a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also consent to the reference to us under the heading &quot;Experts&quot; in such Registration Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Baker Tilly US, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>aethlon_ex107.htm
<DESCRIPTION>FILING FEE TABLES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.2b -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: 16f0248bb9bd4f80f3fb177861f8a383 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">S-1</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0000882291</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_2">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>2</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_3">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>3</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_4">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>4</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_5">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>5</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_6">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>6</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_7">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>7</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_offering_8">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>8</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2025-08-18</xbrli:startDate>
          <xbrli:endDate>2025-08-18</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">S-1</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">Aethlon Medical, Inc.</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457oFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">457(o)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">10,000,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">1,531.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_2" format="ixt:booleanfalse" id="fee_016">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_2" id="fee_017">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_2" id="fee_018">Common Stock Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(2)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_2" format="ixt:booleantrue" id="fee_019">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_2" id="fee_020">0.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_2" id="fee_021">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_2" id="fee_022">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_3" format="ixt:booleanfalse" id="fee_023">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_3" id="fee_024">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_3" id="fee_025">Common Stock Underlying Common Stock Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(3)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457oFlg" contextRef="c_offering_3" format="ixt:booleantrue" id="fee_026">457(o)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_3" id="fee_027">10,000,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_3" id="fee_028">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_3" id="fee_029">1,531.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_4" format="ixt:booleanfalse" id="fee_030">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_4" id="fee_031">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_4" id="fee_032">Pre-Funded Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(4)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_4" format="ixt:booleantrue" id="fee_033">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_4" id="fee_034">0.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_4" id="fee_035">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_4" id="fee_036">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_5" format="ixt:booleanfalse" id="fee_037">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_5" id="fee_038">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_5" id="fee_039">Common Stock Underlying Pre- Funded Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(5)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457oFlg" contextRef="c_offering_5" format="ixt:booleantrue" id="fee_040">457(o)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_5" id="fee_041">0.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_5" id="fee_042">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_5" id="fee_043">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_6" format="ixt:booleanfalse" id="fee_044">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_6" id="fee_045">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_6" id="fee_046">Placement Agent Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(6)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_6" format="ixt:booleantrue" id="fee_047">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_6" id="fee_048">0.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_6" id="fee_049">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_6" id="fee_050">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_7" format="ixt:booleanfalse" id="fee_051">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_7" id="fee_052">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_7" id="fee_053">Common Stock Underlying Placement Agent Warrants</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(7)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_7" format="ixt:booleantrue" id="fee_054">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_7" id="fee_055">400,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_7" id="fee_056">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_7" id="fee_057">61.24</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_8" format="ixt:booleanfalse" id="fee_058">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_8" id="fee_059">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_8" id="fee_060">Common Stock, underlying the Inducement Warrants held by the Selling Securityholder</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(8)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:FeesOthrRuleFlg" contextRef="c_offering_8" format="ixt:booleantrue" id="fee_061">Other</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_8" id="fee_062">1,550,000</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_8" id="fee_063">1.14</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_8" id="fee_064">1,767,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_8" id="fee_065">0.0001531</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_8" id="fee_066">270.47</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_067">22,167,000.00</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_068">3,393.71</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_069">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_070">3,393.71</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_071">Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(2)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_2" id="fee_072">No fee required pursuant to Rule 457(g) under the Securities Act.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(3)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_3" id="fee_073">Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. Represents shares of common stock issuable upon exercise of the common stock warrants. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act and based on an assumed per-share exercise price for the common stock warrants of 100% of the combined public offering price of the common stock and common stock warrants; the proposed maximum aggregate offering price of the common stock and pre-funded warrants is $10,000,000. For each share of common stock issued in the offering, the Registrant will issue a common warrant to purchase one share of common stock.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(4)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_4" id="fee_074">No fee required pursuant to Rule 457(g) under the Securities Act. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000. The registrant may issue pre-funded warrants to purchase common shares in the offering. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.0001 per share (subject to adjustment as provided.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(5)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_5" id="fee_075">Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. Represents shares of common stock issuable upon exercise of the pre-funded warrants.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(6)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_6" id="fee_076">No fee required pursuant to Rule 457(g) under the Securities Act. Represents shares of common stock issuable upon exercise of the placement agent warrants.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(7)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_7" id="fee_077">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The placement agent warrants are exercisable at a per share exercise price equal to 110% of the combined public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the placement agent which is equal to 4% of $10,000,000.</ix:nonNumeric></td></tr>
  </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(8)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_8" id="fee_078">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on August 18, 2025 ($1.14 per share of common stock). This calculation is in accordance with Rule 457(c) of the Securities Act.</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>aemd-20250820.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa2KmaPty552eYkxvmR3fWnqDy0hhycJki0XACnmgbQP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:AEMD="http://aethlonmedical.com/20250820" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20250820">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aethlonmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20250820_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20250820_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>aemd-20250820_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>aemd-20250820_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="aemd-20250820.xsd#Cover" roleURI="http://aethlonmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>aethlonlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aethlonlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !, .H# 2(  A$! Q$!_\0
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M2VL>"OV6OC1X-N/@'X\U!]5ENE35='MM1:ZM(EW)\G_ OFK[$_:A^.GB"_\
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MS5+G_2KQO^FK?PU[+L_VVI$3^*G[1ZU\S5DZTN:1[%*G"C'E04444S4****
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M7 ]O9NB?ZJ)OX*ZNAZCGE$?)&1R6E?#'PUHFO:MJ]CHMI!J>K+_IUPB_Z_\
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B[YMO^[7OD*;*2.GI7SLL1*M+FD>M3H1HKEB%%%%6:G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 20, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AETHLON MEDICAL,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3632859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11555 Sorrento Valley Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-0360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Aug. 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Aethlon Medical, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Aug. 18, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 10,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,531.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">No fee required pursuant to Rule 457(g) under the Securities Act.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock Underlying Common Stock Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 10,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,531.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. Represents shares of common stock issuable upon exercise of the common stock warrants. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act and based on an assumed per-share exercise price for the common stock warrants of 100% of the combined public offering price of the common stock and common stock warrants; the proposed maximum aggregate offering price of the common stock and pre-funded warrants is $10,000,000. For each share of common stock issued in the offering, the Registrant will issue a common warrant to purchase one share of common stock.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Pre-Funded Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">No fee required pursuant to Rule 457(g) under the Securities Act. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000. The registrant may issue pre-funded warrants to purchase common shares in the offering. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.0001 per share (subject to adjustment as provided.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock Underlying Pre- Funded Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. Represents shares of common stock issuable upon exercise of the pre-funded warrants.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=6', window );">Offering: 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Placement Agent Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">No fee required pursuant to Rule 457(g) under the Securities Act. Represents shares of common stock issuable upon exercise of the placement agent warrants.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=7', window );">Offering: 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock Underlying Placement Agent Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 400,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 61.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The placement agent warrants are exercisable at a per share exercise price equal to 110% of the combined public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the placement agent which is equal to 4% of $10,000,000.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=8', window );">Offering: 8</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, underlying the Inducement Warrants held by the Selling Securityholder<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">1,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 1,767,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 270.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on August 18, 2025 ($1.14 per share of common stock). This calculation is in accordance with Rule 457(c) of the Securities Act.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=8">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=8</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Aug. 18, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 22,167,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">3,393.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 3,393.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>10</ContextCount>
  <ElementCount>39</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="aethlon_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aethlon_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aethlon_ex107.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aethlon_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aemd-20250820.xsd</File>
    <File>aemd-20250820_lab.xml</File>
    <File>aemd-20250820_pre.xml</File>
    <File doctype="S-1" isOnlyDei="true" isUsgaap="true" original="aethlon_s1.htm">aethlon_s1.htm</File>
    <File doctype="EX-FILING FEES" original="aethlon_ex107.htm">aethlon_ex107.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>aethlonlogo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="76">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aethlon_s1.htm": {
   "nsprefix": "AEMD",
   "nsuri": "http://aethlonmedical.com/20250820",
   "dts": {
    "schema": {
     "local": [
      "aemd-20250820.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aemd-20250820_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aemd-20250820_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aethlon_s1.htm"
     ]
    }
   },
   "keyStandard": 16,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 16
   },
   "report": {
    "R1": {
     "role": "http://aethlonmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_s1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_s1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    }
   }
  },
  "aethlon_ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "aethlon_ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/ffd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 9,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 76,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001683168-25-006352-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-006352-xbrl.zip
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MJ9I!I3'X*GAGD./;"P,:8-QDZ(@("+T!-J$;#GDDRD,_H"(8U:(]G9^EARR
M)/Z\OR</1*CW#I9DEWV6.WKJ.,,8$.OZ[&UP<\R3N=[ ("!\JUOH5"]%]0K0
M2CTC5E:!?E>5H+P6V^^7US==RT]RL]XD_UKAE,@M_P502P,$%     @ _8D4
M6YGH(\)>!P  X%<  !4   !A96UD+3(P,C4P.#(P7W!R92YX;6S-G-]SVC@0
MQ]]OYOX''_=,".3::VARG92&#M.TR86TO;N7CK %:")+C"0'^.]/LC'EAR5O
M7KS)0T+,2MKO9V79:TF^>+=*>?1$E6927+:Z)Z>MB(I8)DS,+EM?Q^VK\6 T
M:D7:$)$0+@6]; G9>O?7K[]$]N?BMW8[&C+*DW[T0<;MD9C*M]$7DM)^])$*
MJHB1ZFWTC?#,'9%#QJF*!C)=<&JH_:)HN!^]/NE.HG8;4.TW*A*IOMZ/MM7.
MC5GH?J>S7"Y/A'PB2ZD>]4DL4UB%8T-,IK>UG:Y.-S]%\0O.Q&/?_9H032.+
M2^C^2K/+EFMWT^SR[$2J6:=W>MKM_//Y9AS/:4K:3#AL,6V5I5PM5>6ZY^?G
MG?S;TO3(<C51O&SCK%.ZLZW9?LL"]CN>:-;7N7LW,B8FCWIM,Y'7POW7+LW:
M[E"[VVN?=4]6.FF5\'."2G)Z3Z=1+K-OU@O;DS1S':&U.397='K9(C1-;$6]
M5Z=O>J>NFM\'TO;/5N0JL&'?NDNHF=L.F=*$Q82[>'><26=CWMEK?:&HIL+D
M@F_L@3TWZ,K83D63TA%7#;2933W,N"*;CM.-VJZ79:EMT7XL+#?NE YQ&>_Y
MP%TTI-IG4?;LG+FF\<E,/G42RCJ.C_N0@\HAV7]^Y U=3;11)#9E39Q,*,_K
M_V%M#DPZ#7A5DGBP-58[M6]QZ--NZ*Y4'$F54&59EW41%>\%[+B3;BPZ"Z)L
M1>UXSO@VUE,E4Q^=#0GI<707E&VB&9I7MOW$^3#D9%:-\\ $R+.+ ;12#1;1
M#U3'BBT<EQJP>Y9 OCU4OA7:&L9<GCOW=,:<O\X5=^FE[F!X7/ 4 8(_PQPI
M@FJ1(G E1$;X/5U(50-^WQ+(^P],WE7:D##_G1%EJ.)K".DC8R#L5YBP/0J1
M>#\H(C1S?"# CZV!Q%^CWGAX-"(A'\\IYRZ;(P+4RZOL@=C_Q,3NU_D"P%\_
MN>N[O;3 V>\4 >)_\U+P'ZE%BL =54PF]I*N .R/C('4SS&I>Q2B\KX6"93V
MUA2<_^##/I"'A'K(=$QXX='0'M-AW!7F4.0H.6>M3%3L_U*BP-!WC*'(4=+0
M&HD- Q]D2NTY$QQ5_-90Y"@):)W(AIE?"\/,VCW^_Y*EDY\/3O=9'UM!&:,D
MG3Y1*&S+)PW"N&F-$-]#2RACE%PS) Z%\\#J482/1$)7G^@Z!/K(%$H:)<<,
MRD-!?:=82M1ZS.+Z0>/8%@H;);,,"T2A_4!6H\2J8E-63 S60_<6@;)'22M!
M<E%",!*Q5 NY\[AX(#-[/JX',@D.Z34%H>% R3>?(1TE*%=)8G'IS9\;)F@W
M%(I*<_ <$5X  C)?"/;>\[#WX-A1\M!:F2\$^]GSL)_!L:/DHK4R,;$/[,=;
M]2"7GAEHKS$4.4HN6B,1$WA^I;E5=TH^L6)]5!WUHQ)0](@I:E@L:H<O+O*0
MWEY:0GDCIJO5XC YWTEM"/^/+>KN)*OMH<P1$]>0T*8?,!9Q=P\M?$N)#DR@
M?%%RU4HY32-U$5:4^+OOO@44*$H"6B6F89XWTLU]S*4(/H\]MH)R1<DD?:*:
M'GC=<F+M/?5WO@:O8$,95@]E-(SQNV+&>C"0:9J)S3,:SZR8QQ2*%R7]"\IK
M&/58<A8SP\3LL[U#5(SP:LY5=E#(*,F>7UC#A.\4=9&F]K8[7\?E]ANHV^G4
M-_*&[*'$47*]>J&XY$=:9U0]EW]%*6@44-(^J.BFQQD:9W;86W=[DP>W8\8S
MRAQ905FCI'P^40VS_2(?%'';]L;K="*Y?WM(I2&4,$J"%Y#6,.0]/ZKQ'IA
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M@0 Q8F\2/K9);[M $@T_1?+2[2^-'S&%Y)?CQVI<N"80B2FIS//:S@)(,16
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M #&H1W0-M4?N]3NBNVN;@X5"/4O75I"10Q2J;1&%DB-N H4J\HI1:'9R@,P
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MBH#-+0) ^]8QXF[2C;JMS<U.J]/I++B;MSU__8S,^6 5'\J"C2:0*^R1?)
M%8^4_U,23? ;+W.4QL2#;CU0^@[.Y(XM+&Q@(;$4,4 VE 12&LFMXK1.LR+W
M[$_57?>KNSX0A,EQ$BW2+C+_(HA+Y?^UTT:6 D0X>=I?T5Y!]PWM"GPJ$<$P
M:[ UCTUL#KF9:'+C-2XA+;/:,OR !%E\TV?97:+1G&"9+!HPEOUU675R%OV;
M]BY4<190"W?KKX T:4!I8Z\@/CUD@+4,M^B](EL0YVEU'G2@Q2BEPS6GG"%H
M',;>:8L4!/K%GG_C:1O=;!9<_F5:QJ%D_UZ"L!"ZE'&!Y]F29:=KT1+.Q;$/
MY<J#$3 8DK85B<&0SFJ@,FB"-$3,SBO"<^@T+;HIB1I&L/C&4S^]3##O.&6=
MAJ3FC?;N[M_,HE.'J-4W,$8-3AJ7AK Q'1X0@130O!QK;30=-N^S)?K3!*XJ
M%#!C6[@?1ZKDX$S9Y>RD+?=:02E<'0H';+QVB^]:"RI;P^MM_S  C.=^(1"S
M>1&).Z#WS !@7$<FD+TL<X>\DI?]WTE511!4$ +)F#%S0*FVJ>NPE$Q%R5,F
M 02C@E#6#PH-H0J,RA>NH95NP8?YM4)_UFR);0##,HY;=D9/&W/M8&9K], H
MZD?LY<S2L1E#B,\\I#FQ83$UBX8M[#,P^$O/\'K-REI>M8095/:_!I7U=;E,
MFA 84Q1I$<1.T%#3FCU9,ST.ZT->T@28U,']MO\FO507$ADS-:"#:21*!ID"
M.LIQT.[HB&%*PIDC^H7WY7P/$P'M1'V!'1_KV,5R9P\(K]JA[>6O1A&#-\;J
MNP9OP8RMKA\&TUR'*M-#X!WL,8(]1;E72',5U8SW'B.'^J,,Q,8CSU?<,;!>
M@ROXVDUXY,PK-+1$ .<$:'J.D46SQ$64L^6/HZ3,A8=W=;;.R%[9ZS?K.YN5
M09R=6EXHN-)&L-S"@<RNPL5DWB%V=<ITJ60=)#26 [$R-2"O5X/7Y8PX1,(F
M$:8V%![KO]"60&,[:YF79MC:2"T0D_ABU)43-:.<7%KEI(E@X#PF5CF1["C[
MHXGC%C_9 Y,5;L'<<*7 P4QH(5=I>8W,RV(4<Y.4R&^4UR^12V(#^YI[":_D
M9IHYNI?%&P6(#DUF[]A$L/6OKAR=*5ISKL2Y#*^)(=#7B+P-5]!PUQH</+VP
MIXO%5',9S0PDP!OFYTHS+H_'6$(6ODRB3/D:\X?1D%WI280V!K!*Z\VD643'
M'<0>WQ9X2N!Z%*I[#8VL+DI67T^NB-O55X,5"Y^2'_$<B75E):A8$N39@U]$
MBS1/6'!E:\L"OT&XKLZX@*R2!2P;(FQ!%?(&;3K5; Z1"<P))Y-XRAD >!TO
M", 6B''NQ&W_$V$L\6*)264V)[.)#!E'?Y112!)D-:0=QT #S@,QR-_E/5X:
M 9HO,WOEO&?-B@4NK/BI.;0@84I 2(%;/U5!%5)="R5HD4P10U+!L:H!22C,
M3>PX*R( 7(JCB [>%6(Q.N%Z&.4DR7!U(MSJ-/.8(=&3<CL^:9['Y 3+&<0I
M"YZ<,B(.'=<I<P/^2BS02#M7$QC/H5&-A/6IBXT6HX;1ETIZ]\,RNUK=>6 <
M[>NT7SX6E9P3SP[]=\&7:.R_SM)RXK]]N\_<B*6S.FMG50W5"4D)  J0N!N7
M.9!J5@:(V&69*.U;,XY"Y[B-<-!G_YR%;92X'[T9<C8S"^*G@O-,2:820J>@
M94"\3A.FK; >^=IZQ&O'>9\K)V] RE4O6-N"Q3@^6"-YM?T/.AP_2)H@5U$O
MHXKD[*-52<XXUFI\R?@>*\69;EFN+8[-.78S4F,E,2\8.T-CD$P :*!3N-J$
M\8.F; :QD41.KI4+."(+"*:@"SY&S-GW2IN_8LZCQ&;&M6:Q@N5P3]3;7.1U
MMOT GJR.,SW%]Q'J%.BK8 Y8PW6JK<HU@QP*K>GCG+7)^;8'0MB J$XZSR 0
M,X0><J;4^\Z3%]:V75\(BKF;Q DZ?C&$5A;\*R0BX2HL"FF]PYO3.^3%RCX5
M53NU=V@!)(Q]WEHGP8,F"(A,RYQD+GWU&M[P]-DT[U@LT<18+L ;[45JU4+)
M C.8._X>B!/_%;*%XUU M\KO;HF;_=9NQ_W<A+/% "0IHN4U8#Q0O24AKCKF
MHK*1HM=+FEO"HX4&H7C1#&*E&8NEA'=%KJGVW",BVO('3^D(E981<<$/M- [
M# 91S))GHA%6*S2NULQ/2U8R36=0@S<2,,\3,<5N0V=!Z4B<H!!1PV-AA:!.
M7P!/@RAVQ&[YT=@,&7"@MD0\] O\LS&>:0Q>, R_<4$ZC161\BK ,?0:YP#$
M"S]1YVD1B7V.WY/\KD:BT5U_ E\M2TP'B!N*2'NAC;L48YXD,3>&H<]S(IXJ
M^5&XU$!QSF+"H4(#XOBYIJ 51;7U-1V0._IH=7R:SC;C:MNS1L'*:B.S"WSU
M[!HM!T$^JM$N/-1 8:Z 6F?[R8N/\O*Q'MT!F-=7=!/9FH\0<)@)>]MN:MO7
M'\'\B!M=*^0VG(L;B=;VSD:.48KADZNBB*%(Q-"<I]P%D%Z?!%,&@?&V'?QZ
M;"CS&H.4R-""1T^J1]O^'H<8TVQ0AR^5D6B\>6GP0I39,5U-/APMT. 9,4SB
M#=K-!=$)VAM4 AT,YBM29M)+$RLO]  -.\P7.0KN-0E2WAR2SH_?* I?+7K"
MWL.L^@=C$A_F? H5+4W8(OP^R,/@#W\_F$0P\K\3*F8P0WZULDXES>33<3^-
MS:5 6[FVP?</MOU*=T<XKS8R!'FA$ZMTR1"M/39:<_+J412!E55>TM=_[;:[
MVY5)BRD7&V&OS52UB:H@QD-69ZL-#17]%<2>@QQQ<,EFE)9^# 887<#D^@!X
M/RMC)29BT?UTX@G="\DF$=RLG#*@84:_]DS>;[4'3 ,; &GU9::,(L%W[0?#
MV7^G)1TM^Z1(MPSGK.[>C!FV*I3AAO"&(#%1OW;&Z.-$L,P7T')B#)\X+!4K
MV"<J]8I6YK\#23ZJ1@9I-SG/WH P#[Y!R!D(L_:G]*I0)!/VJK&[PJN?0$LS
M!H_*6D LIT[./5W;3='<Q-' _>"V%.VDT.:$.+UL&36&M(FQR:.Y%+7-$5$7
MVCIF[ 9_2IC*U:!FH;J&>2.<.V!6JFVJ+H-D@373 <]PNT7C<ERYJ;P%'J1F
MISN^-D,$Y^>8%\'H8V&NPTJ,8NAQ>0IBDG)OM'7&L>DSC2(ZH]J>CEUG8 _5
MI3&YN'!O7B=[JIH66G-2F</E.0BM.&DJ*>*IZ[J3;7CN-C3O#\5$*587(P?D
M<SZ*!L'6Q[7%2T/'U'X#E-*^-:]FANBK0: 3">V!S@@X6&#3,<]8<^9/K.7L
M:\ TL:^T@JQE;L^&TD_ETLD+8HX <-BEH2IY+0LXJB$O4? SPB6T<)V#' ==
MP)TK,2JEMFZ)4P*T-9>S9P'1C,+\U5#?!N/=CT__[K*\Q+*K2%P5G^A6;*!Y
M$.#_]R>]V50O$S_?G\TNN_7R@,=TJ3BD]:O:'3S4G<R')W_WV_I1]G&&B*B;
M[.+&912:"L5DY_V5WOI.2__S]*Y*OAPW.?EN4-REN]15_/4F,W:OS92\8JTW
M>^IQ1X\[NJ4=_2GJ\$EZ!M]"597C&5,?E+1?\G+R8J7[E,!33IK)WAT=PLT
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MY]I3Q2BF4WRG(,S%+>*& U/%! C@O5'CE*X*^*BVE^!ZVVFYNGIRKHL\"^O
MZ8ND<EI=7]H$85*$U;?<]WE$?/23 $#F/>K69O,"9,NKN%Z<GJ>XAEEQF6:?
M'=9U$>5(UT=#F3B8YBTQ'DTFR,V_U TLI1=5=WOC.:[3V3O=B2*7.M?Z"EIH
MF^(:MF!UD7I&_&T9XG@9($%>UY6WM<*)_1%?;QFBB#(&W-[N2X%;,=<1(@XN
M131C$WUNK"3FDRY\9)_WZ+\JR=-,CY^K*V#+UK!Z/U#,5$J_. TNOJ(,1LE<
MIG/4(D[MF%(7]Y 4'G$SBD"K:$1*1M&$H<TMB6@N$B8T \A\-L31%W@&L@^A
MT=2UJMFI'UB*\D\PU/4>P(U'#^#M9\,N]OYU'[U_#SX#=MVZZ"J_G'_Z\=V[
MO9-_WVIA@7NI8A))F^-<L@%9L8V%7[F.N)I=2,@\I.N\P0B'TD&B<4:L9(A4
M:R9HX=LP5>)7T,/:WL2N::*AEI"G2Z:*G5?7Y[JF';@L J7\;'].=*PU57$T
M[[+*@%@[0MU"['=2[&T/,3%:<M>\4-&R8Q[-L:6PD()5J3A78L)M:EL[ZP_%
MYEEF"=-!*8W3;,VD%FG<HDH[]9.,>J_%J=FJ1]<4!C(VD( $,3P#X(+*\PN5
M%\+J?%41(-/W$"II7IO(:YC(%KBU):2T4VCQ@;5]L5/:(C6$L,;4G5=]*ENN
M=-?@DZ1Y3$\R$9!-JR;SM:[9,OOUI9K]IK05IISN?[1J\RVO _MJE,0] VH4
M;2,0P R$+D&DL%Y:#<NM;ZGH_>R<1EQQVI-Q!R0N(^4^KST[T2T66KI]C8NI
M[P?BXA<1/0MH[1N4\M]$\.1,EU9S8-FE:&IK__$J)MF&>F/!:*ZU&$Q420*7
MZ:7G#8E@:<MRJ"X(3R<&K6<43T+;*&%)C<@*R071>%PFJ3LDO4_*$,R@M#;;
M(J^/\ .8*<5T2R1<K18CHIJD_V"JBPCM^H@(JT%EHX3"RNP'[K=SU$9$CUA2
MC[2=A(W&HW+,"C8;[%M^=VO#UUZO7*(CUG>(PQ616(MFM\1-"/-@"/V8EA\C
MU()O.^E4-$(AU)=M4"E4Q4@*R6;TZX5JW ::*/'"4(S*0*M:W]P"1DPA%DWF
M59,1L1VC-)CZDL*0ILVX_ &.#9C(!K'2SH]^1!?]G*<>QF6$*N6R/>:U!5/9
M"8S9$!70S!#B(CL7"C48)7AYJH,(=#4KK+."@=9]Y:S 8OEL6]K?>=T280F@
M!8QA$64,0CG,"4Q6N?%EC&EIA&)YE)N&8'/0MNA2(MPE5P%#'B$%DH.6IB&_
M>I"5Y_Y>B+JBQA#*VO"K@[V6!C]PU0*_=CQ<453SBY>0O6D!:7D^\@\8STWK
M0#9G7J8U[X@V37 !G9^LVLIU!;9OTEU#GEN<OW#*IJ+&*L/=G?7G-TU&NH6J
MMAQG C0UEG9@PD44DNB:FS:7%[@P$C(EF,[D6"@DW/B@V3I<J4Q,S)3X\:1A
M=QHK[IB.^KCH]QYD7'80 J<F\5H>ELZD,G)!VJWCUK7W%+:A^6O*_CQV I*4
M>YE(YT?\&$W V'64@F88UJB$_L\2H64\_;B9+'C]F;K,7UE;_SO"CD5<1*R8
MQNA)EQKTT50OM:4FY:S%2'=;!7&7+2F2KOHA&3"3$<EW>8(<#6W6NK2!OT[:
MLAYWX^IS^8EGNMB[]9\-.3 %?N<PQ,@O,\3#X9,.]3 ,"EQ>.!OK:Y'X#"3F
M 0*%9P2*.?F"F"3X2!D'F4_ZN1"#BBQ(")-FWU@KZ1:76!>4[PEKPKC[)2G8
M(@E]("47I;Q[G5Z/>RA#U<;Z0>E('UXEXD)BEU6N$!G@[\&O3R /Q 41Z4+9
M.B*#)%7!GU6CRUI1JXKH*.!RRY7Z#"<H[09JB+XX #K[U<9CM!,((/BQAE<[
M+'<9/T&CRT_*%IT%<NDE1"\(#!=1D:6X4O(EL D2&,1:IO0+D(9E48V7&HE)
MVL84><L-9:[)R@I?Z8@&B(5<[9F];+@K&J6U4R7)Q<]!DC))79,TXF:\"&V1
MI=GH*!V(=*%L**:.BX;)#(^V]&+8[&-7P+'$,VBA+TR^8-,MA%(?_HI(4 X
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M9"ZXY@\V5TG>.R>TG]MKWF0$&^LZ>D9W^PFNR&&S-F@IF%>G8.(#$5,= F$
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MWT ^<NOWU+*#_!2G0:@C*%"QF*-1=]?_9B*D='0+<*U7CWYW)(45CN0 TOA
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MD=3 UAF2+'_U-GHSF@)4,[ODTA3X$]W"361O5!!FDF4-.,<!E\WFA *=8T<
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M(A$HD0QAO.":YLRE6LX!57>RXF.!95>(K@A$E %.\]LZB_NL=FG1E)/I 9?
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M'&I&Y^*B04W3>5@^TRME=$<N-Y(X0JU'E\'T?AR@]R&1[S7)OZYOW./+)0A
M]TM[T0V=&,[)=@V7W#P,8=FR!7V]SUC'OW(%8C+.B9F1X@O:/ 8CAS]4A$="
M=J%H^E8ONO]Z&-#*ZV:L]LS$7JR++&+F=.,\V'E=F8FH Y/XF!19 R U&"7B
M&Z;)C/FW51F"B1 0T9BQO8B(ILTO&(9V2;0" IQRP&Y42]*WBR@?:IN((RXH
MR _72 M&"I7SNBO[:&^CO5GW,#U.>@N3WL!#O/'H(;X'#W'WT4/\@UPUPT!9
M*FXT(]78J/@:A(.V:BQQ8],/@VDNY+Z SI,HXIS<X$/\E@YGXF&&Q-.@G6D7
M;*R$.["^! G8JAH7RC5'%Z,R]]R!K<5I&,5J;JHA:_UXNY)UL=[N3L<NV(S.
M(X37 8&4F!CJ]?G(PV3Z9?9?UF8^-P8W/QT,2KA!+AC&CB>3?HO3Y)R^IEU'
M:<C<C [3^*K](OA,<O,$B\RAF]!*IB3M0RD45@L?@*>7(&-4QP(=5BNBKM<X
M2EB)%@]$!CDZJ\0+S4[=9XP54"OT(8D>I">T>+OA193#(30)$A5[G#]"JRAR
M,2^D99'#!. NR$0R)B)A. >K",ZEF!_K1Z@],MJ:P'H-J?XVY-%J>^:3IT^M
M'\61.!-N14)X"'*O1D0+@XC#!_T^HKB-H:!^2 2' 5O@!$_X.VODGX4NM#;Q
MI 1)T2"Z,4H3BMM!:1>?Q6:FI=2CQ#.H5T=,0@+VJ##-L=<L2F!*<C&Q+EG2
M7W*H<-(GT#&%=D2L_[)]%2_]3QGP4Z?3O%!CQP'<\@CC_^?T1&@!NRVGHO9B
M37IVL1!G(J%7,0]1(7Y+T6WGYG7!XK@N?VB15*/AQPF=EZ;ASM%!PY;[W?*<
MHW_FKT1/99G:0&.?%DTK* FK,Q*1<L>(X5@B&-QL<B2R!?3)!UG4UU$_EFR!
M\+L'26LV@=(F"D9'5O//5NL1/0PF$%K#><21(B0WTBTCV6(E,DN']U%IDL_$
M!JYK]C[J7>CY5#YW:=B^,137B-FYA)2;@=BFJAU$,((LH-X&J%H=%:,=WVHX
MK.VE A"C0OQR;%,QBF$ 1P7;-L7A!.36+_%69_;*I&71=HG6TTVA!=.-FS@:
M,AO!K-,&.J8^9/B1IQ-<+8(O'P&=%F(5/.<(8"UJ +'8PPU_@^O,C8JJ*Z>R
M94R7DI"3,(=B!5BD"7!;HD5Y.3::*[ B5'$P]2P$AXQ$23'* 6&%D"EFP\_Q
M<26ZT'"B2S&=Y5Y$ H<.>29 YC-;HB$: =MRATH*;UYJX82"EC9IUJP4#B5B
M_CJ(4]* V%66JZ7D!#QPB] AD0VA[A\)C?8T13'7GT!^^'$O%W/T>4;0%>,(
MGU'B3\H^P=P?*0AZOM)#P7L _!7'9IDK0^<LO0J-Z3%-8',U$IIRI3N6&(7)
M72BO>::IX'>8,F(,Z#J<*_VF=;$# Q"A1Z0 D6OL? 8AJ216Q@IW?=J )&L!
M-BD$S-T+,KC_OFT+Z;ZA!V=,#W[,F(3]&:('Q [B,3QC07Q)%,-S7%G&(MBL
MZ1CW;PK_[5C-T/)9IP-$O/FXAA8_Z\9LLFO9.#\\<4+HM1H:/N.42>;T./KJ
MZ.#0D4-%C,-WU]H]>7_$YJ!@B.63'0-P'21TB6)CM$2D)81E'5:F V$1"C1*
M+UG&X- (]F"PA30O7/<240^.E<VUKJH]&&8T6D.1#M*8AV#ME^$#7UH.F;W:
MD.71(B*)XR2\8'G3\0"*C\D*0TDY[M.M)_!IUR>BR<S/*N3 W:F(LHX*J4^"
M&8X'II*GVAWEAGG-LA:LLA;OA;5$I-K15L\!1")*L0CS+9D /!11L.R'K +G
MQ D/A_QGI1!LS5#PW*%R68YV?!FWKLA"G#B7Y!*V%IVGF3@@AZD.0%'.HD1"
M@+=3RUBE*+9\*"T;=<$'&A$D\DBBY89S8UC'OPZ9M,%P',^S<&LUB,'O_O^S
M]Z[-;2-9FO!W_ I$;?>&'0%I)%^JRET]%:&RY2Y-^[:6/-Z.B8D.D  EC$F
M#9"2N;]^\SF7O.!"4;9D22Z^;VQ/F2*1B<R3)\_E.<\)C^VZ4Q/!WN$TJ%$/
M\=+(#L^T+?_6E@R!UPHR\4^"\7@6Q6)I$9YD+(PJSJN;N1R]_PVW) NQ&E81
M;Z9(T4&);]&@I?]L"NO(X\U$4%D\YP.!JV>4YW2F9YR>=#6084Q !,:BK6"^
MI#59U^?5]-PL:"0I/=X)-H+.I%13+CYV%V5)$JMN9E5FXQ[(7G+*NVC4*;%C
M,9AA07E#7,)4O);X*8F+?#H!H,;("2/E[6]U=B[X)"8ZULRL!=! M)+XAUC&
M+0L62SO*!4H@ @]1@+AE=7KA5#>ELEN[!-L75BGL7$@7()8,"$:>I?$30*GO
MF<BK-I_(UA2]H4MMC/V+O)"XPR@O\PGPG*2*)FV,:*3>L<A3ZP0<PI@F0)I]
M68T&2BA+-#"AHNS"B#[5(Q%DF,[RP711% 2#$HU($8ZAXG(!^LRBS^3 >>%*
MO)GH(;?PM9>%ER$$,GK'<LE_@$=MD#5ZNLT:W4+6Z-$V:W0W,21OR],*VO1]
M4#LB=L,?!T5"5U$JF3"QYXWQEA> D%G]'GD!+;I@S(TEB+8 )YWT%M\$!C.,
MMI5<@9>.&[?&C;YZ7*[=$7#E7[Y-8N1.\SX9;= E?5)2IR?SSX'F6?N]82*6
MX]5L5$U[-+IY],^/?]F4\<6=X&NC?+%%CS,/,NLR<"*8"KV^.A.NQQ[4LXSK
MEG9ME.6ZQK^/6T:YKN/WB7@.F@<(<*6!B;\X*^IL!Q1]J_:7C%DK+C/@G>4I
ME0*37^;5V(F#G%CDM =*I83\OR3SYJ#>7JFT1$3A(J<4 FWZLWR2/=S*V%V0
M,0OD\^LQ-98 M\[LUEDQ*N0/IREB"NH!<14EQ:/8'>(0Q[(4>#A*FFRLPOP!
MP:5'>[]4D\D.C4O_WO\%T?;&D[+@-N,:$JV1X1%Q1<+I*U#@URM'T>T*TO86
M&A"W5F64"Z5YXM?2=Y+4=.JLD9_YZ)""%$UA:_;AY3-!44JX=+CP4&Y204/E
M#%F>+LYB"F1RT 1%GR F0*"S\[SI1 I"@0N6\Z'Y(,;]F!5)O1]()8.8VD$M
M +,2H"J+B0D034DIY>1/<^TL98;^Q.*+G",SQKI<UEOU>A?DG9CAO#IB[2M]
M;8(_@4\:^\,0(HY&:2 D5(0&H%G)H@$B"B-6%'HV'TAN$D4AG$CQA)J^;T[L
MBFC^JVF (7OYXOF!SG!%, V8%.T'_X*WWDKB'9#$H3*Z/@$D#Y*T$D1'*[EB
M+I/UZR<NSHQ8E3G,.13=MT+I8?J;!4J1?AZB8Q#\3U0U$XFH6X#??26M['>?
MCU&"QA@ AI^5+KOS[O5!I*%L9^3KEXLR #VYD@P*<O<8W#GI!L'8$4=(3VH6
MN^"*ZR3K0"7>@!]P53:E7J=2=ILV?EHHB3D0QQDEAC8(#@MEB/0;8$R/[1/X
MK?GIA.!QVJ^5,XXX]#\C9!$%XGVT5 A)*BV\B\O(\\_C?+YPJ0_W!@CP."RO
M7QU#9?+>"%RL'7D)=C&#67G*V]K*6\OI8?2+LP/\:;FL$1G ]O4\GXK2]6-+
M_<BY,^3%PFUHB#'#>'15'GXO&.^;H15O,<JG)"9FN9<D[^8_P.5$:U6XXLE^
M>I/^@-J84W[+*>0ASB$27'2N3"\A_Q5!^VQVD@X:JU4&H5(\+D+63FY2]LN)
M>D:I2:XQ7'?EC=K&\.[L':X\..1C+XH%RADL)\X$^,R N291Y 0 W'6N< 8B
MRK'\.%L_X2[L[-@\TE@"=5 -:KY_7DW-3L.VXEL]4_4$5!%[A419I)1U&H?9
M[NI=V-5J3HPGC#.S5?4)-U&!Y;ML"*W,I3J+"KR2S=ERD547?E0-E"G;_;P#
M^TFX<8(0LT7-='%JHC:2PW.,[3!%83K;Z"@!S7U<$@I=/A<6/;@]NW=FKQ5_
M12D-<88:1;BAO$#JY@CJ)B#S;;3CKNS> %_?3<4.[KA3]$<9<P-LV(];;-@M
M8,,>;[%AW]5!0]Q*R1B9ORQ^;S,:H/B-VA2_&M5;!NQQ0;FC2VI06/G"PJ0L
M.15!=H6"/+W@HK]6R22Q#@K'S"IJEJ>GQO)N?#KOKT@-(LH&,G*FI.JF!GE\
M2>IQDH\&B3IYO2_-ZE$]3K?D6I/T31 _E@E21)(@YI'-2E+YK*;A$7YTL4B7
MA[>\SY1LQSM)[(O&[65RMF@!+8WS00)VP CQ3JZ"2X6/?Q4K+>D$E3*40<(F
M%3,$6/-ZNI)G8<?\B3>*\O;(O_P:BVDA3 %^#-WCN8OZ*8-OC/'W=@ZL>1CS
MQ&DXFOG_P B=9Y%D8%#\VDW ^'6X?J)"_15;,60IN0-$DDOU0 3@#4D42XMK
MS+%(@^IM$@LMVO>S 3:#8!.1@A=!RM$LE)%7BLK.C ) ]%RI+##HJ2.,]V.[
MX5Q1DVQ;(S#!+GX[!5A.& 9L38'"Z8!RJ2Q5B5V,N3$<Z.P0&P(MFX:!QZ08
MV)>L:F)5%$B>1I]]5&CD9V+\$(_0BWJ\WO>'_:)MMQ%.^7?*$XZAUGU.?]?P
MZWNKZNQI)N83I[69&#VRQDF[#X8*!5\)'W:/=R7M2LO9JZIM[CZE,T^RI:0J
M*(*AV%6N[*Q_X52%L %/ZG3),)AT!-P*!F@?>_TNU.S.IV+\"1THZ3<3<[J)
MX;&8-?337^R72>/,Z^(\'7-&&*H7-5X1?X]^+M\U>J,TAG5-=>#TBCY6+%U)
M8HSIWUE3T$\FTK0 A#2X:C,F)CI;-2"(-ROS(,LGA3#8*#EM5HU1J)A$V,&B
MP4I7<X1LS1;1O^955J3\#U9L9P62HBG][*%WJWK[8G9MDE/L"+&%!Y9&V4T%
M))AT4_%#RV7=Y$)93%@D\VC2EPM4FF'EC0ZC_C2@,\:M*CP3=)<J1&F].&2%
MD8>:K0:J7Q-CP%MYM'LKRN":11$R"G^74N!%ZAS9:L>C8NX6,#$S76K^.84V
M3X();B J;IY&"8_J*H4.Q%S&1F"9WL-<!-/J%%03WGP;RRG!X ;SZFF=385C
MT$A+U;:M.(T7"*2;@ ]S4!'%@P3KX-ND9LQHS9JZLD_<!""5YF2Q-W<P4]=Y
M1>2URA/E+YNQ6\8+2@79>THN.0HK!IJBU;MC :8G8P&=Z@&!$!EI=BURG-;Q
MMM*\_FF=SBCK-%4"A&*L9-NNHIBFB4OSD_<MQH6@<]-X6M%-#?5&E+2R)#JD
M0WEJ17$KYV_/>P9F<K-/8ZD^=E9# '4GKLDI(ZD8LI3"VA&K0ZU7BWOA1>F;
MF4<;SH46)!LD7^@VTL!:]A1KAV_7L[+M.]*R1<(?P6"0E>U-,0:3: :1=*2E
MGHMDK81%I2B?WHX$1K*( ICF$#;AL+7.M,?1:%D;74=;L[PYY,#MW+R_Y8*W
M9'<+88(,_AC]T_AK5F'@KV5:U]6%TI&FYZE1H@CT0+:79*\QNL0#^5E+CH@$
MS $<5834)P?'K'Y34/,7:!+BH!;3SMRE!8WCR7U$R:*Q>2!\(%+I:P^*+37J
M"HZMS+8>(C'?V(?T"4S"YFH4.EA&TP0-R@B[U<%%-,2.@Q>31)B2CED7;T24
M"@&VT =&6 M"^))X7S)FA (.E]JG$MY'BGH].]_U-'+WFP6V+1O;?VS8=:1,
M>6(]07%8@T,36:?1,W\2R]!/<")Q'+)T9AP4+U%O/-NBX3:^!%":+BD3R"T%
M:-.+N93\E[[_$AH0K(<C#T_G]2PR>O;4P_3C&0T":8@S7-A0BO?Z<,>Y'QGW
MASJEBXV8I&AL:TFYCYBKJ)I23@2"0>.A%+NLRIT>_C9K+]KVR4MHVZD.0';O
M4L%K55N"$A41WYOJ5;IBS4;.FFV=LI)[VWDEZ&Z8[TSCO218&F@"X&D4Z%?L
MF0NH-LQJ: ZVZ@O4 7'+.J _C7U0,_-^NI %#VDN/1(CIQ6];B!A@R^_U9CE
M#O/LDBC4;6BUPK\@]DZ72N5G%;,1K&*615#[5Y.6B=FOUXB;+66JD7=LSBD
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M!,K)EHTW1&>VI-PX(,,\A;.<L;W]E%=/?_C51U6 [TK7I0?30,R19M0!4$,
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ME"^HI+WLVOT"H)^ .\/IEFA"/ \4(NO0"W#SF@!U!N\;B(Q@YEF5,X^ #X9
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MOYK0+NS/#YX\O$&AN<VFB:6M=A>TG@-0&0T8+4L!'PV1Q^#\6K"(EMWWP$S
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M08Q:4V(X!UN*.66PK+)\:J; < FFQXBSY93,XS'Y0-9.YMS5592A68,D7.=
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M$J>I^MA"89(DN/*3_DAPZQ@@,D]0XXB3Y@;HB5!6CH?";RO<5DY(5:@^ZYY
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M.,=F.L !PO$MD3^)^BF117=FI3=241S[08I3%M)\X2)!(4&L$K4_PFFHV(E
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M%&PE!.R*@:?"^>NNL(M$ [_$8!,949%=W>7.K0_DO<PO$C3U8791F&X3H*'
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M587,\PY6CE_G9N/^[#ZKF"H1]$,,S/CBH<-?D3='4"+OQGW+B06E!=BY(BJ
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MIB*<QNV$^H@N7L5G'9X(76"P_RLI]T!@[_2>^FR]\EFASSJ&K85%;Y[1VG>
M8D/ALF914<VJ./68H<+_C9I01 C:+!OU[YEIJ(L;.+7*7ZV$PHM=\LEQ_:T=
M1'KZ_.-=L<E.H=7/=9@2D 7^/?B&C#?ENDJE?]8QD8('5JFD)?JJKD*J8C^J
MW#IP9M1]RI+!>"BR_2X'$OGC2$8YEIJ'7/%:SJ4KU !;H>:2;LC%>RH@B;@^
M*<KZ()*.6<8Q![\U<.H%</F\F_:2L&N@YPO(^]P -,4>>Y+9B"E3BJV4E72S
MQS1/ L?6V>L5EJJ1^ %:MRI76C6 ND$^63-NI]7:?7G8?GEZXFR9.L!M:7;"
MG>PD$LT)MP4;0VV"4B#14K27Q[D+8OQ+8Q\KGDWX_J;N6NC)44EC,Y]/L;T?
M0@[!^8[BFR;Z^Q#1WZ,F^KN&Z.]^$_W=C$<2OCXGT %D3HJK(M<\*U>E2.[9
MKT"U_7C\A(+#A:Z8LSOUN,MI/P;U+N!^,-U RN--/A<UY8P]U9V2T\_4'WRK
MWI]E.$I;HGE,6".#1>OBE"DFW\:,.7$JW QC2K*J]:FISLY;"T9P3(DW^AE)
M'T:@ 9:S/@$NP;'2JZ2&TAEVC]8)6@XYPU6*]/Q 0_N5N[4O<XDF\TYYSO#N
MKG7SW0]2/(.U^R"V6^Z6^2!L8AQS_Y:/U($5/K#O.4:BNULXLIP/?41.A$3]
M2^E$:K:,ISD$)N)& :9#8D]=1KY"C8H0LN3HE>M7^D@:))HN^2D'.;IGC=*'
MNL6\X]A[M=79WO*W<=RM?O%<>&=;&$8H /!D\55 6@.3GAV2@ .0/2O]Q9%O
MJ>T+'I"FX#$\"%7JX N5LA>,RA[B<KJI/ 34ZBQJI//#4;3:I+Q*B#6#>G#I
M'1'Y6VGU9 B;)'N%(6#5:]F+)L)C/SN_*:L_IV=@PKJF!U?(H.^>,[/ Y:=H
M+]DRN@-KOH0]_CM(1H2;_31X<BD?V&I%S*8:O#:KPYEU (8,Y/,F)Q[)^?+L
M[_CIU ()V9*G W_2S *=.G9$52!,U5?HH5 *+:+#2#WF +2YD2!@6 LJO[P9
MMY<&&T%,PD2WT)6*#30[T*/0AS^QUP!ACBC'UZ[C$CP6Q)5S#_8[/N64X@_M
M]KX.Y/'&3^(^N9,^:I^$3A.OG7/$A1/%TC%KRLZA.QCL*( R/&0IM2#4%#V^
M&D9W(%[HA-U;3]AX?:R3=J+J]&[*!4<94\CUMK..9_%&"BXU,7X5(9:3NHUL
M('^[_ICA5J7E/WG/3>7UN(7K<>YP/?9E>&4G6FW4QLJ]&X0C%>_"-:ARP>Z4
MG'O\2H3ZJ$Y9=1,DJ<8UF/ WPC6R-V1S'3.%;EE8Z\BVOY?F$U2&L%"K*_$*
M7H]1@J2.YU(^B2L\UOT.WYV=?S@&E0G_LWW[U,6ZR1+G-*Y1&^V)5Q/TJ0R:
M )8B./_1J""8Z#PN>\, :4DQV).SRV-;'S%E[\A7,FG2XF.?R;[H-1QI8]\Z
MQ5?AXX2\W#,S6@I$*C.:Y>*<)OV?RL%G1RX>RI-2#? ,WN9=/X1?P_$QM@-<
MG"8GYP16F"P=MV%]>D,QO*%41@X!G5((R/FHPBSE)L>D?HM:8<&#7"AQ94ZS
MPG@QCU 1_-MW18*?08+E(!#W92Q5M; QJ95MPEC/II/  DR4Z[UUP; *X%Q%
MG5^:T!.XG5=4_+L*.Y-X-B^ GRN.)"R#8J6(%-%EB3R@(3!W0'CX-=[AE*MV
MIII'5G8AM&\EG9DI,PRZ'+NBP X5NX&*-Z%+YFEIW[8G'7VJ S+O,+0?,J^K
MW(FCX>T+6*IE5WMU4;JB-M$0@)>&P&;ZRO:TTB4+'E_634.5@[!C/V?=GS&I
M0IK0[GZN74=4BKR7J=R-F\CMYZC5P<,A(UZ48+LI[-G G<:YZCE)C)-4/\Z*
MP> A0^\YY;WBM\RTE.Z&"!I:9IC,&%51_:08ZW&.: 6C\,F42)S'5O!1O5?/
M+A-')%,BKZ*9H) :1/.U_SIK](QB2C/3W%8?8V3S+Z2_,\NS=**KVS5O/;X\
M.U&\U7-*$3M;0WSZZO5"U8Y+NDA+LXJ329R(_2C.NG;!_U;^A.V*HT4ZTE0;
M/B50C@P25.;>&EQ+,'LMY((E[,0IK_,)4\QSFG*!N-^K)NZWAKC?01/W>Q+/
M3.%@Z8B6K1;-VM6.'=Y2Y8_*OK'E!ML#1MW2<D-%'.1S:3Q!*+E0I>L7/^YN
M56:6(V(?"97#UM'6D4Z_+LN ;4_-4@B(+3B):T]B 8#;LS@X2]%?:*?#(1P]
MNL* 5NT:3]3(?177LV:IVP<F G'7=8I:<JB*QF=4@Q*$H7BB+7FI8WRH][+,
M/!GZ$T1 /WA;-^LZ).AZ-*]B>CYB;8B:TITJN[;:;"A8X\J,4UTUBI]4$%:Z
M54&[(]#9==US_-$HSDI:CO&8"JK(3,(BI[W?]^X%54;#J(GJIFC;J4[&7824
M"V]%I^D;]V983"CU*]4^-MP9*05Q*M$068"@W6.3Q,N^0WKI16\J7:G"-:'8
MK67>Q-$+NEK;\G_"FF:-;2+\*U5 FDXQWW$TU<8!USE08G2/6A"HN['#Q^1/
MP1HKSW(WI&#RR(")Y:YW(VJ/*%$GZ_?BXG+.LH+I1!#");R7). ^4WT3-S/S
M*EL$W1W8;N4-:1HJ=5AG8+*!'?0X9=5Z81%773D*@14)7"<SV^=4D<8=INPF
MFR2A5*JQ#XCV[%D'Q6AQ]KNG* %A3$8!_)CZ"'V7!L%7A](_U'[8>1136(OR
M0)Z4.^<7A,7]-5X^-MR&!-!5=9C$PEC>. *<-1/Y*0%K%0[(0]&F,I<5BO'4
M\AA994YVG>PBZI0SF[=4\@J](]#&%)-DZ-T%[M:)/]EQ]P]9R]++U,E6'&LF
M?5,)0U"']/>IX&NK:ZH!.1Q9EHPH-,1':FI[2>0JP<)9.;ZU3WF;2E6<W=N)
M3C4J;4>*(#K;3F%+&B]25E*#9F42VFN+*^T3V''!+BO@G!%3TB!8B8FHEZ.P
MI4BBBK,J]S?W3J22P]D_BE)C0,448V8A:W69U=G^-*#G*+9H4R5AO8[2@'0"
MSR!36&ETNNN+Y=6VBFA&X=> 8RZ4$H6<D!</5F/?5<%8C9'GF*FWE$(UL#J)
M8)(]5=18>(OFM$ /3PODNFT_&U)*5'TPP9-5%/U0@D?@Z! 2+UP:HTE'JU(,
M25 2"X>F/K20M3/O>3K5SW/!9_BDA,E??7C6ST*08&=$6W PBC/)#D/W)E9Z
M!OPJR4WYH\[!>N_?(,72P;E;^--YO.-V]LG:>;5W9'=OVF9]Q;=+[ @(\:ZH
MD.JFB#$H?M,%O7009HH;T0<0SIH!$:5)!+W55(*>+^S4%8[@><YM<\I %5,4
M[+,2H"/FA%J CLA%O *8(Z$&AQ'= 0;WK_(0([TP/"J+XWQTQ6T(K$(7/?U5
M#"(@PLMAW)B*#!BI>PI@PZCG9E(E*2-E0&L[;D69EL0._<2_2OS)4+M62CM7
M7(8A-%!>V0(!3C;L<X64NC;3\8,1%K3-9CS_@E04)U<@_8J9+(H'TV!/BO]<
MPI'X<!9/-JNCD+9D> XE@MN?TV'&#W$49'XA4PI[$JAS*A7LEHTKG;?/P22E
M\9$R(_EI<X%A8]4KE=.=E68U,"5W$VVNZAZHQ>I2*P&65%-.C+2S1E0!*^/<
M%F![JY@BNJB4&[98/LR&ZF*+5*I8';NSM(\P<O1Y%VR$T-@(-#6KM$4-1*1)
ML;OBX9Y.;*TV$JBMCW+N=(Y>%>[<L5W.E^]THHYGE0B0%ZF4.E[P,<F"W,[A
M_E9[VU. PK=]4J7F(49L10J2U5RDD.U3VOZ^I_?_[ICFAI6KI5=ZE=6LY<0G
MIS0K0H48@K<DCBZUM6;>?-;YY$:_/;2YWVI"FVL(;1XVH<T-?#P+M:+3P00[
MH,,]K[DHOF^+/K%OG#)+MO@B5<#/2 _EF5@B'.MS1UY].B"K?L&(V=)>+,J"
M):D-.EQH1[O=4JEG@1[WCBURW-YFZL;6X[IYFO: A935.F1GKTF\4XF@:$8E
M </;N#UI*&)_.;Z1_E5VW!HUP>NPG_LCV#,!)]!78D+^JMX/HW\N%Q%VS:BO
MRR2/+,$0XY:)?-(O@F ^D6Q+!P>Z>ZO]1MV-TU6Q(Z1':'9"13P[WYVY6\8H
MK+M0S^:G\XBUL_MJRVJ5#@2K7=4ER]ZX:7!U,"ZJ[NW#'UEVIJ+C<K&(NS6,
M;](8VR'!S,+(MS7.".^('0YB7F6)'Z526BON\S3\5AEPKUJ:'A1M5(T45Y(K
M)60JMA(MW^@\J<+>H3]O\B-9/U!UG1DI7K<9J5Q+E&"M=;;+9I8X[E0Z@'26
M)=@P?9LEQ-B94=O'E/Q3^OW!UMXV&,1;;^PYEPZ1_608(O/!*-9-2WT%N6-5
M^S'<H_+OJN>]T8>Z5BAI6[CP61'>!4B!B3I@H,V1?[/11]A?JZ">[[@YV#HL
MO.\-UWF"33K*"QWM4$'R6YR 6Q\U.J-54K+M;ETRS"\UJPU GZ"/;UL32(]F
MQ!@I>HM7!XK._[/3(9-T':&#$S_R^\NL:=H8 [\"4:(;<'H+QL ="PLO2=4_
M*5\2O>P:2IL*_\W?? P4A!'VY!VQ]D==T&;U8 ;0L_2,<U^4$Q,4=??V7[1;
M!W(ZX6L+_/)4IP ;U'KQS-N\Y7!W9]=HT7J@8JM[,\+6QRC#KJ?BCL:EFPR&
MW@@!"0OK=FK6O=N&=>_JZ2[L7KX7!D05QC+[H!D_1@R6J[X!8UFP%+A0SKP4
M]&F5<%1*6Z:\2Q7-J"CK+>2;HIJF(*5]%G'2H1 - %.BZ96J0&TT6,XBU&YQ
MIY39\?33.BV"&N'5C71B8@\DE1]&#D4**'D*%2]0A4-X!%RR*DR&GJ#T8J#N
MD_+X5/H+0JD'*LB>]J3^#Q^C/_:O,!(]VTQZJQ@2IHP!RES"0$:0Q=LF 17F
M#],B2+.GEM,70XZBV[>NP^<4_:07IE8/[\)V.%O&P0BY.PJQW2;.*V[%;CE@
M5SA3A6:NQA-C5V!/J:K7'/"4:Y7-Y%*A2]:(PIZLBN=4%1=__RKHL$R&K1H\
M#92)'B>.*AH6V'GN4K/\2N$-?4"?+ ^ RGW?/=[91= Q3&S@B)PT)2BTF% Y
M=5>Y3QT<# &9! Z&"XCBZ 4]-4P_+S86M:;<(VE1R=5W@:OO:Z[^&[HF;G =
MT95S$D<#(*+,$D=;H&2<G\FW4'O8KF[4+:XJ71F0Q9SG,C4!4"MQO\QU]0P"
MEX2+R=7* FH"P NS(4.J4 <*K467!+-:[ /]D'K;69KXP>CIY'O,ZP;L%#)!
M"NEH"BF"$R,L9!\B*SZDT+84+- .^L3E,4?QX1]6MXS93KY!Y%BY;G;=#D\B
MF!%L8EC)&PLGIY5; \JXH(UUJ<F%^2.]7(=>?!FSXLQ"T1#.P?H=:G5T./Z(
M!#0,$T1I4 G/4>S!&^NNQ:;7EYKT1R>29%_LC@(GBV$#KLZC5QV Y!VEJLR[
M+U@<'KW9,!D'I@_#*/0%6"1.F#L$68 1"\$JP0=/W6K<>!)&!!NDL;P)%C.;
M.K,"C5.TY0H*BJ5UOHM=2#T4QVPK8$1ZF0?](5X6M6/*X1.-EC/M%(9H38MG
M1=;E_.)2I^<&2OH!H*3WVTW>Q1KR+HZ:O(MU/Y*:V^R*+S#L_^6'M/W/5GL/
MTY?(?_;^].?C]^Z'X\^?3R\N5[J*=?F;0+R&?4DVG<G)M&115?]XJV&?BF1,
M?*I)H39$J'+ IT A[($(C+%B=>K^ NL$BL0RO__RQ_!6+_WK,.L-/??]^T^P
M&[B'MV%P%7M@@H]"&"(*_1WG! PUT)S?!_TI*-1234U?_Q".NGD2\;?Q='Z/
MDZ_VOSC(2?4UXJ<%$T+]V<6RS308*=&I4!J[RNR7LD@1X:K]3_G0$/P'_G1)
M *%?N&^=R4SXI*V+8[(N] ?JCW;'/6$GA1B="M>Z,H?7UGWJ[J'*RH%I/R53
M^..)GPZ!I.K.<#E2>8FNXA6]E7J&L*\9PNG?/YU>?%X-*UAK>\G/G%Y+PI[4
M8:M86:$5I:BP'@?9< 14]2'HH]SUP,CK[6@:FP8^5C2@ZOS!3WI#B8"T/;?3
MZNRC7BW9"*K$ U^ @+<3)1<<LY<:)PG?DN5K-IBIU!!JSJ"DJ%O <DF 4$ZZ
M_,XT5D$D^9$?<36)+@11&1G2ITIE'Y/O+?'#-'#0OYW!<\:3ZL=Y-\-&*WEF
MLQ/MB5+Z,_D3L&]+'G"+1G8QP^]Z01*Q-UNYWM"?'6>!VU8\JOJ6''-+E'/]
MBY]^!:U+F.R788A=:NB!<V9,, F( .QZ*#$<I)B=$@; YO$D/"T'Z-OE":D?
M]NE#N&:NQ2;L4S_ODQ-&-:"3\1[*:28T_0C?D4].(7HZKKR:/3K$P@,KPFU8
MSTU_Q[OC4W/JGIKG?L=;TUT([_C:G-M>F_M K\VYY;6YI=?VQO\*ZLEG$+Y3
M][=+>6@+O3*?AN#ST<>FWYA3\\94"$F>*;TR>7++?V,L%Q_TB:UMRBKI?Z"E
M_X?CBU]//[O'YV_=L_.WOUU^OOC=?7O\^?CAW8]K]'S^%HTH+U=7[Z +BEQH
MG@T!XA1PH,JF@SP^Y: ;,Q.$AT@X'C BHM),[?I)!+)AU'70QI&KY!$\$(\2
M?RC;G8)[!H&$<MVL)^BH0>&U^*-IFE$[VS#IO\ HT!286YZH!B]P4J B$S<,
MX"2PA Y4\@\5OZ7(6A\.$WVX-&4EF+XY%4SK\R4(9S.(F=6)^3"S0 IVWZ!H
M1\;E9SY/B\<3,GXV]78/4!R8F+D^(K +<@EO.Q2,AG7DUA&2'YF&Q:_BJ+KU
M-K<!)#ZNU]J7.U$L[ 9%Q2@,K@/)1 !;+XVIP1]!TYLN1O!Y.)J;P-&?1SJ8
MN> 2JHRX9:OA902P9S05]^PH4(V.]/;,<NR3\&A?#FT[C*[C$9JG29A^Y5O(
M(PD9Z\P=J;I0_E(I$=>S8-/!&#NO@N%)>16&C!F?!J-'>:IK-&COPX!:2#A2
M[_>3[PY!NO[EA_] )M0"$^0"%N2^XR%_>NF_WI%ZP*>O5*UCSD<^6[TX.]3B
M[,LOIQ>G[N\??W-/CL^Q+\-;]\-'^,W9^;N/%Q^./Y]]/']B/J\?X8WVOEXE
MH#CUT>\<)W]&1I0%/[S^$I"FZUB=-RAE[_2$DK$MJ]1"[XT02V#L7KYH6P^Y
MF,HT Y4R+^)3$3^<0>6O0  ;C0SR6 F#*ZA;.W'&##7*(2C<6<JP"(,\$> :
M([+*&\B-:VNAX)*'4H'3.Q"178Y@X65=&K-IKDIAPFLV>@[#+D0P$</S513)
M%]J42;<PA3,6CJ8ZN*<+HJGX!-/WT=BIWETOGFCOH#U]:6HF-E\L(MKQ_//9
M<4^E2(F252RK'\6<W6Z/J$)N+=6WHNVU%9KBM4]LH][[[W!9/1\5,I_U''SI
M<!_P&DL"N^XNP/*[EB?/G4L"#3@"8VDS]";HIB'B7P$KN+G9@2>S<Q5?[[BX
M  R[^Z,T=C"'!+- ?)MRTL LR,^XB"#-"-U,DESH+6;806M_W[V,@8HC()__
MA:L/IG"&/JCDESE.WFGMUCC7W5>==J?-N5&C8#*,(\I7H7&W#MJOMMU7>^T7
MK=V#ULZJ[^]Q$ X("D2ULM2_,N-%-L&^&;#SV07"[1"+>4+X-0TO1$ 0!'+'
MG9G* S"0_+>IY7D@:*.XS*X+HHMR+-)%!W-G!Z-486W("'4KBE99[:<G3H&'
M8J/I'?<+JO.A2*CR*_#9^R5VWPZP6.M!$+(9O4D_BG*R9VC56MZV6R]^]9#;
M852(U'WZNV/]_6^>"Z(I8?Y>_/;1BU]9B5>IER(X4#%7GV7&S (Q"M.A!0]K
M065(X]!=;),)GVWO;_6W58<Y^V:+ZL0@">CLX._)%9T(;E4?4 J6'F>+:&,%
MHU&8 <P9D5S;1Y:8 7<!B8G=II(8FWNB"40[<+B]5V$?*F]8D4?AOFT)Z^ER
M0>"3!<BY; @/XPH'MA8N27.U'D('1Q1[C+HJP.T1C$<Y]O78],VG,?P"B2.=
M)G%D]8DC(+QS:OQ0D4/RJLDA>3POZ2%L^2-MRY^=GWR\^/3Q@JQV]^,[]^3T
MXO/QV;EMS+MO?G<O3M^!T7]^<KI"RWZ.\K0VO_6<-7T6'08AZ6]25*D-V*@E
MS0K"3 $!SGB<BP:>Q*Z43D=J0*B=I0Q1K#Z!0E:RRD%6CE$/\<DQ;&: =:&-
MJ19"&1_:Z"2_HIIW5K+/B=RENCC9%)"Q<"ZW5$,?[ER0;VH."BH"Y>DN,KE]
M/B6WRP1T5H46[*B^ 2M1%AZ-X6&=HU.*OM(YS8("SG&U:'"4*J1VIH"R91/;
MI,UMJ]%_']\8A.&(L3FH,*3\]6)K$(HT*$^(F%$!MC_-U.O32JM&]XVX;8/Z
M.Q*-0L5S%"E1P'J6GI8(9W2O:WQX]*/JE:P(%NFPLQQ8I,OIN!N/*G0X&/IH
M]\<UUGNCT:.F7]J@.MPSS+))^N>7+RU?T<OPV_^!A_*7E\=);X@=$EX&_2L_
M>8GQJI='0/VOVB];K5;[X&@7_J^SWVKM'1ZU7HJ-_<^PW?KZHK6[V^[L[PRS
M,;9#(JOZ@FS=@E&-8279FKN\O:G<E0%(-YBWG"/FZO2P"B$ J_MK'@5NYX _
M\Y"(#AM.@DNEF(/6WBN;8O[UHG6PVU(4\S?M:IDEFK\AT>C\)''*R/W2U>VV
M^.J\FOL]SJ^PEJ2]V]QP-9.Q+[ITSPO?;^?@:%_?;S\8M/=\OMKE+9DJ\$,J
M_"MY%_&6L=5Z/P=AU]X[UN?J+Y7-5%,7J)$CMWW4$->*)=B)N%LO9MVM*Q I
ME7>]7):XN_<*A>BX_\^CK_Q6/OA3S::0>+TES[C7V3O2CU1-2CQT?X63'A[M
M%;?) O?03$EZ]]+E3:<X:TD,X+RL\#=/%C'CJ#K5PCCGWI4]KCQ)L?+$ZBDS
MT^1"87NW.]61)^PJE"=S\ASN+XM:[5<'1X=MDD5[>X;,_7:GNVQ1)(S'%C3+
M&[Q.C_EK#OH1R9GV?KGS@XXU<7&P'60JM1'"^\DGV+T-OLHVLKGVG>K'L!1@
MIT<=E+53"]&19[DI"( (/>69BHI)SF-%0"]U*9CGX7]Z^)\].ZY7\6YL'Q6"
MBXS#2#PE' 74A5GH'['HH> WU*$Y>'BZZ0"M=%N /[%MDHWO-"\-?]81].QS
M/;X$W'Y'0?G $9&3:B+M;(IO50.WC@@S&/,WX0L$"NR7W&38N>8:V:QG96Y0
MBE%B9V7I"+3E/F-WE2FNN*5>(RAE3]MY4+4>OF[._5OU,@W/LJC#D>/12$>"
M@U.Q:"Y1P.23C%NEP7I'KDY>T3DJ)HF)_A(D'-T7J!]&+*!S4D/)!U-G4)@N
MBU?HM7MHVKTU.%)9$O3PRYB33>3H;**'7]:<[*6'7\QGR94"I:"8)/7P2]DH
M3HNOG!+:K$2>0B:;RAW1BE-U>ASW_2LFQM1G#IU5QABP7CN1183H9E=35V2M
M^"KB-1,,$>WLMAA*F*$B-U:1$T\'7TBVI()_4]A/OY_@\=2TRD6)X#.,$MX
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M '-Z\O)>!.2OZ+N<.:%"T@(?UPB#1A@L7QATJ.WSJT88;"8;WHPAUB@,]C;
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MUQU3WX-&8#P_@;%A11J-P-A\5KT90ZQ58-PK;7R9 F._U=H[M "=2&"\6K;
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MC@8/3>#GV3!.@)?T'1%,/32O$3\1KO!M".J>YY[  <!KB4+?<TDNPFHZK9_
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MSO[")_*R&_>G^-]A-AZ]_O]02P,$%     @ _8D46R%?Z?15%   9Q4   \
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MRU<-;UM:W[6UO^_H[.WK'Q@<^C3,X?$G_IZ<FOXR,RM96%Q:ELJ@E=6ON#0
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MD=^"<U2K>-!L5Q4#/L(=T9]:87&IVM"VQV_D!U7 F^/P/R+&OB^0.PV]PZ@
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MWP!02P$"% ,4    " #]B11;JJFSSRL#  #T"P  $0              @ $
M    865M9"TR,#(U,#@R,"YX<V102P$"% ,4    " #]B11;?*-.P/T*  !_
MA@  %0              @ %: P  865M9"TR,#(U,#@R,%]L86(N>&UL4$L!
M A0#%     @ _8D46YGH(\)>!P  X%<  !4              ( !B@X  &%E
M;60M,C R-3 X,C!?<')E+GAM;%!+ 0(4 Q0    ( /V)%%N\YBT[R@\  /")
M   1              "  1L6  !A971H;&]N7V5X,3 W+FAT;5!+ 0(4 Q0
M   ( /V)%%O>3IL!6 ,  +8,   2              "  10F  !A971H;&]N
M7V5X,C,P,2YH=&U02P$"% ,4    " #]B11;,'*%K&@"   _!P  $@
M        @ &<*0  865T:&QO;E]E>#(S,#(N:'1M4$L! A0#%     @ _8D4
M6\@ZSSA"4 $ A!X)  X              ( !-"P  &%E=&AL;VY?<S$N:'1M
M4$L! A0#%     @ _8D46R%?Z?15%   9Q4   \              ( !HGP!
F &%E=&AL;VYL;V=O+FIP9U!+!08     "  ( /T!   DD0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>aethlon_s1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aemd-20250820.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2025-08-20</startDate>
            <endDate>2025-08-20</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-20" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-20" id="Fact000004">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-20" id="Fact000009">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-20" id="Fact000010">AETHLON MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-20" id="Fact000011">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-20" id="Fact000012">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-20" id="Fact000013">11555 Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-20" id="Fact000014">Suite 203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-20" id="Fact000015">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-20" id="Fact000016">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-20" id="Fact000017">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-20" id="Fact000018">(619)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-20" id="Fact000019">941-0360</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="AsOf2025-08-20" id="Fact000020">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="AsOf2025-08-20" id="Fact000021">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-20" id="Fact000022">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>aethlon_ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_offering_8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>8</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">S-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0000882291</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">Aethlon Medical, Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Common Stock, $0.001 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="c_offering_1" id="fee_012">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_013"
      unitRef="USD">10000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">1531.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_2" id="fee_016">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_2" id="fee_017">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_2" id="fee_018">Common Stock Warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_2" id="fee_019">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_2"
      decimals="INF"
      id="fee_020"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_2"
      decimals="INF"
      id="fee_021"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_2"
      decimals="INF"
      id="fee_022"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_3" id="fee_023">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_3" id="fee_024">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_3" id="fee_025">Common Stock Underlying Common Stock Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="c_offering_3" id="fee_026">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_3"
      decimals="INF"
      id="fee_027"
      unitRef="USD">10000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_3"
      decimals="INF"
      id="fee_028"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_3"
      decimals="INF"
      id="fee_029"
      unitRef="USD">1531.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_4" id="fee_030">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_4" id="fee_031">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_4" id="fee_032">Pre-Funded Warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_4" id="fee_033">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_4"
      decimals="INF"
      id="fee_034"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_4"
      decimals="INF"
      id="fee_035"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_4"
      decimals="INF"
      id="fee_036"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_5" id="fee_037">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_5" id="fee_038">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_5" id="fee_039">Common Stock Underlying Pre- Funded Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="c_offering_5" id="fee_040">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_5"
      decimals="INF"
      id="fee_041"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_5"
      decimals="INF"
      id="fee_042"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_5"
      decimals="INF"
      id="fee_043"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_6" id="fee_044">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_6" id="fee_045">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_6" id="fee_046">Placement Agent Warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_6" id="fee_047">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_6"
      decimals="INF"
      id="fee_048"
      unitRef="USD">0.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_6"
      decimals="INF"
      id="fee_049"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_6"
      decimals="INF"
      id="fee_050"
      unitRef="USD">0.00</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_7" id="fee_051">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_7" id="fee_052">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_7" id="fee_053">Common Stock Underlying Placement Agent Warrants</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_7" id="fee_054">true</ffd:FeesOthrRuleFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_7"
      decimals="INF"
      id="fee_055"
      unitRef="USD">400000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_7"
      decimals="INF"
      id="fee_056"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_7"
      decimals="INF"
      id="fee_057"
      unitRef="USD">61.24</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c_offering_8" id="fee_058">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_8" id="fee_059">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_8" id="fee_060">Common Stock, underlying the Inducement Warrants held by the Selling Securityholder</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c_offering_8" id="fee_061">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_8"
      decimals="0"
      id="fee_062"
      unitRef="shares">1550000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_8"
      decimals="INF"
      id="fee_063"
      unitRef="USD">1.14</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_8"
      decimals="INF"
      id="fee_064"
      unitRef="USD">1767000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_8"
      decimals="INF"
      id="fee_065"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_8"
      decimals="INF"
      id="fee_066"
      unitRef="USD">270.47</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_067"
      unitRef="USD">22167000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_068"
      unitRef="USD">3393.71</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_069"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_070"
      unitRef="USD">3393.71</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_071">Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_2" id="fee_072">No fee required pursuant to Rule 457(g) under the Securities Act.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_3" id="fee_073">Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. Represents shares of common stock issuable upon exercise of the common stock warrants. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act and based on an assumed per-share exercise price for the common stock warrants of 100% of the combined public offering price of the common stock and common stock warrants; the proposed maximum aggregate offering price of the common stock and pre-funded warrants is $10,000,000. For each share of common stock issued in the offering, the Registrant will issue a common warrant to purchase one share of common stock.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_4" id="fee_074">No fee required pursuant to Rule 457(g) under the Securities Act. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,000,000. The registrant may issue pre-funded warrants to purchase common shares in the offering. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the pre-funded warrant will equal $0.0001 per share (subject to adjustment as provided.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_5" id="fee_075">Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions. Represents shares of common stock issuable upon exercise of the pre-funded warrants.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_6" id="fee_076">No fee required pursuant to Rule 457(g) under the Securities Act. Represents shares of common stock issuable upon exercise of the placement agent warrants.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_7" id="fee_077">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The placement agent warrants are exercisable at a per share exercise price equal to 110% of the combined public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the placement agent which is equal to 4% of $10,000,000.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c_offering_8" id="fee_078">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on August 18, 2025 ($1.14 per share of common stock). This calculation is in accordance with Rule 457(c) of the Securities Act.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
